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The existence of a patent foramen ovale (PFO) has been known about for nearly 
2,000 years. The prevalence of a PFO has been shown to be 25-40% in the general 
population. Despite the fact that blood flowing through a PFO acts as a shunt, there has 
been little research looking at the effect a PFO has on physiology in otherwise healthy 
humans.  
In Chapter IV, the effect of a PFO on core temperature (Tcore) prior to, and during 
exercise, was investigated. The design of this experiment included appropriate controls 
for a thermoregulatory study (i.e. measuring at same time of day, appropriate hydration 
and food intake, etc.). Results from this study indicate that subjects with a PFO (PFO+) 
have a Tcore that is ~0.4°C higher at rest and during exercise than subjects without a PFO 
(PFO–). Additionally, this study showed that PFO– subjects do not increase Tcore to the 
same extent breathing cold air as they do breathing ambient air during a 10-minute 
exercise bout, whereas there was no difference in Tcore increase between these two 
conditions for PFO+ subjects. These findings suggest that the difference in Tcore between 
PFO+ and PFO– subjects is potentially due to differences in respiratory heat loss. 





ventilatory responses during hot water (40°C) and cold water (20°C) immersion. This 
study found that compared to PFO– subjects, PFO+ subjects 1) increase Tcore at the same 
rate during hot water immersion and 2) do not cool off as quickly during cold water 
immersion. Additionally, in subjects who reached a ventilatory threshold, PFO+ subjects 
had blunted ventilatory responses to increased Tcore compared to PFO– subjects.  
Finally, in Chapter VI it was shown that PFO+ subjects have blunted ventilatory 
responses during acute exposure to hyperoxic and normoxic hypercapnia. However, there 
were no differences in ventilatory responses between PFO+ and PFO– subjects during 
exposure to either isocapnic or poikilocapnic hypoxia. These findings suggest that PFO+ 
subjects have a blunted central chemoreflex. 
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 A primary function of the cardiopulmonary system is to transport deoxygenated 
blood from the systemic circulation back to the pulmonary circulation where it is 
oxygenated and then returned to the systemic circulation. When blood reaches the 
pulmonary capillaries, oxygen binds to hemoglobin on red blood cells and is also 
dissolved into the plasma. At the same time carbon dioxide diffuses out of the plasma and 
into the airways. This oxygenated blood travels to the left side of the heart, where it is 
pumped to the systemic circulation so that oxygen can be delivered and carbon dioxide 
can be removed from the tissues. Deoxygenated blood leaving the tissues then returns to 
the right side of the heart where it is pumped into the pulmonary circulation, and the 
process starts over. An additional function of the cardiopulmonary system in humans is to 
dissipate heat via conduction and evaporation through the airways. This occurs when “hot 
blood” travelling through the pulmonary circulation dissipates heat into the alveoli and 
airways (Afonso et al., 1962) where it is then exhaled into the environment.  
The cardiopulmonary system is normally thought of as a closed system, such that 
all blood travels from the systemic circulation to the right heart, pulmonary circulation 
and left heart. However, there are a few known shunts in this system, such as 
intrapulmonary shunt pathways, bronchial and Thebesian circulation, and a patent 
foramen ovale (PFO), which allows blood to bypass part of this circuit. Of these three, 
the presence of a PFO is possibly the biggest break in this otherwise efficient system. 
The foramen ovale, which is an opening between the right and left atria, is a 





right atrium to bypass the pulmonary circulation and travel directly to the left atrium, 
where it is pumped into the systemic circulation (Murphy, 2005). While in utero the 
foramen ovale remains patent because right atrial pressure exceeds left atrial pressure. At 
birth pulmonary vascular resistance decreases due to the increased partial pressure of 
oxygen that occurs upon commencement of breathing. Decreases in pulmonary vascular 
resistance increase pulmonary blood flow, which reduces right atrial pressure causing left 
atrial pressure to exceed right atrial pressure, and the valvula foraminis ovalis to be 
forced against the left side of the septal wall. Normally, this valve fuses to the septal wall 
within the first two years of life (Geibel et al., 2007). However, in ~35% of the 
population, this opening fails to close completely, and is referred to as a PFO (Hagen et 
al., 1984; Marriott et al., 2013; Elliott et al., 2013).  
 Despite the relatively high prevalence of a PFO, little research has examined 
potential effects on physiology in healthy humans. Blood flowing through a PFO 
represents a right-to-left shunt that potentially affects the physiology of subjects who 
have this opening. For example, blood flowing through a PFO bypasses the pulmonary 
circulation, and therefore it does not undergo gas exchange or respiratory system cooling. 
This could reduce gas exchange efficiency, and the amount of respiratory heat loss (RHL) 
that occurs, which could result in decreased oxygen content and increased core body 
temperature (Tcore), respectively. Consequently, changes to these physiological processes 
could in turn impact other physiological processes such as ventilation, heart rate, skin 
temperature (Tskin), and sweat rate. Accordingly, we sought to investigate the impact of 





 The first objective, addressed in Chapter IV, was to determine if PFO+ subjects 
have a higher Tcore than PFO– subjects. The second objective, addressed in Chapter V, 
was to determine if PFO+ subjects have altered thermoregulatory and ventilatory 
responses to passive heating and cooling. The third and final objective, addressed in 
Chapter VI, was to determine if a PFO affects ventilatory responses during acute 
exposure to hypoxic and hypercapnic environments.  
 
Historical Perspective 
“In the case of the other two (vena cava and pulmonary vein), which lie in contact 
with each other, there is a kind of orifice or fenestra (foramen ovale), common to both. At 
this orifice there is attached a membrane, like a lid or cover, opening toward the 
pulmonary vessel [left atrium], so that it will yield to the influx of blood from the vena 
cava, but will prevent its regurgitation into that vessel. So far, no doubt, we have much to 
admire in these contrivances of nature; but what surpasses them all is the way in which 
the foramen not long afterward becomes occluded. For soon after birth, either within a 
day or two, or, in some animals, after four or five days or a little longer, you will find the 
membrane at the foramen coalescing but not yet fully adherent. Looking at the same 
place in the adult animal, you would say there had never been a time when it was open; 
and, on the other hand, in a fetus, before or immediately after birth, when this membrane 
is attached, so to speak, only by its root, the rest of it hanging free in the vascular cavity, 
you would hardly believe in its ever becoming agglutinated.”  
 – (Claudius Galen, ca 200 AD, from the Opera Omnia, vol. IV, p. 243; 






Embryologic development of the fetal heart begins as a single opening that 
eventually divides into the right and left atria and ventricles (Patten, 1938). As 
development of these chambers occur, one-way valves form which divide the right atrium 
and ventricle, as well as the left atrium and ventricle. These valves cause uni-directional 
blood flow through the heart. Conversely, the septal wall separates the right and left sides 
of the heart. This division forces deoxygenated blood entering the right atrium to go 
through the pulmonary circulation and undergo gas exchange before returning to the left 
side of the heart, where it is pumped into the systemic circulation. 
While in utero, fetal gas exchange occurs at the maternal placenta, thus 
eliminating the need for gas exchange to occur in the fetal pulmonary circulation. 
Accordingly, prior to birth there is an opening in the septum that allows most blood 
entering the right atrium to go directly into the left atrium, with the remaining blood 
traversing the pulmonary circulation (Rasanen et al., 1998; Murphy, 2005). This opening 
is referred to as a foramen ovale. Throughout fetal development, the foramen ovale 
changes from an opening between the right and left atria, to an incompletely formed 
septal wall.  
 Initially, the foramen ovale is an opening between the two atria. The septum 
primum then grows inferiorly from the superior portion of the heart until it connects with 
the endocardial cushion. Shortly after merging with the endocardial cushion, the superior 
portion of the septum primum dies, ostensibly due to apoptosis. This results in the 
foramen ovale consisting of an opening between the superior portions of the two atria. 





begins to grow from the superior wall of the right atrium, and to the right of where 
formation of the septum primum began. By birth the septum secundum has descended 
low enough that it is overlapping the septum primum. However, these two structures have 
not merged together. This results in the overlapping portion of the septum primum acting 
as a valve called the valvula foramina ovalis, which prevents left-to-right blood flow. 
While in utero, right atrial pressure exceeds left atrial pressure in part due to high 
pulmonary vascular resistance. Thus, 80-90% of in utero cardiac output bypasses the 
pulmonary circulation (Rasanen et al., 1998; Murphy, 2005). However, after birth 
pulmonary blood flow increases due to decreased pulmonary vascular resistance, while at 
the same time systemic vascular resistance gradually increases (Emmanouilides et al., 
1964). Once systemic vascular resistance exceeds pulmonary vascular resistance, mean 
left atrial pressure surpasses mean right atrial pressure, and the valvula foramina ovalis is 
forced against the septum secundum, thus preventing right to left blood flow across the 
foramen ovale (Patten, 1938; Hagen et al., 1984; Gao & Raj, 2010; Kerut et al., 2013). 
Over the next several months, the valvula foramina ovalis progressively adheres 
to the septum secundum, thus forming a permanent anatomical closure of the foramen 
ovale and preventing right to left atrial blood flow. However, permanent anatomical 
closure of the foramen ovale does not occur after birth in all humans, with the resulting 
opening called a PFO. PFOs can occur due to the valvula foramina ovalis failing to 
completely adhere to the septum secundum, fenestration of the valvula foramina ovalis, 
or the valvula foramina ovalis being too small to cover the foramen ovale (Patten, 1938; 





 A comprehensive publication by Patten (Patten, 1938) summarized PFO data in 9 
autopsy studies which occurred from 1837 – 1934. This summary identified the presence 
of a probe patent PFO in 864/4083 subjects with prevalence ranging from 15% to 43% 
with an average of 21%. More recent autopsy studies (Hagen et al., 1984; Kerut et al., 
2001) and studies using saline contrast echocardiography in living humans (Marriott et 
al., 2013; Elliott et al., 2013) support Patten’s findings that PFO occurs in 25-40% of the 
population.  
In addition to determining the overall prevalence of a PFO, Hagen et al. (Hagen et 
al., 1984) found that the incidence of PFO decreases with age, declining from 34% in 
subjects between the ages of 0 and 29, to 25% in subjects between the ages of 30 and 79. 
While the incidence reportedly decreases, the average size of the PFO reportedly 
increases from 3.4 mm during the first decade of life to 5.8 mm during the 10th decade of 
life. These changes in incidence and size are likely due to the fact that complete adhesion 
of the valvula foramina ovalis and septum secundum can happen at any point, and that 
smaller PFOs are more likely to experience complete adhesion compared to larger PFOs. 
Although a significant proportion of the population has a PFO, little research has 
examined its impact on physiological processes in healthy humans, presumably because it 
has been assumed to be of little significance. This is surprising as the normal model of 
cardiovascular physiology states that blood travels from the right side of the heart 
through the pulmonary circulation to the left side of the heart and then into the systemic 
circulation before it returns to the right side of the heart. This “normal model” of blood 
flow allows the lung to effectively perform several physiologically important roles 





However, PFO+ subjects have an opening between the right and left atria that can allow 
for varying, but potentially physiologically significant, amounts of cardiac output to 
bypass the pulmonary circulation in otherwise healthy humans. In order for a PFO to 
have a physiologically significant impact, right atrial pressure must exceed left atrial 
pressure for a time sufficient to allow for right-to-left blood flow across the foramen 
ovale. These conditions exist in the adult human at the end of a normal inspiration 
occurring concomitant with the end of ventricular diastole and beginning of ventricular 
systole (Strunk et al., 1987; Aslam et al., 2006; Fenster et al., 2013a). Accordingly, right 
to left blood flow would likely occur to a greater degree under conditions of elevated 
right heart pressures such as exercise, high altitude, and in patients with pulmonary 
hypertension. Thus, blood that circumvents the pulmonary circulation will not undergo 
pulmonary gas exchange, be filtered in the pulmonary capillaries, or participate in 
respiratory system cooling, and there are certainly consequences that can occur as a 
result.  
 Interestingly, the foramen ovale and PFO have been studied for centuries. Dalton 
(Dalton, 1884), Patten (Patten, 1931) and Christie (Christie, 1930) have suggested that 
the scientific community has known about the existence of a PFO since the times of 
Galen (ca 200 AD), while Leonard Botali described the PFO in 1564 (Aslam et al., 
2006). Furthermore, as stated previously, 80 years ago the prevalence of a PFO was been 
estimated to be at least 25% (Patten, 1931). Although a significant proportion of the 
population has a PFO, little research has examined its impact on physiological processes 
in healthy humans because it has been assumed to be of a lower prevalence than actually 





Recent work completed by Lovering et al. showed that during rest PFO+ subjects 
have decreased gas exchange efficiency, as measured by the alveolar-to-arterial oxygen 
difference (AaDO2), compared to PFO–subjects (Lovering et al., 2011). These findings 
are likely explained by the fact that blood flowing through the PFO does not undergo gas 
exchange in the pulmonary capillaries. Consequently, some deoxygenated blood enters 
the left ventricle, which reduces the arterial pressure of oxygen (PaO2). Similarly, Elliott 
et al. showed that after 16 days of exposure to 5260 m PFO+ subjects have blunted 
ventilation responses, despite having lower PaO2 and SaO2, and an increased partial 
pressure of carbon dioxide (PaCO2) than PFO– subjects (Elliott et al., 2015). While the 
reasons for this blunted response are unknown, these findings demonstrate that the 
presence of a PFO affects physiologically relevant measures such as ventilatory 
acclimatization to altitude. Additionally, since blood flowing through a PFO does not 
undergo gas exchange or heat loss, it is plausible that in addition to the AaDO2, a PFO 
may affect other measures such as Tcore. If a PFO alters Tcore then minute ventilation (VE) 
and heart rate (HR) might also be affected. Reasons that a PFO could affect Tcore include 
the fact that blood flowing through a PFO would not be able to dissipate heat into the 
airways, which could lead to a higher Tcore in PFO+ subjects. Since PFO+ subjects have a 
widened AaDO2, it is possible they could have a decreased PaO2, which could stimulate 
an increased VE. If PFO+ subjects have a lower PaO2, this could decrease oxygen 
delivery, which could be offset by increasing heart rate, and therefore cardiac output.  
The purpose of providing this historical perspective is to show that knowledge of 
a PFO is not new. However, despite the relatively large prevalence of PFO in the general 





a PFO. For example, although gas exchange has been studied extensively for over 100 
years, it was not known until recently that a PFO affected gas exchange in otherwise 
healthy humans (Lovering et al., 2011). Consequently, it is quite possible that some of 
the variation that is so often attributed to “normal biological variability” is caused by the 
presence or absence of a PFO. 
 
Background and Significance 
Patent Foramen Ovale 
 The cardiopulmonary system serves several important functions. Perhaps the most 
important of these functions is to transport oxygen from the inspired air and deliver it 
throughout the body, while eliminating carbon dioxide produced through metabolic 
processes. Additionally, the pulmonary circulation is generally thought of as a closed 
circuit. Deoxygenated blood enters the right side of the heart from the systemic 
circulation, where it is then pumped through the pulmonary circulation. Once blood 
reaches the pulmonary capillaries, oxygen diffuses from the alveoli into the blood, where 
it either binds to hemoglobin molecules on the red blood cells, or is dissolved into the 
plasma. Concomitantly, carbon dioxide in the plasma diffuses into the alveoli where it is 
exhaled into the ambient air. Oxygenated blood that returns to the left side of the heart is 
pumped into the systemic circulation. Despite the fact that the pulmonary circuit is 
generalized to be a closed circuit, there are multiple potential “holes.” Perhaps the largest 
of these holes is a PFO.  Blood flowing through a PFO is unable to participate in gas 
exchange. Consequently, this deoxygenated and carbon dioxide laden blood combines 





circulation having lower oxygen and higher carbon dioxide concentrations than blood 
leaving the pulmonary capillaries. Despite the fact that there are certainly implications to 
these changes, and that the prevalence of PFO is ~25-40% among otherwise healthy 
humans (Hagen et al., 1984; Marriott et al., 2013; Elliott et al., 2013; Fenster et al., 
2013a), little is known about the effect of a PFO on physiological responses in healthy 
humans.  
Patent Foramen Ovale and Thermoregulation 
Research completed by Lovering et al., demonstrated that PFO+ subjects have 
decreased gas exchange efficiency during rest as measured by the AaDO2 (Lovering et 
al., 2011). A surprise finding from that study was that PFO+ subjects had a higher Tcore as 
measured by Tesoph than PFO– subjects. However, this study did not control for biological 
sex, ambient room temperature, time of day, or body surface area so it is difficult to 
definitively conclude, based on that study’s design, if having a PFO results in a higher 
Tcore. Despite these lack of controls, it is conceivable that PFO+ subjects have a greater 
Tcore, as one of the functions of the lung and bronchial tree is to dissipate heat (Burch, 
1945; Hanson, 1974). Blood flowing through a PFO would be unable to dissipate heat via 
respiratory system cooling, as it would not come in contact with the respiratory system, 
where up to ~10% of total body heat loss occurs (Burch, 1945).  
The amount of heat retained could be affected by the amount of blood flowing 
through the PFO. It has been suggested that in some patients up to 21% of the cardiac 
output might flow through the PFO (Devuyst et al., 2004). However, it is likely that in 
otherwise healthy, human subjects only 1-5% of the total cardiac output might flow 





subjects who have blood flowing through the PFO could plausibly have a greater Tcore 
due to decreased RHL. 
Effect of a Patent Foramen Ovale on Heart Rate 
 In addition to finding that PFO+ subjects have worse gas exchange efficiency, 
findings from Lovering et al. suggest that PFO+ subjects might have different heart rates 
prior to exercise (Lovering et al., 2011). While the 10-bpm difference between PFO+ and 
PFO– subjects was not significant, it is possible this was due to the study not having 
enough power to answer this question. The amount of oxygen delivered to the systemic 
circulation is determined by oxygen content and cardiac output. Since blood flowing 
through a PFO will reduce the overall oxygen content of arterial blood, delivery can be 
maintained by increasing cardiac output. This can be accomplished by increasing heart 
rate (HR). In addition to increasing HR to maintain oxygen delivery, HR might be greater 
in PFO+ subjects than PFO– subjects due to their higher Tcore, because it is known that 
increasing Tcore augments HR (Cabanac & White, 1995; Minson et al., 1998). 
  
Effect of a Patent Foramen Ovale on Ventilatory Responses to Hypercapnic and 
Hypoxic Environments 
 It has been well established that humans in hypercapnic or hypoxic environments 
increase ventilation in an effort to decrease carbon dioxide or increase oxygen in the body 
(Dempsey et al., 1974; Powell, 2007; Duffin, 2007). However, until recently it was 
unknown if a PFO affected these responses. Elliott et al. recently demonstrated in a field 
study that PFO+ subjects have blunted ventilatory acclimatization to extreme altitude 





responses after 1 day of exposure at 5260 m. It was expected that after several days of 
hypoxic exposure that ventilation would increase in both groups. However, they found 
that PFO+ subjects had a non-significant increase in ventilation compared to Day 1, while 
PFO– subjects had a larger, significant increase in ventilation. These findings were 
surprising since PFO+ subjects had a lower PaO2 and SaO2, while having a higher PaCO2 
than PFO– subjects.  Although the physiological basis for this blunted response in PFO+ 
subjects is unknown, it provides some insight into the effect a PFO has on ventilatory 
responses. While Elliott et al. showed no differences in ventilatory responses during acute 
exposure to hypoxia, it is possible these findings were due to some unknown factor, such 
as a pyrogen, that couldn’t be controlled for in a field study and/or wasn’t measured. 
Furthermore, that study only provides information on poikilocapnic hypoxic exposure. To 
date there has been no research looking at the effect of PFO on ventilatory responses 
during acute exposure to normoxic hypercapnia, hyperoxic hypercapnia or isocapnic 
hypoxia.  
 
Statement of Problem 
 The prevalence of a PFO is ~25-40% in the general population (Marriott et al., 
2013; Elliott et al., 2013). However, to date, little research has examined the effect a PFO 
has on physiological processes in otherwise healthy humans. This is surprising as blood 
flowing through a PFO is a right-to-left shunt, which bypasses the pulmonary circulation. 
Blood flowing through the pulmonary circulation will undergo oxygenation and heat 
exchange. Thus, blood flowing through a PFO remains deoxygenated, and will not 





with blood returning from the pulmonary circulation, that the overall partial pressure of 
oxygen in the arterial blood will be reduced, while the temperature of the blood will be 
increased, which could then affect thermoregulatory and ventilatory responses. 
 
Purpose and Hypotheses 
 The primary purpose of this dissertation is three fold:  to determine if the presence 
of a PFO affects 1) core temperature during rest and exercise; 2) ventilatory and 
thermoregulatory responses to passive heating and cooling; and 3) ventilatory responses 
during acute exposure to hypoxic and hypercapnic environments. 
 
Aim #1:  Determine whether or not the presence of a PFO causes subjects to have a 
higher Tcore as measured by Tesoph during rest and exercise in a thermoneutral 
environment due to reduced respiratory system cooling (~20°C). 
 To ascertain if a PFO is physiologically relevant as it relates to thermoregulation, 
we intend to determine if subjects with a PFO have a higher Tcore, as measured by Tesoph 
before and during exercise. Previous research that provided a potential answer to this 
question was not designed to answer this question, as the main variable of interest was 
the alveolar-to-arterial oxygen difference (Lovering et al., 2011). Consequently, 
appropriate controls were not in place for a temperature regulation study including the 
time of day, nutrition, fasting state and other factors known to influence thermoregulation 
(Sawka et al., 2011). Therefore, it is still unknown if a PFO affects Tcore. By establishing 
that a PFO plays a role in temperature regulation, it could cause a paradigm shift in our 





thermoregulate in different ways. The experimental designs in this dissertation will allow 
us to determine if a PFO plays in thermoregulatory and ventilatory responses. Thus, the 
first aim of this dissertation is to establish whether or not a PFO actually plays a role in 
thermoregulation, specifically Tcore, before and during exercise while breathing ambient 
and cold air. 
 
Aim #2:  Determine whether or not the presence of a PFO affects ventilatory and 
thermoregulatory responses to a) passive heating, and b) passive cooling.  
 With passive heating, ventilation increases once a threshold Tcore is achieved 
(Cabanac & White, 1995; Lucas et al., 2015). Potential explanations for this phenomenon 
include 1) increased metabolic activity and 2) the body making an effort to increase heat 
dissipation through respiratory system cooling in a two-phase panting response (White, 
2006). This response also appears to be variable, and it is possible some of this variability 
might be explained by a PFO. If PFO+ subjects have a higher Tcore, this might be due, in 
part, to reduced respiratory system heat loss. By having diminished respiratory system 
heat loss, PFO+ subjects would be unable to dissipate heat as effectively as PFO– 
subjects, which would result in PFO+ subjects increasing their Tcore at a greater rate than 
PFO– subjects. Similarly, if PFO+ subjects are unable to dissipate heat as effectively as 
PFO– subjects, it is possible this will allow them to retain heat during cold exposure. 
Thus, the second aim of this dissertation was to determine if the presence of a PFO 






Aim #3:  Determine if the presence of a PFO results in a greater hypoxic ventilatory 
response (HVR) and/or hypercapnic ventilatory response (HCVR) compared to PFO– 
subjects 
 Prior work done by Lovering et al. has shown that during resting conditions, 
PFO+ subjects have worse gas exchange efficiency as measured by the AaDO2 than 
PFO– subjects (Lovering et al., 2011). Additionally, Elliott et al. showed in a field study, 
that although there was no difference in HVR after 48 hours of exposure to 5260 m, over 
16 days PFO+ subjects had decreased ventilatory acclimatization to altitude when 
compared to PFO– subjects despite a lower PaO2 and higher PaCO2 (Elliott et al., 2015). 
Worsened gas exchange efficiency not only decreases oxygen content, but also augments 
PaCO2. Increasing PaCO2 has been shown to increase ventilation, but it is unknown if the 
response to elevated PaCO2 is affected by the presence of a PFO. Therefore, the final aim 
of this dissertation is to determine if the presence of a PFO plays a role in the ventilatory 
responses during acute exposure to hypoxia or hypercapnia.  
 Chapter IV was published in the Journal of Physiology and Chi-Yan A. Ng, Sierra 
D. Hill, Dr. Richard C Padgett and Dr. Andrew T. Lovering are co-authors. I performed 
the experimental work, led the project, and the writing is entirely my own; Chi-Yan A. 
Ng and Sierra D. Hill assisted with data collection; and Dr. Richard C Padgett and Dr. 
Andrew T. Lovering helped develop the protocol, and provided guidance and editorial 
assistance 
 Chapter V will be submitted to the Journal of Physiology and Madeline W. Hay 
B.S., Alyssa M. Hardin, Dr. Matthew D. White and Dr. Andrew T. Lovering are co-





own; Madeline Hay B.S. and Alyssa Hardin assisted with data collection and data 
analysis; and Dr. Matthew D. White and Dr. Andrew T. Lovering helped develop the 
protocol, and provided guidance and editorial assistance. 
Chapter VI will be submitted to the Journal of Physiology and Lindsey Boulet 
B.S., Alyssa M. Hardin, Alex J. Chang, Dr. Glen Foster and Dr. Andrew T. Lovering are 
co-authors. I performed the experimental work, led the project, and the writing is entirely 
my own; Lindsey Boulet assisted with data collection, Alyssa M. Hardin and Alex Chang 
assisted with data collection and data analysis; and Dr. Glen Foster and Dr. Andrew T. 






REVIEW OF THE LITERATURE 
Introduction 
 This literature review will sequentially follow the order of Chapters IV – VI, and 
the topic being addressed by each chapter. However, the patent foramen ovale is 
applicable to all chapters and will be addressed first. Additionally, Chapters IV – V 
address the topic of thermoregulation, although each chapter answers a different question 
related to thermoregulation. Therefore, thermoregulation will be addressed before delving 
into chapter-specific topics. Finally, ventilatory responses to hypoxia and hypercapnia 
will be addressed in the final section of this literature review as it relates solely to 
Chapter VI. 
 
Patent Foramen Ovale 
 As stated previously, a PFO has been known to exist since the time of Galen (ca 
200 AD) (Christie, 1930; Patten, 1931).  However, despite this knowledge, little research 
has been done to investigate what effects the PFO might have on physiology in healthy 
humans. The most widely researched area with regards to a PFO is whether or not it 
contributes to the occurrence of stroke, transient ischemic attacks, or migraine, as blood 
clots can pass from the right atrium into the left atrium and then enter the systemic 
circulation. However, the literature is mixed, and debate continues as to whether or not 
PFO plays an important role in these issues (Kerut et al., 2001; Meissner et al., 2006; 





 Surprisingly, very little research has looked at the effects the presence of a PFO 
might have on other physiological processes. This is evidenced by a January 2016 search 
in the Journal of Applied Physiology only returning 12 articles that contain “patent 
foramen ovale” in the title or abstract, 9 of which were published since 2009. The 
pulmonary circulation is generally thought of as a closed circuit with blood entering the 
right side of the heart continuing thorough the pulmonary circulation, before entering the 
left side of the heart, where it is then pumped out to the systemic circulation. In PFO– 
subjects this is true, and the ability of the lung to perform its main functions of gas 
exchange and RHL is maximized. However, until recently, no research had looked at the 
effect of a PFO on gas exchange. Lovering et al. showed that during resting conditions in 
normoxic and hypoxic conditions, gas exchange, as measured by the alveolar to arterial 
oxygen difference (AaDO2), was worse in PFO+ subjects (Lovering et al., 2011). 
Furthermore, this study also suggested that a PFO might affect other physiological 
variables such as Tcore. Similarly, Fenster et al., demonstrated that in 97 patients who 
underwent PFO closure, dyspnea  and oxygen desaturation during exercise were reduced 
(Fenster et al., 2013b). Elliott et al. has also shown that PFO+ subjects have an increased 
incidence of acute mountain sickness and blunted ventilatory acclimatization to altitude 
after 16 days at 5260 m (Elliott et al., 2015). Taken together, these studies support the 
notion that the presence of a PFO can affect physiological responses in healthy humans.  
 
Thermoregulation 
 Thermoregulation is vital to survival. One of the main functions of the body is to 





defined as the mean temperature of the thermal core (Anon, 1987). Tcore is monitored by 
the hypothalamus. This area of the brain receives afferent input from multiple places 
throughout the body, such as temperature sensitive neurons in the skin, muscle and 
abdomen. Additionally, the spinal cord is sensitive to changes in temperature (Satinoff, 
1978). Since it is an integration center, the hypothalamus is the main regulator of Tcore,” 
with “normal” Tcore being between 36.5 and 37.5°C under resting conditions, with some 
of this varability being attributable to Circadian rhythms. It must be noted that Tcore can 
be measured by rectal and esophageal temperature in humans. Furthermore, there is inter- 
and intra-subject variability within this measure with studies demonstrating that resting 
Tesoph is 36-37°C (Curras et al., 1991; Montain & Coyle, 1992; Cabanac & White, 1995; 
Griffin & Boulant, 1995; Altareki et al., 2009; Lovering et al., 2011).  
While thermoregulation has been studied extensively for years, it is still disputed 
as to whether or not there a set-point temperature (Tset) or temperature null zone (Tnull) 
(Bligh, 2006; Cabanac, 2006). A Tset implies that there is a specific Tcore that is 
maintained and deviations from this temperature cause heat loss or conservation 
mechanisms to be activated. Thus, when Tcore exceeds Tset, heat loss mechanisms, such as 
sweating and increased skin blood flow, are initiated. Conversely, when Tcore falls below 
the Tset, heat generation and conservation mechanisms, such as shivering and increased 
central blood flow occur (Gonzalez-Alonso et al., 1999; Coris et al., 2004; Boulant, 
2005). Alternatively, proponents of a Tnull argue that there is a range of temperatures that 
exists, such that heat loss or conservation mechanisms are not initiated until Tcore 
exceeds/falls below Tnull (Mekjavić et al., 1991). While Tset or Tnull might not be the most 





range (Toperate) that is regulated within the hypothalamus. Thus, Tcore refers to the actual 
temperature of the hypothalamus which is estimated by rectal and esophageal 
temperature, and Toperate refers to the temperature or null-zone of temperatures the brain is 
trying to maintain. 
Tcore can change for several reasons, including metabolic rate, illness or 
environmental conditions. Some of these conditions, such as when a person has a fever, 
cause the Toperate to be shifted to a higher temperature. However, other circumstances, 
such as increased activity state, result in a change in Tcore without a concurrent resetting 
of the Toperate. When Tcore deviates without a concomitant change in Toperate, heat 
conservation or heat loss mechanisms are employed. Furthermore, as the difference 
between Toperate increases, the response will be magnified. Multiple studies have shown 
that there are warm sensitive neurons that increase their firing rate, as Tcore increases, as 
well as cold sensitive neurons that have increased firing rate as Tcore decreases (Curras et 
al., 1991; Griffin & Boulant, 1995; Noakes et al., 2001). Additionally, Toperate has a 
Circadian rhythm, such that Tcore fluctuates throughout the day, with the lowest Tcore 
occurring in the early morning hours, and the highest Tcore happening during the late 
evening (Aschoff, 1983).   
As mentioned previously, exercise results in Tcore increasing above Toperate, 
initiating the onset of heat loss mechanisms including eccrine sweating and thermal 
hyperpnea (White, 2006). However, it is possible these mechanisms are not enough to 
return Tcore back to Toperate. When heat loss mechanisms are unable to return Tcore to 
Toperate, the priority of thermoregulation shifts from maintenance of a ~37°C Tcore, to 





hypothesized to be ~40°C (Nielsen et al., 1993; 1997). However, it is unclear what 
physiological processes are employed to prevent Tcore from reaching Tcritical. One leading 
theory is that when Tcore equals Tcritical, the body begins to shutdown to prevent further 
damage from occurring (Gonzalez-Alonso et al., 1999; Coris et al., 2004). Another idea 
is that there is an anticipatory mechanism that prevents Tcore from equaling Tcritical 
(Noakes et al., 2001). As Tcore rises due to increased metabolic rate arising from exercise, 
afferent feedback reaches the hypothalamus. This is interpreted to mean that Tcritical will 
be reached unless heat accumulation is reduced. Accordingly, exercise intensity decreases 
which leads to reduced heat production. While there is debate on how the body prevents 
Tcore from reaching Tcritical, it is generally accepted that the body is trying to prevent Tcore 
from reaching a point that will cause damage (Gonzalez-Alonso et al., 1999; Noakes et 
al., 2001; Gonzalez-Alonso, 2007). Since maintenance of Tcore in a physiological range is 
vital for normal human function, it would be important to understand why some people 
are better able to thermoregulate than others. If PFO+ and PFO– subjects have a different 
Tcore, then it is conceivable that they would have different Toperate, otherwise they would 
have the same Tcore. However, it is also possible that PFO+ and PFO– subjects have the 
same Toperate, despite differences in Tcore. A possible explanation for this situation is 
selective brain cooling (SBC). SBC occurs when  heat from: 1)  the nasal cavity is lost in 
expired air, 2) the surface of the head and face is lost to the ambient air and 3) the internal 
carotid artery blood in the cavernous sinus is lost in  countercurrent heat exchange in the 
carotid rete with the blood in the cooled venous drainage from the brain (Mariak et al., 
1999). Since SBC is affected by pulmonary ventilation, having a PFO would not inhibit 





Consequently, PFO+ and PFO– subjects could have different Tcore, but have the same 
Toperate, if SBC occurs to a greater degree in PFO+ subjects than PFO– subjects. This 
could allow blood reaching the hypothalamus to be the same temperature in both groups. 
Thus, allowing PFO+ and PFO– subjects to have different Tcore, but the same Toperate. 
Some animals, such as canines, are known to dissipate large amounts of heat 
through a two phase panting response that includes a thermal tachypnea and a thermal 
hyperpnea. Humans in contrast only exhibit a thermal hyperpnea in an effort to dissipate 
heat (White, 2006). It has been suggested that up to 10% of heat loss from the body is 
carried away through expired air (Haldane, 1905; Burch, 1945; Hanson, 1974). As blood 
leaves the left ventricle and travels through the systemic circuit it picks up heat produced 
from the ongoing metabolic processes occurring within the body, resulting in an 
increased temperature of the blood and surrounding tissue (Afonso et al., 1962). Blood 
flowing through the respiratory system is able to lose heat into the airways, which is then 
removed through the expired air. Once the blood reaches the pulmonary circulation, two 
things occur. First, carbon dioxide unloads from hemoglobin and oxygen loads onto 
hemoglobin. Both of these processes are exothermic (Haldane, 1905; Wyman, 1939; 
Hills, 1973), meaning that heat is produced which will further increase blood 
temperature. Second, assuming the airways have a lower temperature than pulmonary 
arterial blood, heat will be dissipated from the blood into the airways. This heat will then 
be lost to the environment as long as airway temperature is lower than environmental 
temperature. However, it is possible there is a perfusion component such blood flowing 
through a PFO, as well as a ventilation component to RHL. Thus perfusion dependent 





PFO and decreased VE, respectively. Consequently, it is possible that in studies utilizing 
mouth breathing on a mouthpiece would essentially eliminate the amount of RHL that 
occurs in the upper airways. Thus, any differences seen would be attributable to RHL 
occurring in the lower airways. 
Having a PFO could potentially hinder thermoregulatory processes in hot 
environments. While a PFO is considered a right-to-left shunt as it relates to gas 
exchange (Lovering et al., 2011), this could also be the case for temperature (Afonso et 
al., 1962). This will presumably lead to blood leaving the left side of the heart having a 
higher temperature than blood entering the left side of the heart. It follows that PFO+ 
subjects who have this “heat shunt,” will have a higher Tcore than PFO– subjects. 
Additionally, in environments where ambient temperature exceeds Tcore, only evaporative 
RHL occurs. Consequently, the amount of blood flowing through a PFO would likely 
have no effect on RHL, since the temperature gradient will go from the environment into 
the body. Under these circumstances the only way to modify RHL would be with changes 
in VE. If PFO+ and PFO– subjects have similar ventilatory responses to heat it follows 
that they would experience the same amount of RHL. However, if PFO+ subjects had a 
blunted ventilatory response in a hot environment, they would have decreased RHL, 
which could cause them to have a higher Tcore. 
Conversely, when Tcore drops below Toperate, as would happen during passive 
exposure to a cold environment the body employs heat conservation mechanisms. A main 
response to reduced Tcore is redistribution of blood from the periphery to the core. This 
can be accomplished by vasoconstriction of the skin blood vessels, which helps prevent 





an increase in central venous pressure, which will increase right atrial pressure and stroke 
volume. These protection mechanisms could be doubly protective for PFO+ subjects, as 
the increased right atrial pressure increases the likelihood that blood will flow across the 
PFO. Increased blood flow across the PFO decreases the amount of blood that enters the 
pulmonary circulation, which is then able to dissipate heat into the airways. 
Consequently, it is plausible that PFO+ subjects do not lose as much heat through the 
airways as PFO– subjects. Therefore, having a PFO could possibly be beneficial in cold 
environments as it would take longer for PFO+ subjects, when compared to PFO– 
subjects, to lose a given amount of heat.  
 
Ventilatory Responses to Passive Heating 
The ability to dissipate heat is of vital importance. Humans can function and live 
in extremely hot environments up to ~50°C, because of this ability. In addition to 
conduction and convection, humans also dissipate heat through evaporation of sweat and 
radiation of heat from the body to the environment. However, there are limitations to 
these processes. Evaporation and heat loss from the upper airways only occurs when the 
atmosphere is not saturated with water vapor, and the ability to lose heat via radiation 
only occurs when the environment is cooler than the body. Therefore, if a subject is in an 
environment that is hot and/or extremely humid, the ability to dissipate heat will be 
severely hampered.  
Up to 10% of total body heat loss can come from the airways (Burch, 1945). 
Additionally, Hanson demonstrated that evaporative heat loss through the lungs is 





ambient temperature (Hanson, 1974). Since 100% of the cardiac output goes through the 
pulmonary circulation in PFO– subjects, it follows that more RHL should occur in these 
individuals than PFO+ subjects. Furthermore, as ambient temperature decreases the 
difference in Tesoph between these groups will be augmented, since convective heat loss 
increases as ambient temperature decreases. Additionally, instead of using the phrasing 
“PFO+ subjects are hotter than PFO– subjects,” it is likely more correct to say that PFO– 
subjects are in fact cooler than PFO+ subjects, because they experience more convective 
cooling than PFO+ subjects. 
While evaporation of sweat, and radiation of heat from the skin to the 
environment are important cooling mechanisms, they are not the only means of heat 
dissipation. As mentioned previously, humans are able to dissipate small amounts of heat 
through expired air (Haldane, 1905; Burch, 1945; Hanson, 1974; Cabanac & White, 
1995). Heat loss occurs through evaporation in the inner airways. The amount of RHL is 
dependent on several variables, including VE, inspired and expired temperature and 
humidity (Hanson, 1974; Kenny & Jay, 2011). Increased VE and/or a large gradient 
between inspired and expired temperature are the primary drivers in augmenting RHL. 
The effect of increased Tcore on hyperpnea has previously been examined 
(Haldane, 1905; Gaudio & Abramson, 1968; Cabanac & White, 1995; White & Cabanac, 
1996; White, 2006).  Bligh and Johnson defined hyperthermia as a 1°C increase in Tcore 
above resting values (Bligh & Johnson, 1973). While a 1°C increase in Tcore constitutes 
hyperthermia, this does not appear to be a great enough stimulus to cause thermal 
hyperpnea in all humans. The threshold for hyperthermia induced thermal hyperpnea 





Fujii et al., 2008; Lucas et al., 2015). Additionally, this response is different than the 
panting response which occurs in canines, as VE increases due to an increase in Vt instead 
of an increase in frequency (Gaudio & Abramson, 1968; Cabanac & White, 1995). It has 
been hypothesized this increase in VE occurs in response to an increased metabolic 
demand or as a cooling mechanism, but the physiological basis for this response has yet 
to be fully elucidated.  
Normally VE is primarily mediated by changes in PaCO2 (Nattie, 1999).  
However, during hyperthermic conditions it is unclear if PaCO2 is the main determinant 
of VE. There are a number of hypotheses that attempt to explain increased VE during 
hyperthermic conditions. One notion is that increased Tcore increases afferent signaling 
from temperature sensitive neurons, thereby augmenting respiratory efferent activity in 
an effort to reduce Tcore. Research completed by Cabanac and White supports the idea 
that thermal hyperpnea occurs in an attempt to defend Tcore (Cabanac & White, 1995). In 
their study, subjects were passively heated in a hot tub. VE did not increase until Tesoph 
reached ~38.5°C. They hypothesized the hyperpneic response occurred in an attempt to 
specifically cool the brain.  
While findings from Cabanac and White showed that increased Tcore augments 
VE, it is possible this did not occur solely to cool to the brain. That study also showed that 
oxygen uptake (VO2), which is a measure of metabolism had a non-significant increase of 
0.07 L•min-1 in hyperthermic conditions compared to normothermic conditions. This 
suggests that the augmented VE might be partially affected by an increase in metabolism. 
Similarly, findings from Saxton (Saxton, 1981) showed when going from normothermic 





While both of these studies demonstrated a thermal hyperpnea, which is when VE 
increases out of proportion to VO2 during hyperthermic conditions, they also suggest that 
the increase in VE is not due solely to the increase in VO2. Thus, it is plausible that some 
or all of the remainder in increased VE occurs in an effort to maintain Tcore.  
Another hypothesis is that under hyperthermic conditions there is an increased 
sensitivity of ventilation to CO2 (Cunningham & O'Riordan, 1957; Gaudio & Abramson, 
1968). Gaudio and Abramson demonstrated that an Tcore increase of 1°C resulted in a 
hyperventilatory response, as PaCO2 decreased from 44 to 33 Torr. This appears to 
indicate that CO2 sensitivity increases with a 1°C increase in Tcore (Gaudio & Abramson, 
1968). Additionally, Cunnigham & O’Riordan showed that for a given PaCO2, VE was 
greater in hyperthermic conditions (Cunningham & O'Riordan, 1957). This finding 
supports the idea that increased Tcore might result in an increased sensitivity to changes in 
PaCO2. Likewise the ventilatory response to hypoxia is greater during hyperthermic 
conditions than normothermic conditions both at rest (Curtis et al., 2007), and during 
exercise (Chu et al., 2007). While the mechanism between hyperthermia and increased 
ventilation has not been clearly elucidated, it seems apparent that when Tcore increases, 
there is a concomitant rise in ventilation. Furthermore, it is plausible that the increased 
VE during hyperthermic conditions is a combination of all three factors. However, it has 
yet to be determined if all these factors contribute to the increased VE and how much 
each contributes to the overall response.  
While the mechanisms for thermal hyperpnea are unclear, it is plausible the 
presence of a PFO could affect these responses. Since PFO+ subjects do not have all of 





dissipating less heat into the airways than PFO– subjects. However, it has yet to be 
determined if PFO+ subjects have less RHL than PFO– subjects. 
 
Thermoregulatory Responses to Passive Cooling 
As stated previously humans can live in environments that are several degrees 
different from the normal Tcore of 36-37°C. This is done using heat conservation or 
production mechanisms. According to Young’s Model of Acclimatization, there are three 
classifications of how body heat can be maintained during cold exposure, one of which is 
cold habituation (Young, 2011). Habituation is a desensitization or dampening of the 
normal response to a stressor that occurs when stimuli are repeated. Cold habituation 
results in a blunted shivering response and decreased subcutaneous vasoconstriction. 
Subjects that experience some degree of cold habituation are still able to maintain Tcore. If 
PFO– subjects are colder than PFO+ subjects, it is plausible they shiver at a lower Tcore 
and/or have reduced subcutaneous vasoconstriction. If either of these responses are 
evident in PFO– subjects, this would suggest they have a reduced degree of cold 
habituation compared to PFO+ subjects. 
In cases where repeated exposure results in decreased Tcore, metabolic or 
insulative acclimatization can occur. Metabolic acclimatization increases shivering and 
non-shivering thermogenesis. Shivering thermogenesis is the process where involuntary 
muscle contractions result in no useful work, but rather most of the energy produced is 
converted to heat, which can be used to maintain or increase Tcore. Nonshivering 
thermogenesis occurs in brown adipose tissue, which contains uncoupling protein 1 





matrix without rephosphorylating ADP. This results in no useful work occurring, and all 
energy is lost as heat. If PFO+ subjects have a greater Tcore than PFO– subjects, it could 
be due in part to having a higher Tcore at the onset of shivering. 
Insulative acclimatization includes enhanced cutaneous vasoconstriction as 
redistribution of blood flow to the core. This results in a decreased amount of heat loss, as 
less skin blood flow results in less heat lost to the environment when Tcore exceeds 
ambient temperature. Consequently, if PFO+ subjects have a greater Tcore they might 
experience a different amount of insulative acclimatization, which would be evident by 
reduced skin blood flow that could contribute to them having a greater Tcore than PFO– 
subjects.  
One way to determine if there are differences in thermoregulatory responses to the 
cold is through the use of a passive cooling protocol. Using cold-water immersion allows 
determination of thermoregulatory responses to cold at a fixed Tskin. This is important as 
Tskin is an important determinant of the Tcore at which shivering occurs (Cheng et al., 
1995). Cheng et al. showed an inverse relationship between the Tcore at which shivering 
occurred and Tskin. Consequently, when trying to determine if there is a difference in the 
rate of heat loss between PFO+ and PFO– subjects, the water temperature needs to be 
cold enough that will allow body cooling to occur, but not so cold that shivering begins 
almost immediately. Tikusis et al. demonstrated that subjects could remain immersed in 
18°C water for up to 90 minutes, while losing ~0.7°C in that time frame. However, it 
must be noted that subjects remained immersed even after they began shivering, and it is 
unclear at what Tcore there was an onset of shivering (Tikuisis et al., 2000). Hayward and 





long it took for shivering to start or the Tcore at which shivering started, subjects did 
achieve maximal shivering metabolism ~15 minutes after immersion (Hayward & 
Eckerson, 1984).  
When humans are subjected to cold water, the initial minute is characterized by a 
large increase in ventilation, followed by a rapid decrease. Over the course of ~5 minutes, 
steady-state is reached, but ventilation is still greater than pre-immersion values 
(Hayward & Eckerson, 1984; Cooper & Veale, 1986; Mekjavić & Bligh, 1989). 
Similarly, VO2 has an initial spike during the first minute of immersion, followed by a 
decrease over the next several minutes before plateauing at a value greater than resting 
values (Mekjavić & Bligh, 1989).  
If PFO+ subjects undergo less respiratory loss as we hypothesize, it follows then 
that they would be better able to retain heat in cold environments than PFO– subjects. 
Furthermore, it is plausible that PFO+ subjects have a higher Toperate and therefore would 
employ heat conservation mechanisms sooner (i.e. higher Tcore) than PFO– subjects. 
Additionally, if this hypothesis is supported, it would be reasonable to conclude that 
PFO+ subjects are better suited to cold environments than PFO– subjects. 
 
Ventilatory Responses to Acute Hypoxia/hypercapnia 
One of the main functions of the cardiopulmonary system is to deliver oxygen 
from the atmosphere to the body, and release carbon dioxide from the body into the 
atmosphere. In healthy humans at sea level this process is accomplished relatively easily, 
as the partial pressure of inspired oxygen (PIO2) is ~160 mm Hg, which results in a PaO2 





low (Prabhakar & Semenza, 2015). However, if PaO2 drops to ~60 mm Hg firing rate 
increases dramatically, which subsequently causes a rapid increase in ventilation.  PaO2 is 
primarily sensed by the peripheral chemoreceptors. These chemoreceptors are located in 
the carotid sinus and the aortic arch. The peripheral chemoreceptors sense PaO2, PaCO2, 
and pH. While the peripheral chemoreceptors primarily sense PaO2, it must be noted that 
the firing rate of these chemoreceptors is affected by PaCO2, such that for a given PaO2 
the firing rate will be augmented as PaCO2 increases (Nielsen & Smith, 1952). Under 
normocapnic conditions when PaCO2 is ~40 mm Hg, peripheral chemoreceptor firing rate 
significantly increases when PaO2 drops below 60 mm Hg. When PaO2 is greater than 60 
mm Hg, any change to PaO2 results in a relatively small change to SaO2. However, when 
PaO2 is below 60 mm Hg, any decrease in PaO2 is accompanied by a large reduction in 
SaO2. Consequently, the oxyhemoglobin dissociation curve, which shows the relationship 
between PaO2 and SaO2, has two distinct portions (Kelman & Nunn, 1966). The point on 
the curve where PaO2 is ~60 mm Hg is referred to as the shoulder of the curve, and it is 
the de facto separation of the two parts of the curve. When PaO2 reaches the shoulder of 
the curve, and drops below 60 mm Hg, the low partial pressure of oxygen results in the 
inhibition of K+ channels while stimulating Ca2+ channels. The influx of Ca2+ stimulates 
acetylcholine release which activates afferent fibers of the glossopharyngeal and vagus 
nerves, resulting in an increased VE. In addition to monitoring PaO2, peripheral 
chemoreceptors also sense PaCO2. As PaCO2 increases, the firing rate of the peripheral 
chemoreceptors for a given PaO2 is augmented (Duffin, 2007; Smith et al., 2010). 
In addition to monitoring PaO2, the body monitors PaCO2, via the central 





While the peripheral chemoreceptors primarily sense PaO2, the central chemoreceptors 
monitor PaCO2 indirectly via interstitial brain [H+]. Unlike H+, PaCO2 is able to cross the 
blood-brain barrier. Once CO2 crosses this barrier it can combine with water to form 
carbonic acid. Furthermore, this reversible reaction is catalyzed by carbonic anhydrase. 
After formation, carbonic acid dissociates into bicarbonate and H+, which is sensed by 
the central chemoreceptors. Consequently, a PaCO2 greater than 40 mm Hg is analogous 
to a high interstitial brain [H+]. Thus, when PaCO2 and therefore interstitial brain [H+], is 
high, VE increases in an effort to increase pH, which reduces PaCO2. Unlike peripheral 
chemoreceptors, which monitor PaCO2 and PaO2, central chemoreceptors are not 
sensitive to changes in PaO2. However, the firing rate of these chemoreceptors can be 
influenced by the other. For example increasing the firing rate of the peripheral 
chemoreceptor will increase the gain of the central chemoreceptor and vice versa (Blain 
et al., 2009; 2010; Smith et al., 2010).  
As mentioned previously, when compared to PFO– subjects, PFO+ subjects likely 
have a greater PaCO2 and lower PaO2. Under normal, resting conditions at sea level, 
these differences are likely negligible without any resulting differences in VE between 
these two groups. This idea is supported by research completed by Lovering et al and 
Elliott et al. In these two studies, under normoxic conditions PFO+ subjects trended 
towards having a PaO2 that was 2-5 Torr lower, a PaCO2 that was 2-3 Torr higher and a 
SaO2 that was ~1% lower than PFO– subjects (Lovering et al., 2011; Elliott et al., 2015). 
Additionally, it is important to note that while PFO+ subjects had a greater stimulus to 
breathe due to the decreased PaO2 and increased PaCO2, they actually had a non-





that PFO+ subjects have an altered sensitivity to decreased PaO2 and increased PaCO2, 
such that for a given PaCO2, PFO+ subjects will have a lower reduced VE. Additionally, 
when PaO2 is ~100 mm Hg, small decreases in PaO2 do not significantly affect 
ventilation.  
While small changes in PaO2 during hypercapnic conditions don’t have a large 
effect on VE, this is not the case under hypoxic conditions. If placed in a hypoxic or 
hypercapnic environment, both groups of subjects will increase their VE in an effort to 
compensate for the low PaO2 or high PaCO2. Due to blood flowing through the PFO 
acting as a shunt, increasing VE will not affect PaO2 or PaCO2 of this shunted blood. This 
will ultimately cause PaO2 to be lower and PaCO2 to be greater in PFO+ subjects for a 
given VE. Consequently, for a given increase in VE, PFO+ subjects will be unable to 
increase PaO2 or decrease PaCO2 to the same amount as PFO– subjects. If PFO+ and 
PFO– subjects have the same set point for chemosensitivity, it follows that PFO+ 
subjects would have a greater HVR and HCVR when exposed to a hypoxic environment 
in an effort to increase PaO2 and/or decrease PaCO2. 
 
Summary 
 This literature review aimed to show that the presence of a PFO might account for 
some of the variability that occurs with physiological responses (i.e. changes in Tcore, 
shivering threshold, heart rate, ventilation) to different stressors (i.e. exercise, 
temperature, low oxygen, high carbon dioxide) in healthy humans. It would be important 





otherwise healthy humans. Consequently, this dissertation was designed in an effort to 








 Prior to the start of any study, the University of Oregon’s Research and 
Compliance Services and the Committee for Protection of Human Subjects formally 
approved the protocols that comprise this dissertation (Chapters IV – VI). Additionally, 
all subjects met with me individually and we verbally discussed the procedures and risks 
involved with each study. Furthermore, written informed consent was obtained from all 
subjects prior to participation.  
 
Echocardiographic Screening 
 Our laboratory has been collaborating with the Oregon Heart & Vascular Institute 
for more than eight years. All echocardiographic screenings for this dissertation were 
completed by one of two highly skilled (combined 40+ years of experience) registered 
diagnostic cardiac sonographers from the Oregon Heart & Vascular Institute. Subjects 
participating in any aim of this dissertation underwent a comprehensive 
echocardiographic screening, performed by Randall Goodman, RDCS, or Eben Futral 
MBA, RDCS and overseen by myself. These screenings involved placement of a three-
lead echocardiogram with subjects positioned in the left lateral decubitus position in a 
reclining chair and with their head resting on their left arm. This position was utilized 
because it allows the heart to move anteriorly and laterally against the subject’s ribcage. 
Additionally, it allows the ribs to spread apart, which enables a clear apical, four chamber 





shirtless, while female subjects wore a loose fitting scrub top. This made it easier for the 
sonographers to use the ultrasound probe. 
 Screenings began with the sonographer thoroughly examining cardiac structures 
in an effort to rule out any cardiac abnormalities, including obstruction of the right 
ventricular outflow tract or stenosis of the pulmonary artery and/or aorta. Left ventricular 
function and all valves were inspected to rule out indicators of congenital heart disease, 
while the pericardium was examined to rule out pericardial effusion. After confirming 
normal heart function without signs of heart disease, identification of a PFO was the next 
phase of the echocardiographic screening. 
 
Patent Foramen Ovale Detection 
 The foramen ovale is an opening between the two atria of the heart. This opening 
is a critical component of the fetal cardiopulmonary system as it allows ~90% of the 
blood entering the right atrium to bypass the pulmonary circulation and enter directly into 
the left atrium (Rasanen et al., 1998). Consequently, in utero the foramen ovale is patent 
in 100% of healthy humans. At birth, left atrial pressure increases above right atrial 
pressure due to decreased pulmonary vascular resistance and pulmonary pressure. These 
changes cause blood flow to be reversed through the foramen ovale. However, the 
septum primum, which is a flap of tissue on the left atrial side of the foramen ovale, is 
forced against the septal wall, thus preventing a left-to-right shunt from occurring. Over 
time the septum primum will fuse with the atrial septal wall, thus completely closing off 
the foramen ovale. However, in 25-40% of the population the septum primum fails to 





al., 1984; Marriott et al., 2013; Elliott et al., 2013). Even if a PFO is present, right-to-left 
atrial blood flow can only occur when right atrial pressure exceeds left atrial pressure, 
which forces the foramina ovalis away from the septal wall. This normally only occurs 
when inspiration coincides with either ventricular diastole (Fenster et al., 2013a), or early 
ventricular systole (Strunk et al., 1987). 
 In order to determine if a subject had a PFO, a technique called saline contrast 
echocardiography was utilized. This involved the placement of an intravenous catheter 
(refer to Subject Instrumentation) in the antecubital fossa, which was attached to an 
extension set and a three-way stopcock. Two 10 ml syringes were attached to the 
stopcock. One syringe contained 3 ml of sterile saline, while the other contained 1 ml of 
air. The contents of these two syringes were vigorously agitated for ~10 sec, which 
created a suspension of microbubbles that were then injected into a peripheral vein, while 
the solution was being agitated, the heart was visualized in the apical, four-chamber view, 
which allowed simultaneous visualization of the right and left side of the heart. Within 3-
5 heartbeats after injection, microbubbles were visualized as a “cloud of echoes” in the 
right heart. Microbubbles appearing in the left heart within 3 cardiac cycles of initial 
appearance into the right heart constitute evidence of a PFO (Marriott et al., 2013; 
Fenster et al., 2013a). 
 The timing of when contrast appears in the left side of the heart is important. In 
addition to a PFO, blood flow through intrapulmonary shunts can allow contrast to appear 
in the left heart. However, it has been shown that during resting conditions in humans, 
pulmonary transit time is ~9 sec (Hopkins et al., 1996), which would mean that in a 





contrast could appear in the left heart. Consequently, any left-sided contrast that appears 
within 4 cardiac cycles is strong evidence of a PFO (Fenster et al., 2013a). However, 
contrast that appears after 4 cardiac cycles would not be conclusive evidence of a PFO, 
because this contrast could have travelled through the pulmonary circulation.  
 Since right atrial pressure is generally lower than left sided pressure, saline 
contrast injections were performed under two conditions– normal resting conditions and 
upon the release of a Valsalva maneuver. Utilization of a Valsalva maneuver transiently 
increased right atrial pressure above left atrial pressure, which allowed right-to-left blood 
flow if a PFO existed.  
 Performing a Valsalva maneuver is straightforward. Subjects were instructed to 
take in a small breath of air and then hold their breath for 10-15 seconds while “bearing 
down.” This increased intra-abdominal pressure while reducing blood flow from the 
inferior cava into the right atrium. Once the Valsalva maneuver was released a large, 
transient increase of blood flowed into the right atrium, causing right atrial pressure to 
exceed left atrial pressure. When performing a Valsalva maneuver in an effort to detect 
the presence of a PFO, the saline contrast was injected just prior to release of Valsalva. 
Thus, if a PFO existed, microbubbles would be able to cross the PFO and visualized in 
the left heart. Since correct performance of a Valsalva maneuver is key in detecting a 
PFO, subjects practiced its performance and timing prior to completion of a Valsalva 
maneuver in conjunction with saline contrast echocardiography. Only after the subject 







Lung Function Testing 
 The second phase of the initial screening of subjects was pulmonary function 
testing. These tests were performed to confirm that all subjects had normal pulmonary 
function without indication of lung disease. All tests were conducted according to the 
guidelines established by the American Thoracic Society/European Respiratory Society 
(ATS/ERS) (Macintyre et al., 2005). 
 
Forced Vital Capacity 
 The forced vital capacity (FVC) maneuver measures the maximal amount of air 
that can be exhaled after a maximal inspiration and is performed during a maximal 
expiratory effort. Subject instrumentation consisted of a low-resistance mouthpiece fitted 
over a MedGraphics PreVent pneumotachograph, which was connected to a 
MedGraphics Elite Series Plethysmograph, and a noseclip. For this maneuver, subjects 
were seated at a 90° angle with their feet flat on the floor. Subjects were instructed to 
breathe normally for several breaths. Once normal tidal breathing was established, 
subjects were instructed to exhale until residual volume (RV) was reached. At that point, 
subjects then inspired to total lung capacity (TLC) as rapidly as possible. Once TLC was 
achieved, subjects then exhaled maximally for ~6 sec until attainment of RV. Correct 
performance of this maneuver produces a flow-volume loop, which represents the 
subject’s FVC and provides information about pulmonary function. 
 In addition to the total volume of air expired during this maneuver, the volume of 
air expired during the first second (FEV1) is also an important measure.  The ratio of 





limitation due to some obstruction. This can occur due to some pathological condition 
(i.e. asthma or chronic obstructive pulmonary disease) or with age (Fuhlbrigge et al., 
2006; Vestbo et al., 2011).  
 According to ATS/ERS guidelines, there must be a minimum of 3 trials to ensure 
validity and repeatability. Repeatability is achieved when the difference between the 
largest and second largest FVC and FEV1 is < 0.15 L. Additionally all parameters 
measured during the FVC have predicted values based on the subject’s sex, age, height, 
weight and race. All subjects used in this dissertation had values, specifically FVC, FEV1 
and FEV1/FVC, ≥ 85% of predicted values. 
 
Slow Vital Capacity 
 After completion of the FVC maneuver, subjects performed a slow vital capacity 
(SVC) maneuver. Completion of a SVC is similar to the FVC. Subjects were seated in the 
same manner as the FVC maneuver while performing regular tidal breathing. After 
completion of 4 successive breaths that were similar in size and duration, subjects were 
instructed to inhale to TLC after reaching functional residual capacity (FRC) during 
normal exhalation. Once subjects reached TLC, they relaxed and allowed the elastic 
recoil of the lungs to force out the air. Subjects then exhaled all the way to RV, before 
inspiring back to TLC. Performance of a SVC reduces the rate of small airway collapse, 
which can allow for a value greater than the FVC.  
 





 While spriometric measures like FVC and SVC are clinically useful to identify 
lung diseases, they are unable to provide measures of lung volumes (i.e. TLC, FRC and 
RV), due to the limitations of spriometry. Despite this fact, whole body plethysmography 
can be used to measure thoracic gas volume (TGV) so that RV, FRC and TLC can be 
calculated, and it is considered the gold standard of measurement of TGV. Whole body 
plethysmography utilizes Boyle’s Law: 
P1V1 = P2V2 
Equation 3.1. Boyle’s Law 
This law states that in a closed system under isothermal conditions, the volume-pressure 
product remains constant. During the test, subjects sat in a closed box (i.e. closed system) 
while breathing on a mouthpiece. Within the plethysmograph there were two pressure 
transducers, one that measured mouth pressure where the subject is breathing, and one 
that measured box pressure. Applying this to whole body plethysmography, the volume 
and pressure of the subject’s thoracic cavity is related to the volume and pressure of the 
plethysmograph. Performance of this maneuver begins similarly to that of the SVC, 
however the subject placed their hands on their cheeks to prevent “puffing” of the cheeks, 
which would alter the measurement. After completion of 4 tidal breaths that were of 
similar size and duration, subjects were instructed to pant at a rate of 70-90 breaths per 
minute. These pants were very shallow breaths that corresponded to a specific mouth 
pressure generated by the panting maneuver and box pressure generated by the chest wall 
movement. After panting at the appropriate rate for  ~5 sec, a shutter within the 
mouthpiece apparatus closed, and subjects would continue to pant for 2-3 sec. Once the 





Referring back to Boyle’s Law (Equation 3.1) for box pressure 
PInitialBoxVInitialBox = PFinalBoxVFinalBox 
Where 
VFinalBox = VInitialBox – ΔV 
Therefore 
PInitialBoxVInitialBox = PFinalBox(VInitialBox – ΔV) 
 We can then solve for ΔV, which can be used in combination with the values 
determined using mouth pressure. Therefore, by using Boyle’s Law for mouth pressure 
PInitialMouthVInitialLungs = PFinalMouthVFinalLungs 
Where 
VFinalLungs = VInitialLungs + ΔV 
Therefore 
PInitialMouthVInitialLungs = PFinalMouth(VInitialLungs + ΔV) 
 Taken together, this set of equations allows for determination of VInitialLungs, which 
is the volume at FRC. This value can then be subtracted from expiratory reserve volume 
to determine RV. TLC can then be calculated by adding RV to VC (Levitzky, 2013). 
Repeatability was achieved when at least 2 FRC values were within 5% agreement 
(ATS/ERS). 
Diffusion Capacity for Carbon Monoxide 
 While several methods exist for determining lung diffusion capacity for carbon 
monoxide (e.g. intra-breath, rebreathing and steady-state), our laboratory uses the single-
breath, breath hold technique (Knudson et al., 1987; Macintyre et al., 2005) using a 





upright in the plethysmograph and their feet on the ground. Subjects were instrumented 
with a noseclip while breathing in a normal, relaxed manner through a mouthpiece and 
pneumotachograph that was attached to the plethysmograph. Once there were four 
consecutive breaths that had similar depth and duration, subjects were instructed to 
breathe to RV. During exhalation, the expiratory outlet closed. Once RV was achieved, 
subjects rapidly inhaled to TLC. During this inhalation subjects received gas from a test 
cylinder (21% oxygen, 0.5% neon, 0.3% carbon monoxide, balance nitrogen). After TLC 
was achieved, subjects held their breath for 8 sec, after which the expiratory outlet 
opened and subjects were instructed to exhale rapidly. In order for accurate interpretation 
to be possible, subjects needed to inhale >85% of their predicted vital capacity. This 
exhaled gas was forced through a column of diatomaceous earth, which separates gases 
based on their size, and then analyzed by a gas chromatograph. Neon, which is 
biologically inert, was used as a tracer gas to help determine the initial alveolar carbon 
monoxide fraction and the volume at which carbon monoxide uptake occurs. The 
computer then compared the volume of carbon monoxide delivered and exhaled in order 
to determine the amount of carbon monoxide that diffused from the alveolar air into the 
blood. The volume of diffused carbon monoxide is standardized to the breath hold 
duration (Knudson et al., 1987; Macintyre et al., 2005) and is reported as an absolute 
diffusing capacity (DLCO) and a diffusing capacity relative to alveolar volume 
(DLCO/VA). The DLCO/VA value is used to account for differences in lung volume that 








Core body temperature (Tcore) was measured for Chapters IV, V and VI. There are 
several ways to estimate Tcore (e.g. rectal probe, intestinal pill), but there are limitations 
with each that are dependent upon the subject’s activity (e.g. intensity, duration, etc.) 
(Sawka et al., 2011). However, for the protocols used in the aforementioned chapters, 
esophageal temperature (Tesoph) was used as it approximates the temperature of the left 
ventricle and is much more quick to respond to changes, as compared to rectal or 
intestinal measures of Tcore (Sawka et al., 2011). This was an important factor as all 
protocols were less than 60 minutes and involved rapid temperature changes of up to 
3.0°C in that time.  
For all subjects in Chapters IV, V and VI, Tesoph was a main variable of interest. I 
placed all temperature probes (Mon-a-therm General Purpose Probe, 7fr with Thermes 
USB, Physitemp, Clifton, NJ). Prior to placement of the probe and in an effort to 
eliminate the gag reflex, subjects self-administered 1 ml of 2% Lidocaine gel into the 
nostril the probe was going to be placed, which anesthetized the nasal sinus cavity and 
the back of the throat. Two to three minutes after the lidocaine administration, subjects 
were seated in an upright position and then instructed to look up toward the ceiling. The 
probe was then placed into the nasal cavity and advanced until the tip of the probe was 
visualized in the back of the throat. Subjects were then provided a cup of water and a 
straw and were instructed to take and swallow small sips of water through the straw. The 
probe was advanced when the subject swallowed and this process continued until the 
esophageal probe was estimated to be at the level of the left ventricle, based on the 





appropriate depth, it was affixed to the subject’s nose for the duration of the study to 
prevent it from being accidentally swallowed. 
 
Peripheral Oxygen Saturation and Heart Rate 
 For Chapters IV and V, heart rate (HR) and peripheral estimates of arterial 
oxygen saturation were recorded with a forehead pulse oximeter (Nellcor N600x, 
Covidien, Dublin, Ireland) and a finger pulse oximeter was used for Chapter VI 
(ADInstruments, MLT 321, Colorado Springs, CO). These data were recorded 
continuously by the metabolic data acquisition system. The pulse oximetry system was 
composed of an infrared light emitting diode (LED) and a red light LED. The forehead 
pulse oximeter and finger pulse oximeter was placed directly over the pupil and on the 
index finger, respectively, in an effort to estimate arterial hemoglobin saturation. The 
wavelengths of the infrared (940 nm) and red (660 nm) lights are reflected differently, 
dependent on whether or not the hemoglobin molecule is bound with oxygen. Under 
normal, resting conditions ~97% of hemoglobin is bound with oxygen (HbO2) and ~2% 
of hemoglobin is bound with carbon monoxide (HbCO). While HbO2 and HbCO are 
different molecules, the pulse oximeter interprets both as oxygenated hemoglobin. 
Consequently, pulse oximetry overestimates true arterial oxygen saturation by ~2%. In 
addition to estimating oxygen saturation, the pulse oximeter measures heart rate based on 








 All subjects undergoing the echocardiographic screening, as well as all subjects in 
Chapter VI, had a 3-lead ECG placed to continuously monitor electrical activity of the 
heart. Electrodes were placed on the right clavicle, left iliac crest and left clavicle. This 
electrical activity was displayed and recorded in real-time for the echocardiographic 
screening (Phillips ie33) and the Chapter VI protocol (ADInstruments, Colorado Springs, 
CO). 
 
Dynamic End-tidal Forcing System 
 In Chapter VI, an end-tidal forcing system (DEF) developed by Glen Foster, PhD 
(Querido et al., 2013; Bain et al., 2013; Foster et al., 2014) was utilized in order to 
induce hypoxia and hypercapnia, in a manner that would allow for accurate 
measurements of HVR and HCVR. Swanson and Belville developed the dynamic end-
tidal forcing technique as a way to maintain end-tidal oxygen (PETO2), and carbon 
dioxide (PETCO2) values (Swanson & Bellville, 1975). Prior to that, research examining 
HVR and HCVR had used stepwise changes in oxygen and/or carbon dioxide. An 
inherent flaw with use of a stepwise protocol is that it is difficult to maintain stable 
PETCO2 levels. During poikilocapnic hypoxic exposure, when PaO2 decreases, 
ventilation increases, resulting in less carbon dioxide, thus making it difficult to elucidate 
the actual effect that a specific PaO2 has on ventilatory responses.  
Use of a DEF system allowed PETO2 and PETCO2 values to be maintained at 
specific values, which permitted us to measure the responses to isocapnic and 
poikilocapnic hypoxia, as well as normoxic and hyperoxic hypercapnia. This was 





concentrations of oxygen and carbon dioxide, the gas concentration of the next inspired 
breath was adjusted in an effort to maintain or reach the target values. It must be noted 
that PETO2 and PETCO2 are only estimates of PaO2 and PaCO2, and under some 
conditions end-tidal values significantly differ from direct blood gas measurements, 
possibly due to V/Q mismatch, diffusion limitation, intrapulmonary shunt, intracardiac 
shunt, or even body position (Robbins et al., 1990; Tymko et al., 2015). Since blood 
flowing through a PFO does not go through the pulmonary circulation, it is possible that 
PETO2 and PETCO2 will overestimate and underestimate PaO2 and PaCO2, respectively. 
These differences would likely be magnified in subjects who have the greatest blood flow 
through a PFO. However, utilization of this technique will provide initial insight as to 
whether or not the presence of a PFO affects ventilatory responses during acute exposure 
to hypercapnia and hypoxia. Obtaining PETO2 and PETCO2 for each of these four 
conditions allowed us to determine the individual and combined ventilatory responses of 
the central and peripheral chemoreceptors to hypoxia and hypercapnia. This was 
important as stimulation of one chemoreceptor can affect the gain of the other 
chemoreceptor (See – Literature Review), and we wanted to determine how these 
responses might be affected by the presence or absence of a PFO. 
 The DEF system was used in conjunction with a personal computer that was 
interfaced with an analog-to-digital converter (Powerlab/16SP ML 880; ADInstruments, 
Colorado Springs, CO). Acquisition of the respiratory parameters occurred at 200 Hz and 
data were analyzed using commercially available software (LabChart V7.1, 
ADInstruments, Colorado Springs, CO). During all trials, subjects wore a noseclip while 





rebreathing valve (7900 series, Hans Rudolph, Shawnee, KS). The pneumotachograph 
(HR 800L, Hans Rudolph) and differential pressure amplifier (ML141, ADInstruments, 
Colorado Springs, CO) were calibrated with a 3-liter syringe, 
During each trial, various amounts of N2, O2 and CO2 were administered to the 
pneumotach’s inspiratory port. Independent solenoid valves connected to each of the 
three gases controlled inspired gas composition. After the gas was mixed it was sent 
through a humidifier, before being taken up by the subject. Software designed by Foster 
et al. (Querido et al., 2013; Bain et al., 2013; Foster et al., 2014) operated in conjunction 
with PowerLab, determined the composition of each breath. Expired air was sampled at 
the mouth and allowed to flow through nafion tubing and a desiccant to remove any 
moisture. The volume and gas composition of each breath was determined by previous 
measures of PETO2, PETCO2, tidal volume (Vt), breathing frequency (f), and minute 
ventilation (VE). Based on these values, the end-tidal forcing system adjusted the inspired 
gas composition to bring end-tidal gases to the desired target values. Feed-forward 
control of the inspired gas was based on estimates of baseline metabolic O2 consumption 
and CO2 production and employs the alveolar gas equation (Equation 3.2) to determine 
the required fraction of inspired oxygen (FIO2) and carbon dioxide (FICO2). The DEF 
system prospectively adjusted inspired air to bring end-tidal gas to the desired level. Gas 
control was fine-tuned using a feedback control and error reduction algorithm.  
PAO2 = FIO2 (PATM – PH2O) – PaCO2/RER 
Equation 3.2. Alveolar Gas Equation 
This equation states that the partial pressure of oxygen in the alveoli (PAO2) is 





However, for the studies completed in this dissertation we did not measure arterial blood 
gases, consequently we used end-tidal gases, which as stated before can be significantly 






HIGHER OESOPHAGEAL TEMPERATURE AT REST AND DURING EXERCISE IN 
HUMANS WITH PATENT FORAMEN OVALE 
 This chapter was published in the Journal of Physiology and Chi-Yan A. Ng, 
Sierra D. Hill, Dr. Richard C Padgett and Dr. Andrew T. Lovering are co-authors. I 
performed the experimental work, led the project, and the writing is entirely my own; 
Chi-Yan A. Ng and Sierra D. Hill assisted with data collection; and Dr. Richard C 
Padgett and Dr. Andrew T. Lovering helped develop the protocol, and provided guidance 




 The foramen ovale has been studied for centuries and the scientific community 
has known about the existence of a PFO since the times of Galen (ca 200 AD) (Christie, 
1930; Patten, 1931). Autopsy studies (Hagen et al., 1984; Kerut et al., 2001) and studies 
using saline contrast echocardiography in living humans (Woods et al., 2010; Marriott et 
al., 2013; Elliott et al., 2013) have demonstrated that a PFO is present in a substantial 
proportion of the population with a prevalence of ~25-40% of the population. Individuals 
with a PFO (PFO+) have an opening in the heart that can allow varying degrees of 
cardiac output (Qc) to bypass the respiratory system in otherwise healthy humans. 
Accordingly, blood that circumvents the pulmonary circulation via the PFO will not be 
filtered or undergo gas exchange, and there are certainly consequences that occur as a 





gas exchange efficiency found, surprisingly, that core body temperature (Tcore), measured 
by oesophageal temperature (Toeosph), was higher in PFO+ subjects at maximal exercise 
compared to PFO– subjects.  However the reasons for, and significance of, these findings 
were not determined in that study (Lovering et al., 2011). 
Respiratory system cooling, a well-known function of the lungs and airways, 
occurs via convective and evaporative heat loss at rest and during exercise (Burch, 1945; 
Hanson, 1974). Blood flowing through a PFO would not participate in respiratory system 
cooling and therefore would retain the heat that would otherwise be lost at the level of the 
respiratory system. Thus, in addition to affecting gas exchange and reducing the filtering 
ability of the pulmonary microcirculation, a PFO may also affect other physiological 
measures related to cardiorespiratory physiology, such as Tcore. Additionally, any effect 
of the PFO would likely depend on the size of the opening between the atria. 
 While it is known that a PFO exists in a significant proportion of the population, 
there is little known on the potential impact of this intracardiac shunt on physiological 
processes outside of pulmonary gas exchange. Therefore, the purpose of this study was 
threefold. Our primary purpose was to determine whether or not having a PFO is 
associated with differences in Tcore. Our secondary purpose was to ascertain whether or 
not the predicted size of the PFO is an important determinant in the association of PFO 
with Tcore. Our tertiary purpose was to learn whether or not inhalation of cold and dry air 
influences Tcore responses to exercise in subjects with and without a PFO. It was 
hypothesized that 1) PFO+ subjects would have a higher Toesoph compared to PFO– 
subjects, 2) subjects with large PFOs would have the greatest Toesoph, and 3) compared to 





subjects with large PFOs would increase Toesoph to the same or greater degree whereas 




 This study received approval from the University of Oregon’s Office for 
Protection of Human Subjects. Each subject was given documents outlining the study and 
provided written approval prior to participating in the study. 
 
Participants 
A total of 55 subjects were recruited for participation in this study. Researchers 
described orally, and in writing, the nature of the study to all subjects, who subsequently 
provided their written consent. A total of 30 subjects (15 PFO+, 15 PFO−) qualified and 
completed the entire study. Of the remaining 25 subjects who did not complete the study, 
5 did not pass pulmonary function due to forced vital capacity being less than 85% 
predicted, 3 withdrew before completing the entire protocol for reasons not associated 
with the study (time commitment, etc.), 8 individuals could not tolerate the oesophageal 
probe, 7 individuals had late appearing contrast (>5 cardiac cycles after RV 
opacification) and 3 individuals were identified as PFO+ after 15 PFO+ subjects had 
already completed the study. In total we had a PFO prevalence of 52% which is greater 
than what has been previously reported (Hagen et al., 1984; Kerut et al., 2001; Woods et 
al., 2010; Marriott et al., 2013; Elliott et al., 2013), because some subjects were invited to 





the subjects participating in this study and the study completed by Lovering et al 
(Lovering et al., 2011). Ultimately, 30 (15 PFO+, 15 PFO) healthy, non-smoking male 
volunteers, age 24 ± 5 yr., without history of cardiopulmonary disease were recruited 
and, after written informed consent was given, agreed to proceed with the study. 
 
Ultrasound Screening 
Ultrasound screening has been previously described in detail (Lovering & 
Goodman, 2012). Initial agitated saline contrast studies were performed with subjects 
breathing room air and reclined at 45° in the left lateral decubitus position where a clear 
apical, four-chamber view was obtained. Care was taken to optimally visualize all four 
chambers, interatrial septum and delineate myocardial and valvular structures by 
individually adjusting the receiver gain settings. Each saline contrast injection was 
created by manually agitating 3 ml of sterile saline with 1 ml of room air for 15s between 
two 10 ml syringes connected in parallel to two 3-way stopcocks. The saline–air 
microbubble suspension was then immediately injected in a constant, forceful manner 
into a peripheral antecubital vein via an IV catheter (20–22 G). This mixture of saline and 
air provides excellent right-sided contrast. Following opacification of the right atrium and 
ventricle, the subsequent 20 cardiac cycles were recorded at >30 frames/s for further 
analysis. 
 The appearance of ≥1 microbubble in the left atrium or ventricle in any frame 
during the subsequent 20 cardiac cycles served as the criterion that subjects were either 
positive for an intracardiac right-to-left shunt (i.e. PFO) or demonstrated the 





Marriott et al., 2013; Elliott et al., 2013). Saline contrast injections were performed 
during normal breathing, as well as immediately following the release of a Valsalva 
manoeuvre in order to transiently elevate right atrial pressure and create conditions 
optimal for the detection of an intracardiac right-to-left shunt. Effective Valsalva 
manoeuvres were confirmed by a transient leftward shift of the interatrial septum. 
Valsalva manoeuvres do not increase left heart contrast in the absence of a PFO. An 
intracardiac right-to-left shunt was suspected if microbubbles appeared in the left heart 
≤3 cardiac cycles following right heart opacification. Subsequently, these subjects were 
classified as PFO+, while all others without left sided contrast were categorized as PFO−. 
Using this approach we have shown that we have the sensitivity to accurately detect PFO 
in the general healthy population (Elliott et al., 2013). 
It has recently been demonstrated that the degree of left-sided contrast visualized 
upon release of a Valsalva manoeuvre in PFO+ subjects correlates with the size of the 
PFO (Fenster et al., 2013a). Accordingly, those with more contrast likely have a larger 
PFO compared to those with less contrast. Taking a similar approach to that by Fenster 
and colleagues, in this study, subjects who had ≤12 bubbles upon release of Valsalva 
manoeuvre in the left ventricle in any one frame were classified as having a small degree 
of shunt, while subjects with ≥13 bubbles upon release of Valsalva manuever were 
classified as having a large degree of shunt. During the screening process, within the final 
PFO+ group of 15 subjects, 8 subjects were categorized as having a large degree of shunt 
upon the release of a Valsalva and 7 subjects were categorized as having a small degree 
of shunt upon the release of a Valsalva so there was a nearly equal distribution of large 






Pulmonary Function and Lung Diffusion Capacity 
Prior to the pulmonary function testing, using an electronic scale (Ohaus 
Corporation, ES200L, Pinebrook, NJ) researchers obtained the subject’s weight while 
wearing shorts as well as the subject’s standing and sitting height. Baseline pulmonary 
function testing included measures of forced vital capacity (FVC), forced expiratory 
volume in 1 s (FEV1), and forced midexpiratory flows (FEF25–75). Measurements were 
made with a computerized spirometry system (Ultima PFX, MedGraphics, St. Paul, MN) 
according to American Thoracic Society/European Respiratory Society (ATS/ERS) 
standards (Macintyre et al., 2005). Lung volumes and capacities were determined using 
whole-body plethysmography (Wanger et al., 2005). Lung diffusion capacity for carbon 
monoxide (DLCO) was determined by the single-breath, breath-hold method (Knudson et 
al., 1987; Macintyre et al., 2005) using the Jones and Meade method for timing and 
alveolar sample collection (MedGraphics Ultima PFX, Breeze v.6.3.006) . Predicted 
values for DLCO were calculated as previously described (Gutierrez et al., 2004). 
 
Exercise Protocols 
Subjects completed three different exercise protocols, each separated by a 
minimum of 48 hours. After obtaining the subject’s weights, experimenters placed the 
oesophageal probe through the nostril to a specified depth beyond the nasal flare based on 
the subject’s sitting height, as before (Mekjavić & Rempel, 1990). Once instrumentation 
was completed, subjects sat on the exercise bike and remained seated in a forward 





breathed through a low-resistance two-way nonrebreathing mouthpiece (model 2400, 
Hans Rudolph, Kansas City, MO), and pneumotachograph (MedGraphics PreVent). This 
inspiratory side of the mouthpiece was connected to a custom made large bore (~5 cm 
diameter) corrugated stainless-steel tube that contained ~8 L of air [designed by Kris 
Johnson and the University of Oregon Scientific Instrument Fabrication and Engineering 
Shop after that previously described (Muller et al., 2011)]. 
 During the first trial (Trial #1), participants completed an incremental cycle to 
exhaustion to measure VO2MAX. Subjects completed the test on an electronically braked 
cycle ergometer (Lode Excalibur Sport). Following the 10-minute pre-exercise period, 
subjects completed a 2 minute warm-up period at 50 W. Immediately after the warm-up 
period, the exercise protocol began with subjects beginning at 75 W. Power output 
increased 25 W every 60 seconds until subjects achieved volitional exhaustion. 
Researchers obtained all measures every 60 seconds during the entire protocol. Measures 
obtained included oesophageal temperature (Toesoph), inspired air temperature (Tinsp), 
expired air temperature (Texp) (Thermes USB, Physitemp, Clifton, NJ) heart rate (HR) 
(Tyco, Nellcor Oximax N-600, Mansfield, MA), predicted arterial saturation 
(SpO2)(Tyco, Nellcor Oximax N-600, Mansfield, MA), rating of perceived exertion for 
lungs and legs (RPEdyspnea and RPEleg discomfort, respectively) (Borg, 1973), oxygen uptake 
(VO2), minute ventilation (VE) (Medgraphics Ultima PFX, Breeze v6.3.006). 
Environmental measures (temperature [Tair], humidity and pressure) were also obtained 
every minute (Davis, Perception II, Hayward, CA).  
 During the remaining two trials (Trials #2 & 3), subjects followed the same pre-





20% of the maximum workload achieved during the VO2MAX test. These two trials were 
designed so that we could examine the effect of respiratory cooling on Tcore whereby 
subjects either breathed ambient air, or cold and dry air. The two conditions were 
randomly assigned for Trials #2 and 3. The exercise protocol consisted of four stages, 
each 150 seconds in duration. These stages were completed at 25, 50, 75 and 90% of the 
maximum power output attained during the first protocol (Table 4.1). Researchers 
obtained the same measures during Trials #2 & 3 as described above for Trial #1. 
However, during the exercise protocol measures were obtained at the midpoint and 
endpoint of each stage. Measures were obtained every 60 seconds during all other phases 
of the experimental trial. For all exercise trials subjects breathed through the large bore 
corrugated stainless-steel tube. During the cold and dry air breathing trial, subjects 
breathed air, which was cooled by immersing the corrugated stainless-steel tube in a –
13.0 ± 4.3 °C (PFO+ –13.5 ± 4.5 °C vs. PFO− –12.5 ± 4.2 °C) saltwater slurry, which 
resulted in an average Tinsp during the course of the entire exercise trial of 2.0 ± 3.5 °C 
(PFO+ 2.0 ± 3.8 °C vs. PFO− 1.9 ± 3.1 °C). However, Tinsp, which had an inverse 
relationship with VE, decreased as workload intensity increased (Table 4.1). 
 
Confounder Controls 
To minimize confounding variability, investigators directed participants to 
maintain their nutrition, hydration, and sleep schedules for each trial. Researchers 
instructed subjects to maintain their physical activity throughout the study to minimize 
changes in aerobic capacity. Participants refrained from physical activity 36 hours before 





Table 4.1. Workload intensity and inspired air temperature during cold air trial 
Intensity  PFO+  PFO–  Overall 
  Workload (Watts) Tinsp (°C)  
Workload 
(Watts) Tinsp (°C)  
Workload 
(Watts) Tinsp (°C) 
25% of Maximum Workload  75 ± 12 4.0 ± 3.5  79 ± 10 3.7 ± 2.5  77 ± 11 3.8 ± 3.0 
50% of Maximum Workload  149 ± 24 2.5 ± 3.4  158 ± 20 2.3 ± 2.5  154 ± 22 2.4 ± 3.0 
75% of Maximum Workload  224 ± 36 0.8 ± 3.4  238 ± 30 0.8 ± 2.9  231 ± 33 0.8 ± 3.1 
90% of Maximum Workload  269 ± 44 –0.8 ± 3.4  285 ± 36 –0.6 ± 3.3  277 ± 40 –0.7 ± 3.3 
Values are mean ± standard deviation. There were no significant differences between groups or workload intensities. 
 
Table 4.2. Environmental conditions 
 Room Temperature (°C) Relative Humidity Barometric Pressure (mm Hg) 
VO2MAX 21 ± 1 37 ± 10 753 ± 4 
Relative Workload – Ambient air 21 ± 1 36 ± 10 753 ± 4 
Relative Workload – Cold and dry air 20 ± 1 36 ± 12 754 ± 3 






Table 4.3. Anthropometric, VO2MAX and pulmonary function data 
 PFO– (n = 15) PFO+ (n=15) Overall (n = 30) 
Age (years) 23 ± 5 24 ± 5 24 ± 5 
Height (cm) 178.4 ± 5.6 176.3 ± 5.1 177.4 ± 5.4 
Weight (kg) 76.0 ± 9.1 78.2 ± 9.6 77.1 ± 9.3 
BSA (m2) 1.94 ± 0.13 1.95 ± 0.14 1.95 ± 0.13 
Maximal watts 317 ± 40 298 ± 49 308 ± 45 
VO2MAX (mlkg-1min-1) 50.3 ± 6.9 46.0 ± 7.2 48.1 ± 7.2 
FVC (L) 5.47 ± 0.52 5.19 ± 0.53 5.33 ± 0.53 
FEV1 (L) 4.51 ± 0.45 4.27 ± 0.52 4.39 ± 0.49 
DLCO (mlmin-1Torr-1) 32.6 ± 3.0 30.5 ± 4.4 31.5 ± 3.9 
Values are mean ± standard deviation. No significant differences between groups. 
 
 
Table 4.4. Respiratory data during VO2MAX trial 
 PFO– (n = 15) PFO+ (n=15) Overall (n = 30) 
Pre-exercise V
t
 (L) 0.84 ± 0.27 0.98 ± 0.34 0.91 ± 0.31 
Pre-exercise RR (br/min) 16 ± 4 15 ± 5 15 ± 4 
Pre-exercise V
E
 (L/min) 12.6 ± 3 13.1 ± 3.2 12.9 ± 3.1 
Pre-exercise SpO2 99 ± 1 99 ± 1 99 ± 1 
    
Max V
t
 (L) 2.49 ± 0.24 2.35 ± 0.36 2.42 ± 0.31 
Max RR (br/min) 53 ± 9 56 ± 9 54 ± 9 
Max V
E
 (L/min) 130.4 ± 23.7 127.7 ± 22.1 129.0 ± 22.5 
Max SpO2 97 ± 2 97 ± 2 97 ± 2 






water the night before and 500 ml the morning of each trial. Participants self-reported 
that they obtained at least 7 hours of sleep the night before each trial. Subjects completed 




All trials were completed in an environment that was 21 ± 1 °C with a relative 
humidity of 13 ± 4 % and a barometric pressure of 753 ± 4 Torr (Table 4.2). 
 
Statistical Analyses & Power Calculation 
The number of subjects required to see a significant difference in the Toesoph 
between PFO+ and PFO– subjects was calculated based on the findings from Lovering et 
al. (Lovering et al., 2011) and unpublished findings. Accordingly, we used the mean 
Toesoph from these two sources (PFO+ 36.8 ± 0.5 vs. PFO– 36.3 ± 0.5), an alpha level of 
0.05 and a power of 0.80 to determine that at least 12 subjects in each group were needed. 
Retrospective calculations from our findings revealed a power of 0.86. 
Researchers analysed data using GraphPad Prism software (v 5.0b). Overall and group 
descriptive statistics (mean, standard deviation, and standard error of the mean) were 
calculated for all test variables. To determine significance between PFO+ and PFO− 
subjects, data were analysed using a two-way mixed ANOVA (PFO x workload) with α = 
.05. In the event of a significant F ratio, specific pairwise differences were examined with 
Bonferroni’s post hoc test. Additional a priori t-tests were also completed. An alpha of 







Lung Function and Maximal Oxygen Uptake 
Anthropometric, pulmonary function, DLco, and VO2MAX data for PFO+ and 
PFO− subjects are presented in Table 4.3. There were no significant differences between 
the two groups, except for pre-exercise HR, which was higher in PFO+ subjects 
compared to PFO–, 72 ± 13 vs. 62 ± 10 (Figure 4.1). Additionally, during the VO2MAX 
trial, PFO+ subjects had a slightly higher HR of ~5 bpm throughout the exercise portion 
(not significant, p = .27, see Appenidx). 
Environmental Conditions and Exercise Intensities 
There were no differences in ambient temperature, relative humidity or 
barometric pressure among the three trials (Table 4.2). There were no significant 
differences in maximum workload achieved during the VO2MAX test between the two 
groups (PFO+ 298 ± 49W vs. PFO– 317 ± 40W). Additionally, there were no differences 
in workload intensity for the relative workload trials (Table 4.1). 
Respiratory Measures and RPE 
Respiratory measures made during pre-exercise and at VO2MAX, including tidal 
volume (Vt), respiratory rate (RR), minute ventilation (VE) and peripheral arterial 
saturation (SpO2) are presented in Table 4.4. There were no significant differences 
between the two groups at any time point measured for Vt, RR or SpO2. During the 
VO2MAX trial, PFO+ subjects had a greater VE than PFO− subjects with specific 
differences occurring at 200 W (Figure 4.2) but no specific differences in VE occurred 
during pre-exercise conditions or at VO2MAX. There were no differences in VE between 






Figure 4.1. Effect of PFO on HR during pre-exercise conditions. Line indicates mean for each group. PFO+ subjects had a higher 




























Figure 4.2. Effect of PFO on VE during VO2MAX test. Values are mean ± standard error. There was a main effect of PFO on VE. 
Specific pairwise differences are indicated by * (p < .05). 




























RPEleg discomfort or RPEdyspnea at any time point during any of the exercise trials 
(data not shown).  
Metabolic Measures 
Metabolic measures made during pre-exercise and at VO2MAX, including oxygen 





are presented in Table 4.4. There were no statistically significant differences between the 
two groups at any time point measured. However, throughout the VO2MAX trial, PFO+ 
subjects had a VO2 that was ~5% slightly greater than PFO– subjects (not significant, p = 
.25, see Appendix).   
Oesophageal Temperature at Rest and During VO2MAX Test 
During the VO2MAX test trial, there was a main effect of PFO on Toesoph, with 
specific pairwise differences occurring at 150, 200 and 250 W (p < .05). Generally, PFO+ 
subjects had a higher Toesoph of ~0.4°C at each time point (Figure 4.3). Between groups, 
there were no differences in the absolute change in Toesoph from pre-exercise conditions (p 
= .36, see Appendix).  
Comparison of Oesophageal Temperature Change Between Relative Workload Trials 
There were no differences in the absolute increase of Toesoph from pre-exercise to 
90% of maximal workload during the ambient air trial between PFO+ (0.8 ± 0.4°C) and 
PFO− subjects (0.9 ± 0.4°C). There were no differences in the absolute increase of Toesoph 
from pre-exercise conditions to 90% of maximal workload when comparing the ambient 
trial to the cold and dry air trial within either group, PFO+ (p = .98) or PFO− (p = .12). 
However, during the cold and dry air trial, Toesoph in PFO+ subjects remained unchanged 
compared to the ambient air trial (Δ = 0.0 ± 0.3°C), whereas PFO− subjects achieved a 
Toesoph during the cold and dry air trial that was ~0.3°C lower than the ambient air trial (Δ 
= –0.3 ± 0.4°C) (Figure 4.4). 
Effect of PFO Size 
There was no effect of PFO size on data listed in Tables 4.1-5.  There was a main 






Figure 4.3. Effect of PFO on Toesoph during VO2MAX test. Values are mean ± standard error. There was a main effect of PFO on 
Toesoph. Specific pairwise differences are indicated by * (p < .05). 
  
































Figure 4.4. Effect of PFO on differences in absolute change of Toesoph during relative workload tests between breathing cold 
and dry air and ambient air. Values are mean responses ± standard error. There was an effect of temperature of PFO occurring 
during the 90% of max workload (p < .05). 



































when comparing large PFO (≥13 bubbles upon release of Valsalva manoeuvre), small 
PFO (≤12 bubbles upon release of Valsalva manoeuvre) or PFO− subjects (Figure 4.5). 
Specific pairwise differences showed that subjects with a large PFO had a significantly 
higher Toesoph than PFO− subjects at 150, 200 and 250 W (p < .05). However, during the 
cold and dry air trial, Toesoph in subjects with a large PFO had a slight increase in Toesoph 
compared to the ambient air trial (Δ = 0.2 ± 0.3°C), while subjects with a small PFO 
achieved a Toesoph during the cold and dry air trial that was ~0.1°C lower than the ambient 
air trial (Δ = –0.1 ± 0.1°C) (Figure 4.6). 
 
Ventilatory Equivalent for Oxygen (VE/VO2) 
There was not a significant interaction or main effect of PFO on VE/VO2 during 
the VO2MAX trial. However, during both relative workload trials there was both a 
significant interaction and main effect for the presence of a PFO on VE/VO2 (p < .05). 
Specific pairwise differences occurred during exercise at 90% of maximum workload 
during both conditions. When ambient air was breathed, the plot for both groups fell 
along the same trajectory (Figure 4.7A). However, during the cold and dry air trial the 
plot for PFO– subjects (Figure 4.7B, closed circles) was left-shifted compared to PFO+ 
subjects (Figure 4.7B, open circles). 
 
Discussion 
In this study we determined that PFO+ subjects have a higher Tcore, as measured 






Figure 4.5. Effect of size of PFO on Toesoph during VO2MAX test. Values are mean ± standard error. There was a main effect of PFO 
size on Toesoph. Significant differences from PFO– are indicated by * (p < .05). 
  

































Figure 4.6. Effect of the size of PFO on differences in absolute change of Toesoph during relative workload tests between 
breathing ambient and cold air. Values are mean responses ± standard error. There was a main effect PFO size on differences in 
Toesoph. Significant differences from PFO– are indicated by * (p < .05).  







































Figure 4.7. Effect of Toesoph on VE/VO2 in PFO+ and PFO– subjects. Panel A shows 
the relationship during the relative workload trial while breathing ambient air. Panel B 
shows the relationship during the relative workload trial while breathing cold and dry air. 
PFO+ subjects did not show any change in the relationship between the two trials, while 
PFO– subjects showed a left shifted curve when breathing cold and dry air. Values are 
mean responses ± standard error.   


































also determined that the difference in Toesoph was associated with the estimated size of the 
PFO. Additionally, the current study suggest that respiratory system cooling was 
impaired during exercise breathing cold and dry air in subjects with a PFO and the impact 
of this impairment was associated with the size of a PFO. 
 
Presence of PFO and Oesophageal Temperature Pre-exercise and During Exercise 
Breathing Room Temperature Air 
 While investigating the effect of a PFO on pulmonary gas exchange efficiency, 
Lovering et al., reported the surprising finding that a small group of PFO+ subjects (n = 
8) had a greater Toesoph at maximal exercise compared to a small group of PFO− subjects, 
(n = 8) (Lovering et al., 2011). In that study, PFO+ subjects tended to have a greater 
Toesoph than PFO– subjects at submaximal exercise intensities, although this was not 
significantly different. Of note, that study was neither well designed nor appropriately 
powered to examine the differences in Tcore between two groups since the primary 
outcome variable in that study was the alveolar-to-arterial oxygen difference. More 
specifically, that study did not control for ambient temperature, studies were conducted at 
different times of day, subjects included men and women, and there were no controls for 
food intake, hydration status, or menstrual cycle, and their study had a relatively small 
sample size (n = 8 PFO+, 8 PFO–). Additionally, in that study only 2 subjects would have 
been classified as subjects with a large PFO based on the reported bubbles scores.  
The present study was primarily interested in Toesoph between PFO+ and PFO– 
subjects. Therefore, we designed the current study to have the appropriate controls and 





PFO– subjects. The current study shows that in thermoneutral conditions pre-exercise and 
during exercise conditions, PFO+ subjects do in fact have a greater Toesoph of ~0.4°C 
compared to PFO– subjects. In addition to showing that PFO+ subjects have a greater 
Toesoph than PFO– subjects, we have also demonstrated that the estimated PFO size is also 
important. Specifically, subjects with a large PFO (≥13 bubbles with release of Valsalva 
manoeuvre) had a significantly higher Toesoph pre-exercise and during exercise than PFO– 
subjects, however there was no difference in Toesoph between subjects with a small PFO 
(≤12 bubbles with release of Valsalva manoeuvre) and PFO– subjects.  
It has been established that exercise increases Tcore (Galloway & Maughan, 1997; 
Maughan et al., 2007; Altareki et al., 2009; Kenefick et al., 2009).  In resting humans 
~70% of the metabolic heat comes from internal organs and viscera whereas during 
exercise ~90% of the metabolic heat comes from exercising muscles (Sawka et al., 2011). 
The heat balance equation states Tcore increases when heat production is greater than heat 
loss. Conversely, Tcore decreases when heat production is less than heat loss. The 
variables in the heat balance equation include metabolic rate, mechanical work, rate of 
radiant and convective heat exchange, rate of conduction and rate of evaporation. Since, 
PFO+ subjects have a higher Toesoph than PFO– subjects, it follows that there are 
differences in these variables between these two populations.  
PFO+ and PFO– subjects maintained the same differences in Toesoph prior to and 
during exercise (Figure 4.3).  Thus, whatever is responsible for the differences in Toesoph 
between subjects with and without a PFO before exercise is not likely changing during 
exercise. One explanation for these findings is differences in respiratory system cooling. 





system via convective and evaporative heat loss (Burch, 1945). Additionally, Hanson 
demonstrated that within the lungs, evaporative heat loss is dependent on Tcore, while 
convective heat loss is dependent on Tcore and Tinsp (Hanson, 1974). Blood flowing 
through the PFO does not go through the pulmonary circulation, and is unable to 
dissipate heat into the airways, thus diminishing the amount of heat that can be lost via 
respiratory system cooling. Since PFO+ subjects may have up to 5% of the cardiac output 
bypass the pulmonary circulation, and PFO– subjects have none of the cardiac output 
circumventing the pulmonary circulation, it is plausible that PFO+ subjects experience up 
to 5% less respiratory system cooling than PFO– subjects. Consequently, PFO– subjects 
might be able to dissipate more heat through respiratory system cooling than PFO+ 
subjects. Although, the present study was not designed in a manner to accurately measure 
the amount of respiratory heat loss, the current data suggest that less respiratory heat loss 
occurs in PFO+ subjects than PFO– subjects when breathing cold and dry air (Figure 
4.6).  
While it was not possible to determine the magnitude of respiratory heat loss 
occurring in each group, it is possible to calculate the increase in temperature that would 
occur when “warm blood” is shunted from the right heart across the PFO and combines 
with “cool blood” entering the left heart from the pulmonary circulation. Assuming that 
5% of the total cardiac output (QTOT) bypasses the pulmonary circulation under resting 
conditions in PFO+ subjects and the temperature gradient from the right side of the heart 
to the left side of the heart was 1°C, then one would predict this would result in Tcore 





Since the loading of oxygen onto haemoglobin and the dissolution of oxygen into 
plasma are exothermic processes (Roughton, 1935; Roughton et al., 1936; Wyman, 
1939), heat is likely produced in the left atrium and ventricle of PFO+ subjects when 
shunted, deoxygenated blood combines with oxygenated blood returning from the 
pulmonary circulation. These processes could result in an increased Tcore. However, it is 
possible that some or all of the heat produced is eliminated by endothermic processes, 
such as the unloading of carbon dioxide from haemoglobin or the evolution of carbon 
dioxide from the blood (Kernohan & Roughton, 1968). Consequently, while it is 
conceivable that the mixing of oxygenated and deoxygenated blood may increase Tcore, it 
is unknown if this actually occurs, and to what extent Tcore would be affected. If Tcore 
were to increase as a result of these processes, PFO– subjects would not increase Tcore in 
this manner, since their entire cardiac output passes through the pulmonary circulation, 
meaning there would be no mixing of oxygenated and deoxygenated blood from the PFO 
in the left atrium and ventricle.  
It is also possible that PFO+ subjects have blunted skin blood flow and/or 
sweating responses to increases in Tcore. However, the present study was not designed in a 
manner that would detect differences in skin blood flow or sweat rate. It must be noted 
that despite differences in Toesoph before exercise, PFO+ subjects were not sweating, 
despite having a Toesoph that was 0.4°C greater. Additionally, there might be differences in 
metabolic rate between PFO+ and PFO– subjects. While there were not significant 
differences, PFO+ subjects had a metabolic rate that was ~4% greater prior to exercise, 





that the higher Toesoph in PFO+ subjects could be attributed to the non-significant 
increases in metabolic rate.    
Thus, while we have shown a ~0.4°C difference in Toesoph between PFO+ and 
PFO– subjects, the design of the present study prevents us from accurately determining 
what is causing this entire difference in Tcore. We can only estimate how much Tcore 
would increase when “warm” shunted blood combines with “cool” blood. While it is 
likely that the shunted blood might account for up to 0.1°C of the Tcore difference 
between PFO+ and PFO– subjects during pre-exercise and exercise conditions breathing 
ambient air, it does not explain all off the differences in Tcore, and there are other likely 
contributors to the observed differences, such as respiratory heat loss, skin blood flow, or 
metabolic differences. Additionally, there may be other unknown factors which could 
cause differences in the ability to store, produce or lose heat, all of which should be 
investigated in subjects with PFO in the future. 
Interestingly, we found that the estimated size of the PFO was associated with the 
differences in Tcore with a larger PFO associated with a higher Tcore than a smaller PFO.  
On the surface, this finding could be explained by the fact that more blood flow can occur 
through a large PFO than through a small PFO (Fenster et al., 2013a), thereby resulting 
in potentially more blood bypassing the respiratory system, which would decrease the 
amount of heat lost through the respiratory system. Accordingly, subjects with a small 
PFO appear to have a physiologically insignificant amount of blood flowing through it, as 
their temperature responses to exercise are more similar to PFO– subjects than PFO+ 





the PFO cannot explain the entire difference in Tcore between these two groups of 
subjects.  
Alternatively, the reason that the foramen ovale fails to close in all subjects is not known.  
Based on our data, it is tempting to speculate that one reason there are differences in 
temperatures associated with PFO size is because higher core body temperatures, or 
something related to the higher core body temperatures, play a role in preventing the 
closure of a PFO.  Accordingly, higher core body temperatures are associated with large 
PFOs and lower core temperatures are associated with smaller PFOs or PFO closure.  
However, this remains to be directly determined and could not be determined by the data 
collected in this study.  
 
Impact of Breathing Cold Dry Air on Core Temperature in Subjects With and Without 
a PFO 
Previous work has demonstrated that breathing cold and dry air reduces the 
increase in temperature that occurs during exercise, demonstrating a significant effect of 
cold air breathing on respiratory system heat loss (Geladas & Banister, 1988). The 
present study showed that during a 10-minute exercise trial breathing cold and dry air, 
subjects with a PFO increased Toesoph by the same amount regardless of Tinsp. However, in 
PFO– subjects Toesoph did not increase as much when breathing cold and dry air compared 
to ambient air (Figure 4.4). As mentioned previously, both Tcore and Tinsp affect 
respiratory convective heat loss. Additionally, there is an inverse relationship between 
Tinsp and respiratory convective heat loss, so more convective heat loss occurs when Tinsp 





airway cooling increases with increasing ventilation and reduced inspired air 
temperatures such that the temperature gradients were 8-9°C greater when breathing 
frigid air (-18.6°C) compared to breathing room temperature air (26.7°C) (McFadden et 
al., 1985). Since 100% of the cardiac output undergoes convective heat loss in the 
airways in PFO– subjects, but not PFO+ subjects, convective heat loss will be greater in 
PFO– subjects while breathing cold and dry air than PFO+ subjects. Although our data 
support this idea, we did not directly measure respiratory system heat loss between our 
subjects. 
When we examined the differences in Toesoph between subjects with and without 
PFO based on the estimated size of the PFO, we found that subjects with a small PFO did 
not increase their Toesoph as much as they did during exercise breathing ambient air when 
breathing cold and dry air (Figure 4.6). Interestingly, the subjects with a large PFO 
actually achieved a greater increase in temperature breathing cold and dry air.  One 
explanation for this increase in temperature in subjects with a large PFO is that breathing 
cold air has been shown to increase sympathetic nerve activity (Heindl et al., 2004), 
which may cause peripheral vasoconstriction and reduced skin blood flow. Thus, 
assuming similar regulation of skin blood flow between those with and without PFO, if 
breathing cold air reduced skin blood flow, the ability to lose heat at the skin would have 
been reduced in both groups equally. Nevertheless, the subjects with a large PFO 
achieved a higher Tcore when breathing cold dry air, whereas subjects with a small PFO 
and without a PFO achieved a lower Tcore. In combination, these data support the idea that 





subjects with the greatest amounts of blood flowing through the lungs, i.e. subjects with 
either a small PFO or no PFO.   
 
Effect of PFO on Minute Ventilation and Ventilatory Equivalent for Oxygen (VE/VO2) 
During the VO2MAX test, PFO+ subjects had a significantly higher VE than PFO– 
subjects, with specific pairwise differences occurring at 200 W. However, there were no 
differences in VE between groups during either of the relative workload trials. Since 
PFO+ subjects had a greater VE at the same absolute workload, it follows they should 
experience more respiratory cooling than PFO– subjects. However, PFO+ subjects had a 
higher Toesoph and there was no difference between groups in how much Toesoph increased 
from pre-exercise conditions. This suggests that, despite having a greater VE, PFO+ 
subjects did not have as much respiratory system cooling as PFO– subjects. 
During the relative workload trials, PFO+ subjects had a greater VE/VO2 than PFO– 
subjects with specific differences found at 90% of maximum workload during both 
conditions. These findings are in line with previous work by done by Sun et al. (Sun et 
al., 2002) which compared healthy controls to two groups of subjects with primary 
pulmonary hypertension: those with right-to-left shunt and without right-to-left shunt. 
With pulmonary hypertension it would be expected that increased right heart pressure 
would facilitate intracardiac shunting across a PFO because of the differences in right and 
left heart atrial pressure gradients favouring right-to-left blood flow across the PFO. 
Accordingly, pulmonary hypertension subjects with intracardiac right-to-left shunt had a 






In the present study, when comparing the ambient and cold and dry air trials 
within PFO+ and PFO– subjects, there was no difference in VE/VO2 between trials for 
either group. However, as stated previously, PFO– subjects had a decreased Toesoph at 
90% of maximal workload while breathing cold and dry air compared to ambient air; 
PFO+ subjects had no such difference. While it has been shown that increased Toesoph 
augments VE/VO2 at rest (Cabanac & White, 1995; White, 2006), our findings suggest 
that PFO+ subjects might have a decreased ventilatory sensitivity to increases in Tcore. 
Consequently, PFO+ subjects might have impaired control of breathing that could result 
in a decreased amount of respiratory system cooling compared to PFO– subjects.  
Ultimately this could also contribute to PFO+ subjects having an elevated Tcore compared 
to PFO– subjects. 
 
Effect of PFO on Heart Rate 
Despite the fact that ~35% of the population has a PFO (Marriott et al., 2013; 
Elliott et al., 2013), we have been unable to find any previous work examining the effect 
of a PFO on HR. It has been established that increased Tcore leads to an augmented HR 
(Cabanac & White, 1995; Minson et al., 1998). Our findings show that during pre-
exercise conditions, PFO+ subjects have a higher HR than PFO– subjects (Figure 4.1). 
However, there were not any significant differences between the two groups during 
exercise (see Appendix). The differences observed pre-exercise might be explained by 
pre-exercise HR to a greater degree by Tcore (Cabanac & White, 1995; Minson et al., 
1998) and metabolic rate (Spurr et al., 1988), while maximal HR during exercise is 





lesser contributions from Tcore or metabolic rate. Data from the present study support 
these findings as significant differences in HR were only found under pre-exercise 
conditions and not during exercise. However, HR was ~5 bpm higher in PFO+ subjects 
than PFO– subjects throughout the entire VO2MAX test.  
Although not statistically significant, PFO+ subjects had a slightly greater pre-
exercise VO2 than PFO– subjects among all three trials (PFO+ 0.40 ± 0.08 vs. PFO– 0.39 
± 0.07). This 4.2% difference in metabolic rate could be attributed to some of the 
differences in Toesoph, since it has been shown that increasing Tcore by ~1.0°C can increase 
metabolic rate by ~10% (Saxton, 1981; Cabanac & White, 1995). An elevated metabolic 
rate would lead to an increased demand for oxygen, which could be compensated for by 
augmenting HR. However, calculating the Q10 effect during pre-exercise conditions for 
both VO2 and HR resulted in values (5.4 and 144.5, respectively) that were well above 
the typical biological values of 2-3, which would be expected for a Q10 effect. Although it 
is likely that increased Toesoph and the resulting changes in VO2 contribute to the greater 
HR seen in PFO+ subjects, it does not fully account for all of these differences. However, 
this study was not designed to detect differences in HR, and it is possible under longer 
duration steady-state exercise conditions that PFO+ subjects might have a significantly 
higher HR than PFO– subjects. During this study, a steady state was not attained during 
any of the exercise protocols, as each workload lasted no more than 2 ½ minutes. 
Therefore, HR was likely increasing at the end of each workload in an effort to match the 
metabolic demand. Consequently, any differences in HR that might exist due to increased 
Toesoph in PFO+ subjects might be masked by HR increasing to help maintain oxygen 





if a PFO has an effect on any measures, such as HR, that would be affected under steady-
state exercise conditions. Consequently, future studies should be designed to determine if 
the presence of a PFO affects HR during steady-state exercise. Of note, the four classic 
indicators of heat acclimitzation are lower heart rate, lower core temperature, reduced 
sweating rate and improved aerobic exercise capacity during heat stress (Sawka et al., 
2011). Interestingly, our PFO+ subjects had a higher core temp and higher HR during 
pre-exercise under thermoneutral conditions suggesting that these subjects have 
characteristics opposite those of subjects who are heat acclimated. 
 
Limitations    
We did not measure differences in sweat rate, skin blood flow, or skin 
temperature between PFO+ and PFO– subjects. Increasing Tcore by ~0.1-0.2°C induces 
sweating (Kenny et al., 1997; 2003). However, during pre-exercise conditions in a 
thermoneutral environment none of the PFO+ subjects in the present study were 
sweating, despite having a Toesoph that was ~0.4°C higher than PFO– subjects. It is 
possible that PFO+ subjects have decreased thermoregulatory responses to increases in 
Tcore. However, another explanation is that both PFO+ and PFO– subjects are maintaining 
Tcore within their own “normal range.” In order to determine if one group or another has 
altered thermoregulatory responses, future research should look at sweat rates and/or skin 
blood flow between PFO+ and PFO– subjects. Additionally, since skin temperature was 
not measured, it was not possible to calculate mean body temperature. Thus, while 
differences in Tcore existed, it is possible that PFO+ and PFO– subjects had the same 





Trials were completed in thermoneutral (~20°C) and dry conditions (relative 
humidity < 40%). The effectiveness of respiratory cooling depends on the temperature 
and humidity of the inspired air (Hanson, 1974). It is possible that if this study was 
conducted in an environment that was not conducive to respiratory heat loss (i.e. hot 
and/or humid environment), that the differences in Tcore between PFO+ and PFO– would 
not be significant. Furthermore, we were unable to accurately measure the amount of 
respiratory heat loss that occurred. Future research should be designed in a manner that 
will allow respiratory heat loss to be quantified. 
Additionally, we measured SpO2, which only estimates SaO2. There were not any 
differences in SpO2, which is not surprising because it is not a sensitive enough measure 
to detect minor differences in arterial saturation that would occur with an ~0.4°C 
difference in Toesoph in subjects breathing room air.  However, SaO2 was not a primary 
outcome variable for this study. 
We classified PFO+ subjects as those with large PFOs and those with small PFOs, 
but we did not directly measure the size of the PFO. We estimated the size of the PFO 
using saline contrast echocardiography to determine the amount of microbubbles that 
were visualized in the left ventricle upon release of a Valsalva manoeuvre, which 
demonstrates the potential for blood flow to occur across a PFO. Knowing the exact size 
of the PFO might have provided us with a better estimate of the potential for blood flow 
across the PFO, because it is possible that the amount of blood flowing through the PFO 
during the release of a Valsalva manoeuvre would be different than what flows across it 
at rest and during exercise, particularly as right and left atrial pressure increase with 





sided contrast correlates with blood flow across the PFO (Fenster et al., 2013a). 
Additionally, the fact that we saw differences between the two groups suggests that our 
size classification is valid in otherwise healthy humans. Nevertheless, conditions might 
exist where subjects with a pathophysiologic condition, such as pulmonary hypertension, 
and a small PFO have more blood flowing across the PFO than otherwise healthy adults 
who have a large PFO due the increased right atrial pressure and resulting pressure 
gradient. Thus, in addition to the size of the PFO, the driving pressure gradient across the 
right and left atrium would also be important in determining the amount of (or potential 
for) blood flow across the PFO. 
 
Summary 
This study has demonstrated that 1) the presence of a PFO is associated with a 
~0.4°C higher Toesoph than PFO– subjects prior to and during a VO2MAX test, 2) the size of 
a PFO is associated with Toesoph where subjects with a large PFO have a greater Toesoph 
than PFO– subjects and subjects with a small PFO, and 3) compared to breathing ambient 
air, when breathing cold and dry air prior to and during exercise, subjects with a large 
PFO increased Toesoph by a greater amount, whereas PFO– subjects and those subjects 
with a small PFO did not increase Toesoph to the same degree. These findings are 
important because PFO+ subjects may be better able to maintain Toesoph when breathing 
cold and dry air during exercise since they appear to lose less heat than subjects without a 
PFO. For this reason, research examining exercise performance in, and/or tolerance to, 
cold and hot environments may want to consider the effect of a PFO on Tcore and 





Tcore. Lastly, while normal Tcore has been generally accepted to be ~37.0°C, there is some 
amount of variability in this measure. The present study has demonstrated that the 







THE EFFECT OF A PATENT FORAMEN OVALE ON THERMOREGULATORY 
AND VENTILATORY RESPONSES TO PASSIVE HEATING AND COOLING 
 This chapter will be submitted to the Journal of Physiology and Madeline W. Hay B.S., 
Alyssa M. Hardin, Dr. Matthew D. White and Dr. Andrew T. Lovering are co-authors. I 
performed the experimental work, led the project, and the writing is entirely my own; Madeline 
Hay B.S., and Alyssa Hardin assisted with data collection and data analysis; and Drs. Matthew 
White and Andrew T. Lovering helped develop the protocol, and provided guidance and editorial 
assistance. All co-authors will formally approve this manuscript prior to submission. 
 
Introduction 
The scientific community has known of the existence of a patent foramen ovale (PFO) 
since the times of Galen (ca 200 AD) (Christie, 1930; Patten, 1931). Autopsy studies (Hagen et 
al., 1984; Kerut et al., 2001) and studies using saline contrast echocardiography in living humans 
(Woods et al., 2010; Marriott et al., 2013; Elliott et al., 2013) have demonstrated that a PFO is 
present in a substantial proportion of the general population with a prevalence of ~25-40%. 
Individuals with a PFO (PFO+) have an opening in the heart that can allow varying degrees of 
cardiac output (Qc) to bypass the respiratory system in otherwise healthy humans. Previous work 
by Davis et al. (Davis et al., 2015) and Elliott et al. (Elliott et al., 2015), who investigated the 
impact of a PFO on both core body temperature (Tcore), and pulmonary gas exchange efficiency 
respectively, have shown that PFO+ subjects have an increased Tcore of  ~0.4°C, decreased gas 
exchange efficiency at rest, and blunted ventilatory acclimatization to 5260 m. While it has been 





environments, it is unknown if the presence of a PFO affects thermoregulatory and ventilatory 
responses to passive cooling and heating.  
Cabanac and White previously demonstrated that thermal hyperpnoea during passive 
body heating occurs when Tcore reaches ~38.5°C (Cabanac & White, 1995). However, it is 
presently unknown if the presence of a PFO affects the magnitude of the ventilatory response or 
the Tcore threshold at which this ventilatory response occurs. Conversely the shivering response 
allows heat liberation from stored macronutrients (Daniels & Baker, 1961; Mekjavić et al., 1991; 
Cheng et al., 1995; Wadhwa et al., 2005). Similar to thermal hyperpnoea, there is variability 
associated with these responses, and it is unknown if presence of a PFO can explain some of this 
variability as it relates to the rate at which Tcore decreases during whole body cooling or the Tcore 
threshold for the initiation of shivering. Therefore, the purpose of this study was fourfold, does 
the presence of a PFO affect 1) the rate at which Tcore increases during passive heating, or 
decreases during passive cooling), 2) the Tcore threshold at which shivering occurs, 3) the Tcore 
threshold at which thermal hyperpnoea occurs, and 4) the magnitude of the increase in VE during 
hyperthermia. It was hypothesized that during passive cooling PFO+ subjects would 1) shiver at 
a higher Tcore than PFO– subjects, and 2) would take longer to reach a critical Tcore than PFO– 
subjects. Additionally, during passive heating PFO+ subjects 1) would reach a critical Tcore 
sooner than PFO– subjects, and 2) would experience thermal hyperpnoea at a higher Tcore 






This study received approval from the University of Oregon's Office for Protection of 
Human Subjects. Each subject was given documents outlining the study and provided written 
approval prior to participating in the study. All experimental procedures were conducted in 
accordance with the Declaration of Helsinki. 
 
Participants 
A total of 41 subjects were recruited for participation in this study. Researchers described 
orally, and in writing, the nature of the study to all subjects. A total of 27 subjects (13 PFO+, 14 
PFO−) qualified and completed the entire study, 7 (4 PFO+) of which participated in a prior 
study looking at the effect of a PFO on oesophageal temperature (Davis et al., 2015). Of the 
remaining 14 subjects who did not complete the study, 4 did not pass pulmonary function due to 
forced vital capacity being less than 85% predicted, 7 withdrew before completing the entire 
protocol for reasons not associated with the study, and 3 subjects could not tolerate the 
placement of an oesophageal probe. In total we had a PFO prevalence of 48% in our subject pool 
which is greater than reported previously (Hagen et al., 1984; Kerut et al., 2001; Woods et al., 
2010; Marriott et al., 2013; Elliott et al., 2013), because some subjects were invited to participate 
that had been previously identified as being PFO+ or PFO−. Additionally, 9 subjects (5 PFO+) in 
this study also participated in the work previously done by Davis et al (Davis et al., 2015). 
Ultimately, 27 (13 PFO+, 14 PFO) healthy, non-smoking male volunteers, age 26 ± 8 yr., 
without history of cardiopulmonary disease were recruited and, after written informed consent 







Ultrasound screening has been previously described in detail (Lovering & Goodman, 
2012). Initial agitated saline contrast studies were performed with subjects breathing room air 
and reclined at 45° in the left lateral decubitus position where a clear apical, four-chamber view 
was obtained. Care was taken to optimally visualize all four chambers, interatrial septum and 
delineate myocardial and valvular structures by individually adjusting the receiver gain settings. 
Each saline contrast injection was created by manually agitating 3 ml of sterile saline with 1 ml 
of room air for 15 s between two 10 ml syringes connected in parallel to two 3-way stopcocks. 
The saline–air microbubble suspension was then immediately injected in a constant, forceful 
manner into a peripheral antecubital vein via an IV catheter (20–22 G). This mixture of saline 
and air provides excellent right-sided contrast. Following opacification of the right atrium and 
ventricle, the subsequent 20 cardiac cycles were recorded at >30 frames/s for further analysis. 
 The appearance of ≥1 microbubble in the left atrium or ventricle in any frame during the 
subsequent 20 cardiac cycles served as the criterion that subjects were either positive for an 
intracardiac right-to-left shunt (i.e. PFO) or demonstrated the transpulmonary passage of contrast 
(Freeman & Woods, 2008; Woods et al., 2010; Marriott et al., 2013; Elliott et al., 2013). Saline 
contrast injections were performed during normal breathing, as well as immediately following 
the release of a Valsalva manoeuvre in order to transiently elevate right atrial pressure and create 
conditions optimal for the detection of an intracardiac right-to-left shunt. Effective Valsalva 
manoeuvres were confirmed by a transient leftward shift of the interatrial septum. Valsalva 
manoeuvres do not increase left heart contrast in the absence of a PFO. An intracardiac right-to-
left shunt was suspected if microbubbles appeared in the left heart ≤3 cardiac cycles following 





were categorized as PFO−. Using this approach we have shown that we have the sensitivity to 
accurately detect PFO in the general healthy population (Elliott et al., 2013). 
 
Pulmonary Function and Lung Diffusion Capacity 
Prior to the pulmonary function testing, using an electronic scale (Ohaus Corporation, 
ES200L, Pinebrook, NJ) researchers obtained the subject’s weight while wearing shorts as well 
as the subject’s standing and sitting height. Baseline pulmonary function testing included 
measures of forced vital capacity (FVC), forced expiratory volume in 1 s (FEV1), and forced 
midexpiratory flows (FEF25–75). Measurements were made with a computerized spirometry 
system (Ultima PFX, MedGraphics, St. Paul, MN) according to American Thoracic 
Society/European Respiratory Society (ATS/ERS) standards (Macintyre et al., 2005). Lung 
volumes and capacities were determined using whole-body plethysmography (Wanger et al., 
2005). Lung diffusion capacity for carbon monoxide (DLCO) was determined by the single-
breath, breath-hold method (Knudson et al., 1987) using the Jones and Meade method for timing 
and alveolar sample collection (MedGraphics Ultima PFX, Breeze v.6.3.006) . Predicted values 
for DLCO were calculated as previously described (Gutierrez et al., 2004). 
 
Protocols 
Subjects completed two different trials, each separated by a minimum of 48 hours, with a 
randomized order. Experimenters placed the oesophageal probe through the nostril to a specified 
depth beyond the nasal flare based on the subject’s sitting height, (Mekjavić & Rempel, 1990) as 
before (Davis et al., 2015). Once oesophageal probe placement was completed, nude weight was 





breathing through a low-resistance two-way non-rebreathing valve (model 2400, Hans Rudolph, 
Kansas City, MO), and pneumotachograph (MedGraphics PreVent) for 15-minutes. At the end of 
the 15-minute period, subjects entered either the hot tub that was filled with water (40.5 ± 0.2°C) 
or the cold tub that was filled with water (19.5 ± 0.9°C), where they remained for the duration of 
the study. At the completion of both trials, nude weight was obtained and then the oesophageal 
probe was removed. Whole body water loss was calculated as the difference in weight before and 
after immersion. Measures including oesophageal temperature (Toesoph), water temperature 
(Twater) (Thermes USB, Physitemp, Clifton, NJ), inspired air temperature (Tinsp), expired air 
temperature (Texp), inspired relative humidity (Huminsp), expired inspired relative humidity 
(Humexp) (Vaisala HMT 337, Boston, MA) heart rate (HR) (Tyco, Nellcor Oximax N-600, 
Mansfield, MA), peripheral arterial saturation (SpO2) (Tyco, Nellcor Oximax N-600, Mansfield, 
MA), rate of oxygen uptake (VO2), rate of carbon dioxide elimination (VCO2), and minute 
ventilation (VE) (Medgraphics Ultima PFX, Breeze v6.3.006) were continuously obtained. 
Thermal sensation (Young et al., 1987) and environmental measures (temperature [Tair], 
humidity and pressure) were obtained every five minutes (Davis, Perception II, Hayward, CA). 
Due to the rapid cooling of air from the mouth to the expired temperature and humidity sensors, 
which were placed in the expired port of the Hans Rudolph non-rebreathing valve, we measured 
air temperature at the mouth in a subset of 5 subjects (2 PFO+). These data were then used to 
create a regression model which was used to estimate expired air temperature at the mouth, 
which would provide a more accurate measure of respiratory heat loss.  
While in the hot tub, subjects sat immersed to the level of the clavicles. Additionally, a 





in the hot tub until one of the following criteria occurred:  1) Toesoph reached 39.5°C, 2) subjects 
had been immersed for 30-minutes, or 3) subjects requested to exit the tub.  
While in the cold tub, subjects were in a reclined position immersed to the level of the 
nipple line. Subjects remained in the cold tub until one of the following criteria occurred: 1) 
Toesoph dropped to 35.5°C, 2) subjects had been immersed for 60-minutes, 3) subjects displayed 
sustained shivering for 5 consecutive minutes as determined by a 25% increase in VO2 (Doufas 
et al., 2003; Wadhwa et al., 2005) or 4) subjects requested to exit the tub. 
 
Confounder Controls 
To minimize confounding variability, investigators directed participants to maintain their 
nutrition, hydration, and sleep schedules for each trial. Participants fasted for 12 hours preceding 
each trial. Similarly, subjects drank 1 L of water the night before and 500 ml the morning of each 
trial. Participants self-reported that they obtained at least 6 hours of sleep the night before each 
trial. Subjects completed trials at the same time ± 1 hour to minimize circadian variability in Tcore 
(Little & Rummel, 1971). 
 
Environmental Conditions 
All trials were completed in an environment that was 24 ± 1 °C with a relative humidity 
of 29 ± 7 % and a barometric pressure of 752 ± 5 Torr (Table 5.1). 
 
Statistical Analyses & Power Calculation 
Data were analysed using GraphPad Prism software (v 5.0b). Overall and group 





for all test variables. To determine significance between PFO+ and PFO− subjects, data were 
analysed using a two-way mixed ANOVA (PFO x Time Point) with α = .05. Since all subjects 
spent differing amounts of time immersed in the hot/cold tubs, data were analysed by comparing 
three specific time points for the cold tub, which were:  1) just prior to immersion, 2) the time at 
which Toesoph was the highest, and 3) the time just prior to when subjects exited the tub. The two 
specific time points analysed during the hot tub trial were 1) just prior to immersion, and 2) the 
time just prior to when subjects exited the tub. Data collected during the first 5 min of cold water 
immersion were not used because of the reflex hyperventilation caused by cold-water immersion 
(Tikuisis et al., 2000).  
An additional two-way mixed ANOVA (PFO x Time Point) with α = .05 was run on 
Toesoph and VE during hot water immersion from subjects who reached ventilatory threshold. For 
this ANOVA the ventilatory threshold was used as a third time point. This time point was 
determined as the instance where the end-tidal partial pressure of carbon dioxide (PETCO2) 
dropped 5 Torr lower than resting values (Lucas et al., 2015). In the event of a significant F ratio, 
specific pairwise differences were examined with Bonferroni’s post hoc test. Additional a priori 
unpaired 2 tailed t-tests were completed for means comparisons. An alpha of .05 was used for 
the level of significance.   
 
Results 
Lung Function  
Anthropometric, pulmonary function, and DLCO, for PFO+ and PFO− subjects are 






Environmental Conditions and Water Temperature 
There were no differences in ambient temperature, relative humidity or barometric 
pressure between the two trials (p > .05, Table 5.1). Additionally, there was no difference in 
ambient temperature, relative humidity or barometric pressure between subject groups for either 
trial (p > .05, Table 5.1). Similarly, there were no differences in water temperature between the 
two groups during the cold tub (PFO+ = 19.6 ± 0.7 °C; PFO– = 19.4 ± 0.8 °C, p > .05) and hot 
tub (PFO+ = 40.5 ± 0.1 °C; PFO– = 40.5 ± 0.0 °C, p > .05) trials. 
 
Core Temperature 
During the cold tub trial, there was an interaction effect between PFO Group and Time (p 
< .05) on Toesoph. Also, there was a main effect of PFO Group on Toesoph with specific differences 
occurring at the pre-immersion, peak Toesoph and final time points. PFO+ subjects had a higher 
Toesoph than PFO– subjects that was ~0.4°C greater both prior to immersion and at peak Toesoph, 
and this difference increased to ~0.7°C at the end of immersion (Figure 1A).  
There were 9 subjects (6 PFO+) who shivered during cold water immersion. In these 
subjects there was no interaction between PFO Group and time, but there was a main effect of 
PFO Group on Toesoph with specific differences occurring at all time points (Figure 1B). Similar 
to the analysis looking at all subjects, shivering PFO+ subjects had a higher Toesoph than shivering 
PFO– subjects of ~0.4°C prior to immersion and at peak Toesoph (see Appendix), that increased to 
~0.5°C at the end of immersion. The onset of sustained shivering occurred at a higher Toesoph in 
PFO+ subjects (36.3 ± 0.3°C) compared to PFO– subjects (35.8 ± 0.1°C, p < .05). 
During the hot tub trial, there was no interaction effect between PFO Group and Time on 





Table 5.1 Environmental conditions for cold water and hot water immersion 
 
Ambient Temperature  
(°C) 
Relative Humidity  
(%) 
Barometric Pressure  
(mm Hg) 
Cold water immersion 23 ± 1 30 ± 8 752 ± 5 
Hot water immersion 23 ± 1 33 ± 6 752 ± 5 
Values are mean ± standard deviation. There were no significant differences among trial days. 
 
 





(n = 14) 
Overall  
(n = 27) 
Age (years) 25 ± 8 26 ± 8 26 ± 8 
Height (cm) 181.6 ± 6.3 179.0 ± 7.5 180.3 ± 6.9 
Weight (kg) 83.1 ± 10.1 80.9 ± 7.8 82.1 ± 9.0 
BSA (m2) 2.04 ± 0.14 2.00 ± 0.13 2.03 ± 0.14 
FVC (L) 5.36 ± 0.86 5.68 ± 0.66 5.53 ± 0.76 
FEV1 (L) 4.34 ± 0.72 4.62 ± 0.65 4.49 ± 0.68 
DLCO (mlmin-1Torr-1) 41.1 ± 6.5 40.8 ± 9.7 41.0 ± 8.0 






Table 5.3. Respiratory and metabolic measures during cold water immersion  





(n = 14) 
Overall  




(n = 14) 
Overall  
(n = 27) 
V
t
 (L) 0.9 ± 0.7 0.7 ± 0.2 0.8 ± 0.5  1.0 ± 0.5 1.0 ± 0.5 1.0 ± 0.5 
RR (br/min) 15 ± 5 17 ± 5 16 ± 5   16 ± 5 14 ± 7 15 ± 6 
V
E
 (L/min) 11.4 ± 4 10.1 ± 1.6 10.8 ± 3.2  14.2 ± 4.1 12.5 ± 3.3 13.4 ± 3.8 
        
VO2 (L/min) 0.35 ± 0.07 0.33 ± 0.06 0.34 ± 0.06  0.50 ± 0.14 0.45 ± 0.12 0.47 ± 0.13 
VCO2 (L/min) 0.31 ± 0.14 0.28 ± 0.05 0.29 ± 0.10  0.41 + 0.11 0.40 ± 0.11 0.41 ± 0.11 
RER 0.86 ± 0.20 0.85 ± 0.09 0.85 ± 0.15  0.84 ± 0.14 0.91 ± 0.10 0.87 ± 0.13 
        
PETO2 (mmHg) 104 ± 7 103 ± 4 103 ± 6  106 ± 8 105 ± 6 106 ± 7 
PETCO2 (mmHg) 40 ± 3 42 ± 2 41 ± 3  40 ± 5 43 ± 5 41 ± 5 
        
HR (bpm) 65 ± 11 70 ± 7 67 ± 9  58 ± 13* 67 ± 18 63 ± 16 
SpO2 (%) 98 ± 1 98 ± 1 98 ± 1  99 ± 0 98 ± 2 99 ± 1 







Table 5.4. Respiratory and metabolic measures during hot water immersion  





(n = 14) 
Overall  




(n = 14) 
Overall  
(n = 27) 
V
t
 (L) 0.8 ± 0.3 0.8 ± 0.2 0.8 ± 0.3   1.4 ± 0.7 1.1 ± 0.6 1.3 ± 0.7 
RR (br/min) 16 ± 6 14 ± 6 15 ± 6  20 ± 8  20 ± 8 20 ± 8 
V
E
 (L/min) 11.2 ± 2.0  9.9 ± 2.4 10.6 ± 2.3  24.1 ± 8.7 19.7 ± 8.0  22.0 ± 8.5 
        
VO2 (L/min) 0.33 ± 0.06 0.32 ± 0.07 0.33 ± 0.07  0.49 ± 0.08 0.48 ± 0.08 0.48 ± 0.08 
VCO2 (L/min) 0.28 ± 0.06 0.27 ± 0.07 0.27 ± 0.06  0.58 ± 0.16 0.52 ± 0.18 0.55 ± 0.17 
RER 0.84 ± 0.07 0.83 ± 0.07 0.83 ± 0.07  1.19 ± 0.28  1.07 ± 0.25 1.13 ± 0.27 
        
PETO2 (mmHg) 104 ± 6 101 ± 4  103 ± 6  122 ± 16 114 ± 9 118 ± 14 
PETCO2 (mmHg) * 39 ± 4 42 ± 4 41 ± 4  32 ± 8* 37 ± 7 34 ± 8 
        
HR (bpm) 63 ± 10  69 ± 10 66 ± 11  113 ± 10 115 ± 17 114 ± 13 
SpO2 (%) 99 ± 1 98 ± 1 98 ± 1  98 ± 2 97 ± 2 97 ± 2 








Figure 5.1. Effect of PFO on Toesoph during cold water immersion. Values are mean ± standard error. There was a main effect of 
PFO on Toesoph when looking at all subjects (Panel A), and when looking at subjects who began to shiver (6 PFO+, 3 PFO–, Panel B). 
Specific pairwise differences are indicated by * (p < .05). 
  

























































Figure 5.2. Effect of PFO on Toesoph during hot water immersion. Values are mean ± standard error. There was a main effect of 
PFO on Toesoph when looking at all subjects. Specific pairwise differences are indicated by * (p < .05). 
 
 

































Figure 5.3. Effect of Toesoph on VE by group during hot water immersion for subjects who reached ventilatory threshold (n = 8 
in each group). Points and bars on figure are mean ± standard error. Values on the top and bottom of each data point in text are mean 
± standard deviation of PETO2 and PETCO2, respectively. * indicates a significant difference in Toesoph between groups, † indicates a 
significant difference in VE between groups, and § indicates significant difference between groups for PETO2 or PETCO2 (p < .05).
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difference occurring prior to hot water immersion (p < 0.05, Figure 2A). Similarly, in the 
16 subjects (8 PFO+) who reached a ventilatory Toesoph threshold, there was no interaction 
effect; however, there was a main effect of PFO Group on Toesoph with specific 
differences occurring at ventilatory threshold (PFO+: 38.7 ± 0.6°C, PFO– 38.1 ± 0.6 °C, 
Figure 3, p < 0.05). 
 
Ventilatory Measures 
During the cold tub and hot trial, there were no main effects of  PFO Group on 
VE, RR, Vt, or PETO2. Similarly, there was no effect of PFO on PETCO2 during cold 
water immersion (p > .05, Tables 5.3). However, there was a main effect of PFO Group 
on PETCO2 during hot water immersion (p < .05, Tables 5.4) 
 
Ventilatory Threshold During Hot Water Immersion 
In the 8/13 PFO+ and 8/14 PFO– subjects who reached ventilatory threshold, 
there was a main effect of PFO Group on Toesoph with specific differences occurring at the 
ventilatory threshold (PFO+: 38.7 ± 0.6°C, PFO–: 38.1 ± 0.6°C, Figure 5.3, p < .05).   
Additionally, in the 8/13 PFO+ and 8/14 PFO– subjects who reached ventilatory 
threshold, there was a main effect of PFO on PETO2 and PETCO2, with specific 
differences occurring at the end of immersion for both measures (p < .05, Figure 5.3,). 
Thus, compared to PFO– subjects, PFO+ subjects had blunted ventilatory responses to 
heat with decreased VE and increased PETCO2. Consequently, it appears that in subjects 





Toesoph, and with a blunted VE response in PFO+ subjects, when compared to PFO– 
subjects. 
 
Heart rate and Oxygen Saturation 
During the cold tub trial, there was an interaction effect between PFO group and 
Time on HR (p < .05). While PFO+ subjects had a trend towards having a higher HR than 
PFO– subjects (p = .07, Table 5.3), there was not a main effect of PFO on SpO2 (p > .05, 
Table 5.3). Moreover, in PFO– subjects only, HR was significantly lower at the end of 
immersion by ~7 bpm compared to prior to immersion (Prior – 65 ± 10 bpm, End – 58 ± 
13 bpm, p < .05, Table 5.3). 
During the hot tub trial, there was not an effect of PFO Group on HR (p > .05, 
Table 5.4), but there was an effect of PFO Group on SpO2 (p < .05, Table 5.4). 
However, there were no specific pairwise differences between PFO and SpO2.  
Thus, it appears that during cold water immersion, compared to PFO– subjects, 
PFO+ subjects trend towards having a higher HR before and during immersion. 
 
Metabolic Measures 
 During the cold tub and hot tub trials, there was no effect of PFO Group on VO2, 
VCO2, or RER (Tables 5.3 and 5.4, p > .05).  
 
Respiratory Heat Loss  
During cold and hot water immersion, there was no effect of PFO Group on CHL, 





Table 5. Respiratory heat loss during cold and hot water immersion 
   Cold water immersion  Hot water immersion 
 
  PFO+  
(n=2) 
PFO–  
(n = 3) 
Overall  
(n = 5) 
 PFO+  
(n=2) 
PFO–  
(n = 3) 
Overall  
(n = 5) 
CHL  Pre-immersion  1.4 ± 0.8 1.7 ± 1.0 1.6 ± 0.8  1.4 ± 0.9 1.7 ± 0.4 1.6 ± 0.5 
 End of immersion  1.7 ± 0.7 1.9 ± 1.2 1.8 ± 0.9  2.4 ± 0.6 4.0 ± 2.6 3.3 ± 2.0 
          
EHL  Pre-immersion  2.8 ± 1.6 3.6 ± 2.1 3.3 ± 1.7  3.0 ± 1.8 3.5 ± 0.7 3.3 ± 1.1 
 End of immersion  3.5 ± 1.5 3.8 ± 2.4 3.7 ± 1.8  5.1 ± 1.2 8.3 ± 5.3 7.0 ± 4.2 
          
Total RHL  Pre-immersion  4.3 ± 2.4 5.3 ± 3.1 4.9 ± 2.6  4.4 ± 2.7 5.2 ± 1.1 4.9 ± 1.6 
 End of immersion  5.3 ± 2.3 5.7 ± 3.5 5.5 ± 2.7  7.5 ± 1.8 12.3 ± 7.9 10.4 ± 6.2 






when adding a correction factor to the expired air temperature for all subjects, there was 
no effect of PFO Group on CHL, EHL or RHL (see Appendix, p > .05). 
 
Thermal Sensation 
There were no differences in thermal sensation between PFO groups prior to 
water immersion in the cold tub (PFO+: 3.9 ± 0.3, PFO–: 3.8 ± 0.3, p > .05) or at the end 
of water immersion (PFO+: 1.5 ± 0.6, PFO–: 1.4 ± 0.8, p > .05). Similarly, there were no 
differences between groups in thermal sensation prior to water immersion in the hot tub 
(PFO+: 4.0 ± 0.1, PFO–: 4.0 ± 0.1, p > .05) or at the end of immersion (PFO+: 7.5 ± 0.5, 
PFO–: 6.9 ± 0.9, p > .05). 
 
Whole Body Water Loss During Hot Water Immersion 
There was a trend for PFO+ subjects to have a lower absolute amount of whole 
body water loss during hot water immersion (PFO+: 0.6 ± 0.2 kg, PFO–: 0.8 ± 0.3 kg, p = 
.06). However, there was a significant difference in the percentage of total body weight 
lost (PFO+: 0.7 ± 0.2 %, PFO–: 1.0 ± 0.3%, p < .05). Similarly, there was a trend for 
PFO+ subjects to lose less water weight per hour than PFO– subjects (PFO+: 1.5 ± 0.6 
kg/hour, PFO–: 1.9 ± 0.7 kg/hour, p = .10). 
 
Immersion Duration and Rate of Temperature Change 
There was no effect of PFO Group on the amount of time spent in the cold tub 





rate of temperature change between groups during cold water immersion (PFO+: –0.014 
± 0.010°C/min, PFO–: –0.006 ± 0.008°C/min, p < .05). Nevertheless, there was not a 
difference in rate of temperature change when comparing the 6/13 PFO+ and 3/14 PFO– 
shivering subjects (PFO+: –0.020 ± 0.017°C/min, PFO–: –0.008 ± 0.009°C/min, p > .05).  
When comparing all subjects there was no effect of PFO Group on the amount of 
time spent in the hot tub (PFO+: 24 ± 5 min PFO–: 25 ± 6 min, p > .05), or in the rate of 
temperature change between groups (PFO+: 0.11± 0.02°C°C/min, PFO–: 0.10 ± 
0.02°C/min, p > .05). 
 
Discussion 
In this study we determined that during both cold water and hot water immersion, 
PFO+ subjects had a higher Toesoph before immersion and maintained this higher Toesoph 
throughout immersion. Furthermore, during hot water immersion, in the subjects that 
reached ventilatory threshold for thermal hyperpnoea (8/13 PFO+, 8/14 PFO–), PFO+ 
subjects reached ventilatory threshold at a higher Toesoph and had blunted ventilatory 
responses when compared to PFO– subjects. These findings suggest that PFO+ subjects 
regulate and defend a higher Tcore than PFO– subjects.  
 
Presence of a PFO and Oesophageal Temperature During Cold Water Immersion 
 We recently showed that PFO+ subjects have a greater Toesoph of ~0.4°C (Davis et 
al., 2015). However, it was unknown if differences existed in the thermoregulatory 
responses to passive cooling. The present study aimed to determine if the presence of a 





demonstrated that PFO+ subjects have a greater Toesoph by ~0.4°C prior to cold water 
immersion, and this difference in Toesoph is maintained throughout immersion. While there 
was a difference in the Toesoph at which shivering occurred, the small number of subjects 
(PFO+: 6/13 vs. PFO–: 3/14) means this study is underpowered to definitively make that 
conclusion.  
 PFO+ and PFO– subjects maintained the same differences in Toesoph of ~0.4°C 
prior to cold-water immersion and after peak Toesoph was reached during cold-water 
immersion. However, in looking at the final measure made before subjects exited the tub, 
PFO+ subjects had a greater Toesoph than PFO– subjects by ~0.7°C.  These findings are 
likely explained in part by the difference in the Tcore threshold at which sustained 
shivering occurs between the two groups and the variability that exists in this response. 
Only 9/27 subjects experienced 5-minutes of sustained shivering, which demonstrates 
variability in the shivering Tcore threshold. Furthermore, 4 PFO– subjects had Toesoph  drop 
to 35.5°C during 60-minutes of cold water immersion, while none of the PFO+ subjects 
had their Toesoph  drop below 35.9°C. These findings support the notion that there are 
differences in thermoregulatory responses between PFO+ and PFO– groups. It is 
plausible that PFO+ subjects are “defending” a higher Toesoph and thus begin shivering at 
a higher Toesoph than PFO– subjects. However, we are unable to definitively make that 
conclusion. Additionally, there appears to be a difference between groups in heat 
retention. When comparing the 10 subjects (PFO+: 6/13 vs. PFO–: 4/14) that remained 
immersed for 60 minutes, the difference in Toesoph was ~0.4°C through the first 40 
minutes of immersion. However, after 60 minutes of immersion, the difference between 





be due to differences in skin blood flow (Johnson et al., 2014). If PFO+ subjects have 
reduced skin blood flow compared to PFO– subjects, this could limit the amount of 
convective heat loss that occurs, resulting in a greater Tcore. 
 
Presence of a PFO and Oesophageal Temperature During Hot Water Immersion 
 Toesoph was also higher in PFO+ subjects compared to PFO– subjects during hot 
water immersion. Furthermore, when comparing the three main time points of interest 
which were pre-immersion, ventilatory threshold, and the end of immersion, there was an 
effect of PFO Group on Toesoph. This finding was driven in part due to the ventilatory 
threshold occurring at a greater Toesoph in PFO+ subjects (38.7 ± 0.6°C) compared to 
PFO– subjects (38.1 ± 0.6°C, Figures 2A and 4).  When looking at all subjects, the Toesoph 
where ventilatory threshold occurred is similar to the ~38.5°C  reported by Cabanac and 
White (Cabanac & White, 1995), but lower than ~38.9°C that was given by Lucas et al.) 
(Lucas et al., 2015). A possible explanation for the differences between those studies and 
the present study is that this study included an equal number of PFO+ and PFO– subjects, 
and the other studies did not determine if subjects had a PFO. As a result, it is plausible 
that there was an equal distribution of PFO+ and PFO– subjects in the study completed 
by Cabanac and White, as the average ventilatory threshold Toesoph of all subjects in the 
present study is the same as their study. Similarly, the study completed by Lucas et al. 
might have had a higher prevalence of PFO+ subjects, which could explain the higher 
Toesoph at which ventilatory threshold they reported.  
 Despite the differences in Toesoph where ventilatory threshold occurred, the 





was similar, which is in line with findings from our previous work (Davis et al., 2015). In 
that study during thermoneutral conditions and while breathing ambient air, PFO+ 
subjects had a greater Toesoph by ~0.4°C prior to and after a 10-minute exercise bout. 
 
Presence of a PFO and Ventilation During Cold Water Immersion 
 It has been previously been shown that PFO+ subjects had a greater VE during a 
VO2MAX test (Davis et al., 2015). However, in this study there were no differences in VE 
during the cold tub trial. These findings are unsurprising as VE was not different in the 
previous study until the start of exercise. Furthermore, it has been shown that with the 
exception of an initial hyperventilation during the first minute, VE does not significantly 
increase above rest until shivering occurs (Hayward & Eckerson, 1984). Thus, we would 
expect VE to remain fairly constant until sustained shivering occurred. When looking at 
subjects who did shiver, there were no differences in VE between PFO+ and PFO– 
subjects (p > .05, data not shown). 
 
Presence of a PFO and Ventilation During Hot Water Immersion 
Similar to cold tub immersion, there was no main effect of PFO on VE during hot 
water immersion when looking at all subjects. However, when looking at the subjects 
who reached ventilatory threshold, PFO+ subjects had a lower VE at the end of 
immersion than PFO– subjects by ~10 L/min (Figures 5.2B and 5.5). While the 
ventilatory responses to hyperthermia have been shown to be variable (Cabanac & White, 
1995; Lucas et al., 2015), some of this variability appears to be linked to the presence of 





that PFO+ subjects defend a higher Tcore than PFO– subjects. This argument is further 
strengthened when taken in combination with PFO+ subjects beginning to shiver at a 
higher Toesoph than PFO– subjects.  Additionally, these findings support the idea that 
PFO+ subjects not only defend a higher Tcore than PFO– subjects, which is evidenced by 
a blunted ventilatory response to increased Tcore. Results from the present study include a 
blunted ventilatory response to heat stress, while previous research has shown a blunted 
ventilatory response after 16 d of exposure to high altitude (Elliott et al., 2015). While the 
reason for these blunted ventilatory responses are unknown, it appears the presence of a 
PFO plays an important role. One possible explanation for this blunted ventilatory 
response to heat might be that PFO+ subjects operate at a higher Tcore and thus they have 
a shifted response to an increased Tcore. 
 
Presence of a PFO and Respiratory Heat Loss During Cold Water Immersion 
 In a subset of subjects, during cold-water immersion there were no differences in 
convective, evaporative or total respiratory heat loss. RHL is affected by VE, 
inspired/expired air temperature and humidity Since this study was designed to prevent 
differences in Tinsp, and Huminsp, and we have previously shown no difference in resting 
VE between PFO+ and PFO– subjects, the only way we would have seen differences in 
RHL would require differences in Texp and/or Humexp. The fact there weren’t any 
differences in Texp and Humexp resulted in there being no differences in RHL prior to, and 
during cold-water immersion.   
 





 We have previously suggested that PFO+ subjects have less respiratory heat loss 
than PFO– subjects (Davis et al., 2015). These conclusions were based on the observation 
that during exercise PFO– subjects did not increase Toesoph to the same degree breathing 
cold air that was ~0°C as they did breathing ambient air that was ~20°C. However, 
findings from both parts of the present study suggest there is no difference in RHL 
between PFO+ and PFO– subjects An alternative explanation to the findings from the 
previous study is that inhalation of cold air has been shown to induce peripheral 
vasoconstriction (Muller et al., 2014). Consequently, PFO+ subjects might have had a 
more robust peripheral vasoconstrictor response in the skin than PFO– subjects during 
cold air inhalation, which could have attenuated the amount of heat lost through 
evaporation of sweat, and therefore the changes in Toesoph.  
Although there were no significant differences in RHL during hot water 
immersion, PFO+ subjects who showed a trend towards having a lower RHL prior to and 
at the end of hot water immersion. If there were in fact differences in RHL between 
PFO+ and PFO– subjects, it is possible that the experimental design prevented us from 
seeing these differences, as the Texp that we measured during this study was ~4°C lower 
than expected (Hanson, 1974). Reasons for this low Texp are likely explained by the 
temperature and humidity probes being placed in the expiratory port of the Hans Rudolph 
valve. Thus, the expired air had cooled off significantly from the time it left the mouth. 
Consequently, using 5 subjects (2 PFO+), we developed a regression model to predict the 
Texp at the mouth based on the Texp measured in the expiratory port. This resulted in Texp 
increasing by ~5°C. However, the differences between the two groups in RHL were still 





finding is likely due to the differences in VE. If the average VE for PFO– subjects was 
substituted for the actual VE measured in PFO+ subjects, the difference in RHL was 
negligible. Thus, it appears that the differences in Toesoph are likely due in large part to 
other factors such as differences in skin blood flow or circulating factors such as 
pyrogens that are known to increase Tcore (Dinarello, 1999). 
 
Presence of a PFO and Heart Rate During Cold Water Immersion 
 Although there were no differences in HR, PFO+ subjects had a HR that was ~9-
13 bpm greater in PFO– subjects at all time points. While not significant, these findings 
are similar to those of Davis et al., who showed differences in HR prior to exercise 
between PFO+ and PFO– subjects (Davis et al., 2015). It has been well established that 
increased Tcore augments HR (Cabanac & White, 1995; Minson et al., 1998). Since PFO+ 
subjects have a higher Toesoph (Lovering et al., 2011; Davis et al., 2015), it is unsurprising 
that PFO+ subjects trend towards a higher HR. Another possible contributing factor is 
that PFO+ subjects likely have a lower partial pressure of oxygen and higher partial 
pressure of carbon dioxide in the arteries than PFO– subjects, as blood flowing through a 
PFO does not undergo gas exchange. Ultimately this would result in decreased oxygen 
content. Assuming equal cardiac output between the two groups, PFO+ subjects would 
have decreased oxygen delivery. However, this decreased oxygen content in PFO+ 
subjects could be overcome by increasing cardiac output via increased HR, which would 
increase oxygen delivery. 
  





 Similar to the cold-water immersion, there were no differences in HR between 
PFO+ and PFO– subjects during hot water immersion. However, just as with the cold-
water immersion, PFO+ subjects showed a trend toward an ~6 bpm higher HR prior to 
immersion. The reasons for this trend are the same as those during the cold-water 
immersion, which is that PFO+ subjects have a higher Toesoph, and potentially lower 
arterial partial pressure of oxygen and higher arterial partial pressure of carbon dioxide. 
Furthermore, the increase in HR during hot water immersion can be attributed to the 
increase in Toesoph (Cabanac & White, 1995; Minson et al., 1998) and the increased 
oxygen uptake that occurs with immersion (Mekjavić & Bligh, 1989). However, unlike 
the end of cold-water immersion, at the end of hot-water immersion, PFO+ and PFO– 
subjects approximately had the same HR of ~113 bpm. It is possible that smaller absolute 
change in HR is due to the blunted ventilatory responses demonstrated by PFO+ subjects. 
Since PFO+ subjects have a lower VE at the end of hot water immersion, their respiratory 
muscles would not need as much oxygen as PFO– subjects, resulting in a smaller 
absolute increase in HR during hot water immersion. Conversely, PFO– subjects would 
need to increase oxygen delivery by a greater degree, via augmented cardiac output, to 
provide more oxygen to respiratory muscles that augmented VE. 
Work done by Trinity et al. has demonstrated that during exercise in the heat, 
stroke volume is not limited by increased skin blood flow. Rather, stroke volume is 
attenuated by the reduced filling time which occurs with increased HR (Trinity et al., 
2010). However, it is plausible that during hot water immersion, skin blood flow is 
maximized, which could ultimately decrease stroke volume. This notion is supported by 





skin blood flow, cardiac output, heart rate and stroke volume increased 110%, 44%, 32% 
and 9% respectively  (Bonde-Petersen et al., 1992). It is possible that the dramatic 
increase in skin blood flow caused a significant decrease in stroke volume. Consequently, 
if PFO– subjects have greater skin blood flow than PFO+ subjects, it is possible they 
would also have a smaller stroke volume than PFO+ subjects. Thus, PFO– subjects would 
only be able to maintain cardiac output by increasing HR to a greater magnitude than 
PFO+ subjects. While this notion is plausible, it is presently unknown if the work of 
breathing and/or stroke volume is different between these two groups prior to or during 
hot water immersion.   
 
Presence of a PFO and Water Loss During Hot Water Immersion 
 Unlike cold-water immersion, during hot water immersion there was a significant 
amount of water loss before and after water immersion. Although, there were no 
significant differences in the absolute amount of water loss between the two groups, 
PFO– subjects lost a greater percentage of total body weight during hot water immersion. 
While the measurements do not allow us to determine the core or mean body temperature 
for the onset of sweating, these data suggest that PFO+ subjects 1) begin sweating at a 
higher Toesoph and 2) have a lower sweat rate than PFO– subjects. Previous work has 
shown that sweating begins when Tcore increases by ~0.1-0.2°C (Kenny et al., 1997; 
2003), which would mean subjects in both groups would have begun to sweat within the 
first 5 minutes of water immersion. However, this threshold might also be affected by 
skin temperature and rate of skin temperature change, which might have caused sweating 





sweating rates, this would support the notion that they have blunted thermoregulatory 
responses to increased Toesoph. Furthermore, it is possible that water loss would also be 
increased towards the end of the hot water immersion when ventilation was greatest, as 
more insensible water loss occurs with augmented ventilation (Cox, 1987). Consequently, 
future studies need to be completed to determine if there are differences in the Toesoph at 
which sweating begins, or in sweat rate. 
 
Presence of a PFO and Shivering During Cold Water Immersion 
 In this study 9/27 subjects experienced sustained shivering as measured by a 25% 
increase in metabolic rate for 5 minutes. Out of these 9 subjects, the 6 PFO+ subjects 
began shivering at a higher Toesoph than the 3 PFO– subjects. If all subjects remained in 
the cold tub until they began to shiver the average Toesoph at which shivering occurred 
would be lower. Consequently, the actual Toesoph at which shivering occurred in ~20°C 
water is still unknown. Despite this, both groups showed similar initial responses by 
increasing Toesoph by ~0.2°C during the first 10-15 minutes. However, after the peak 
Toesoph was attained, PFO+ subjects decreased Toesoph by ~0.5°C, while PFO– subjects 
decreased Toesoph by ~0.8°C. This suggests that PFO+ subjects do not lose heat at the 
same rate as PFO– subjects, and further supports the idea that PFO+ subjects defend a 
higher Toesoph and/or are able to maintain Toesoph better during a cold challenge. However, 
shivering is not only influenced by Tcore, but by skin temperature as well (Lopez et al., 
1994; Cheng et al., 1995). Consequently, conclusions made from the present study can 






Limitations    
While PFO+ subjects showed a trend towards a higher HR than PFO– subjects 
prior to immersion, this study was not designed to detect differences in resting HR. There 
is likely a sympathetic response just prior to immersion, which would elevate HR. Future 
studies directed at answering this question should be completed in an environment 
conducive to achieving a true resting HR.  
Additionally, people with a greater amount of subcutaneous fat have more 
insulation, which could prevent them from decreasing Tcore at the same rate as people 
with less fat (Daniels & Baker, 1961). Although we did not measure actual body 
composition, the fact that we did not have any differences between groups in height, 
weight and body surface area (Table 5.2) suggest body composition was similar. 
However, future studies should determine body composition to ensure that the amount of 
subcutaneous fat is not a confounding factor. 
 Finally, we measured sweat rate by taking the difference of weight prior to and 
after water immersion. This will overestimate actual sweat rate due to insensible water 
loss that occurs due to ventilation. Additionally, the measurements made in this study did 
not allow determination of the Tcore threshold for the onset of sweating, and consequently 
it still remains to be determined if the Tcore at which sweating occurs is affected by the 
presence of a PFO. Therefore, future studies should be designed in a manner that allows 







This study has again demonstrated that PFO+ subjects have a greater resting 
Toesoph of ~0.4°C than PFO– subjects. Additionally, we have shown that compared to 
PFO– subjects, PFO+ subjects 1) begin to shiver at a higher Toesoph during cold water 
immersion and 2) have a higher Toesoph prior to and during cold water and hot water 
immersion. Additionally, in subjects who reached ventilatory threshold during hot water 
immersion, PFO+ subjects attained the ventilatory threshold at a greater Toesoph and have a 
blunted ventilatory response. These findings are important because they support the 
notion that PFO+ subjects might be more susceptible to heat related illnesses as they 
might attain a critical Tcore sooner than PFO– subjects when all other things are held 
constant. Although the rate of change of Toesoph was the same in PFO+ and PFO– 
subjects, the difference in resting Toesoph between these two groups could be important as 
it relates to both fatigue and potential cellular damage. PFO+ subjects are hotter than 
PFO– subjects and are therefore closer to a Tcore at which fatigue and/or cellular damage 
could occur. Consequently, it is plausible that PFO+ subjects are more susceptible to heat 
related illnesses than PFO– subjects. 
Similarly, PFO– subjects might be more disposed to experiencing cold related 
illnesses. Based on these findings, research examining exercise performance in hot and 
cold environments may want to consider the effect of a PFO on Tcore and performance. 
Finally, this study further supports the idea that some of the normal biological variability 
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THE EFFECT OF A PATENT FORAMEN OVALE ON ACUTE VENTILATORY 
RESPONSES TO HYPOXIA AND HYPERCAPNIA 
 This chapter will be submitted for publication to the Journal of Physiology and 
Lindsey Boulet, B.S. Alyssa M. Hardin, Alex Chang, Dr. Glen Foster and Dr. Andrew T. 
Lovering are co-authors. I performed the experimental work, led the project, and the 
writing is entirely my own; Lindsey Boulet, Alyssa Hardin, Alex Chang assisted with 
data collection and data analysis; Dr. Glen Foster and Dr. Andrew T. Lovering helped 
develop the protocol, and provided guidance and editorial assistance. All co-authors will 
formally approve this manuscript prior to submission. 
 
Introduction 
 The existence of a patent foramen ovale (PFO) has been known for nearly 2,000 
years (Christie, 1930; Patten, 1931; Aslam et al., 2006). Individuals with a PFO (PFO+) 
have a small tunnel between the right and left atria, which can allow varying degrees of 
cardiac output (Qc) to bypass the respiratory system. Autopsy studies (Hagen et al., 1984; 
Kerut et al., 2001) and studies using saline contrast echocardiography in living humans 
(Woods et al., 2010; Marriott et al., 2013; Elliott et al., 2013) have shown that a PFO is 
present in a substantial proportion of the population with a prevalence of ~25-40%. 
Despite its high prevalence, little work has explored potential effects of a PFO on 
physiology in healthy humans. 
Previous work by our lab has shown there is no difference in resting ventilation in 





after 16 days of exposure to 5260 m, PFO+ subjects showed blunted ventilation 
compared to PFO– subjects, despite PFO+ subjects having a lower arterial partial 
pressure of oxygen (PaO2), higher arterial partial pressure of carbon dioxide (PaCO2), and 
lower arterial oxygen saturation (SaO2). However, there were a disproportionate number 
of females in the PFO+ group, and sex hormones can affect ventilatory responses 
(Schoene et al., 1986; Slatkovska et al., 2006). Consequently, it is possible these findings 
were driven by differences in sex hormones and not the presence of a PFO. Additionally, 
we have shown that in subjects who reached ventilatory threshold for thermal hyperpnoea 
during passive heating, compared to PFO– subjects, PFO+ subjects had blunted 
ventilatory responses (in submission).  
Taken together these studies suggest that PFO+ subjects have blunted ventilatory 
responses compared to PFO– subjects. Presently it is unknown if PFO+ subjects exhibit 
blunted ventilatory responses during acute exposure to isocapnic hypoxia, as well as 
hyperoxic hypercapnia and normoxic hypercapnia, when compared to PFO– controls.  
Therefore, the purpose of this study was fourfold. We wanted to determine if the presence 
of a PFO affects ventilatory responses during acute exposure to 1) poikilocapnic hypoxia, 
2) isocapnic hypoxia, 3) hyperoxic hypercapnia and 4) normoxic hypercapnia. These 
conditions were chosen to isolate differences between central and peripheral 
chemoreceptor sensitivity, as well as the cumulative effect of both. Based on findings 
from Elliott et al. (Elliott et al., 2015) and Davis et al. (in submission), it was 
hypothesized that compared to PFO– subjects, PFO+ subjects would have blunted 







This study received approval from the University of Oregon's Office for 
Protection of Human Subjects. Each subject was given documents outlining the study and 
provided written approval prior to participating in the study. All experimental procedures 
were conducted in accordance of the Declaration of Helsinki. 
 
Participants 
A total of 62 subjects were recruited for participation in this study. Researchers 
described orally, and in writing, the nature of the study to all subjects, who subsequently 
provided their written consent. A total of 31 subjects (16 female) qualified and completed 
the entire study. These 31 subjects included 15 PFO+ subjects (8 female) and 16 PFO– 
subjects (8 female). Of the remaining 31 subjects who did not complete the study, 5 were 
excluded for having poor pulmonary function (forced vital capacity < 85% of predicted), 
11 withdrew before completing the entire protocol for reasons not associated with the 
study (e.g. time commitment, moved out of town, etc.), we were unable to place an 
intravenous catheter in 3 subjects to screen for PFO, 7 had late appearing contrast (i.e. 
contrast appearing after more than 3 cardiac cycles with greater than 4 bubbles appearing 
in the left ventricle), 5 subjects were excluded because their group was already filled (i.e. 
we already had 8 PFO– males). In total we had a PFO prevalence of 46% which is greater 
than what has been previously reported (Hagen et al., 1984; Kerut et al., 2001; Woods et 
al., 2010; Marriott et al., 2013; Elliott et al., 2013), because some subjects were invited to 
participate that had been previously identified as being PFO+ or PFO−, six of which (4 





2015). Ultimately, 31 (15 PFO+) healthy, non-smoking volunteers, age 25 ± 8 yr., 
without history of cardiopulmonary disease were recruited and, after written informed 
consent was given, agreed to proceed with the study. 
 
Ultrasound Screening 
Ultrasound screening has been previously described in detail (Lovering & 
Goodman, 2012). Initial agitated saline contrast studies were performed with subjects 
breathing room air and reclined at 45° in the left lateral decubitus position where a clear 
apical, four-chamber view was obtained. Care was taken to optimally visualize all four 
chambers, interatrial septum and delineate myocardial and valvular structures by 
individually adjusting the receiver gain settings. Each saline contrast injection was 
created by manually agitating 3 ml of sterile saline with 1 ml of room air for 15 s between 
two 10 ml syringes connected in parallel to two 3-way stopcocks. The saline–air 
microbubble suspension was then immediately injected in a constant, forceful manner 
into a peripheral antecubital vein via an IV catheter (20–22 G). This mixture of saline and 
air provides excellent right-sided contrast. Following opacification of the right atrium and 
ventricle, the subsequent 20 cardiac cycles were recorded at >30 frames/s for further 
analysis. 
 The appearance of ≥1 microbubble in the left atrium or ventricle in any frame 
during the subsequent 20 cardiac cycles served as the criterion that subjects were either 
positive for an intracardiac right-to-left shunt (i.e. PFO) or demonstrated the 
transpulmonary passage of contrast (Freeman & Woods, 2008; Woods et al., 2010; 





during normal breathing, as well as immediately following the release of a Valsalva 
manoeuvre in order to transiently elevate right atrial pressure and create conditions 
optimal for the detection of an intracardiac right-to-left shunt. Effective Valsalva 
manoeuvres were confirmed by a transient leftward shift of the interatrial septum. 
Valsalva manoeuvres do not increase left heart contrast in the absence of a PFO. An 
intracardiac right-to-left shunt was suspected if microbubbles appeared in the left heart 
≤3 cardiac cycles following right heart opacification. Subsequently, these subjects were 
classified as PFO+, while all others without left sided contrast were categorized as PFO−. 
Using this approach we have shown that we have the sensitivity to accurately detect PFO 
in the general healthy population (Elliott et al., 2013). 
 
Pulmonary Function and Lung Diffusion Capacity 
Prior to the pulmonary function testing, using an electronic scale (Ohaus 
Corporation, ES200L, Pinebrook, NJ) researchers obtained the subject’s weight while 
wearing shorts as well as the subject’s standing height. Baseline pulmonary function 
testing included measures of forced vital capacity (FVC), forced expiratory volume in 1 s 
(FEV1), and forced midexpiratory flows (FEF25–75). Measurements were made with a 
computerized spirometry system (Ultima PFX, MedGraphics, St. Paul, MN) according to 
American Thoracic Society/European Respiratory Society (ATS/ERS) standards 
(Macintyre et al., 2005). Lung volumes and capacities were determined using whole-
body plethysmography (Wanger et al., 2005). Lung diffusion capacity for carbon 
monoxide (DLCO) was determined by the single-breath, breath-hold method (Knudson et 





(MedGraphics Ultima PFX, Breeze v.6.3.006) . Predicted values for DLCO were 
calculated as previously described (Gutierrez et al., 2004). 
 
Protocols 
Subjects completed four different protocols, 1) hyperoxic hypercapnia, 2) 
normoxic hypercapnia, 3) isocapnic hypoxia and 4) poikilocapnic hypoxia. Each trial was 
separated by a minimum of 40 minutes. The hypercapnic trials were completed prior to 
the hypoxic trials. This was done in an effort to prevent the carry over effect of 
sympoathoexcitation which can occur following hypoxic exposure (Morgan et al., 1995). 
Furthermore, the order of the hypercapnic and hypoxic trials were each randomized.  
 
Respiratory Measurements  
Acquisition of respiratory parameters occurred at 200 Hz using an analog-to-
digital converter (Powerlab/16SP ML 880; ADInstruments, Colorado Springs, CO) 
interfaced with a personal computer. Commercially available software was used to 
analyze ventilatory and cardiovascular variables (LabChart V7.1, ADInstruments, 
Colorado Springs, CO). Subjects breathed through a mouthpiece with a noseclip, a 
bacteriological filter, and a two-way nonrebreathing valve (7900 series, Hans Rudolph, 
Shawnee, KS) during all four trials. Airflow resistance for the breathing apparatus was 
0.80 and 0.73 cm H2O· l-1·sec-1 at flow rates of 1.5 and 3.0 l/sec, respectively. Respired 
gas pressures were sampled at the mouth, dried with nafion tubing, and analyzed for end 
tidal oxygen (PETO2) and end tidal carbon dioxide (PETCO2) (ML206; ADInstruments, 





concentration. Measured PO2 and PCO2 were time corrected for gas analyzer sample 
delay, and the values corresponding to the end of expiration (i.e., when respiratory flow 
crossed zero in the positive to negative direction) were identified as the PETO2 and 
PETCO2. The fraction of inspired oxygen (FIO2) and carbon dioxide (FICO2) delivered to 
the subject for each breath were determined by the dynamic end tidal forcing (DEF) 
system (see below) and recorded in a text file for subsequent analysis. Respiratory flow 
was measured near the mouth using a pneumotachograph (HR 800L, Hans Rudolph, 
Shawnee, KS), and a differential pressure amplifier (ML141, ADInstruments, Colorado 
Springs, CO), which was calibrated with a 3-liter syringe. Total apparatus dead space was 
250 ml.  
 
End-Tidal Forcing  
A portable DEF system controlled PETO2 and PETCO2. This system used 
independent gas solenoid valves for O2, CO2, and N2, which controlled the volume of 
each gas being delivered to the inspiratory reservoir through a mixing and humidification 
chamber. PETO2, PETCO2, tidal volume (Vt), breathing frequency (f), and minute 
ventilation (VE) were determined for each breath using specifically designed software 
(Labview 13.0, National Instruments, Austin, TX). Using feedback regarding PETO2, 
PETCO2, inspired Vt, and expired Vt, the DEF system adjusted the inspirate to bring end-
tidal gas to the desired target values. Feed-forward control of the inspirate was based on 
estimates of baseline metabolic O2 consumption and CO2 production, and employed the 
alveolar gas equation to determine the required FIO2 and FICO2 and fraction of inspired 





physiological stressors (Bain et al., 2013; Tremblay et al., 2014; Tymko et al., 2015; 
2016). End-tidal steady state was defined as the timepoint when PETO2 and PETCO2 
values remained within 1 mmHg of the desired target for 3 consecutive breaths. 
 
Hyperoxic Hypercapnia 
 Baseline values of PETCO2 values were determined after 5-minute of breathing 
room air without aid of the DEF system. The DEF system was then utilized, such that the 
FIO2 and FICO2 were adjusted to maintain PETO2 and PETCO2 at 250 mm Hg and 
baseline values, respectively. Once steady-state was attained, subjects continued to 
breathe that mix of gas for 90 seconds. PETCO2 was then increased in a stepwise fashion 
+3, +6 and +9 mm Hg from baseline. Each step in PETCO2 lasted for 90 seconds after a 
steady state in end-tidal gases was achieved. HCVR was determined by creating 
regression lines for individual subjects of PETCO2 based on the change from baseline 
PETCO2 (0, +3, +6, +9 mmHg) and associated VE. Significance was determined by 
comparing the average group slopes. Although the use of a hyperoxic condition does not 
eliminate all afferent input from the peripheral chemoreceptor, it will reduce peripheral 
chemoreceptor input below that found in normoxic conditions. Thus, the use of this 
protocol allowed us to estimate central chemoreceptor sensitivity, while minimizing 
peripheral chemoreceptor input. For all subjects used in the analysis, the Pearson 







Baseline values of PETO2 and PETCO2 values were determined after 5-minute of 
breathing room air without aid of the DEF system. The DEF system was then utilized, 
such that the FIO2 and FICO2 were adjusted so that PETO2 and PETCO2 were clamped at 
baseline values for both gases. Once steady-state was attained, subjects continued 
breathed that mix of gas for 90 seconds. PETCO2 was then increased in a stepwise fashion 
+3, +6 and +9 mm Hg from baseline. Each step in PETCO2 lasted for 90 seconds after 
attainment of steady state. HCVR was determined as above. For all subjects used in the 
analysis, the Pearson correlation (r) was suitably linear, with r > 0.7.   
 
Isocapnic Hypoxia 
After determining baseline PETO2 and PETCO2 values, the FIO2 and FICO2 were 
adjusted, such that PETO2 and PETCO2 were clamped at 45 mm Hg and resting values, 
respectively. Subjects remained in the hypoxic condition for 20-minutes after steady state 
in end-tidal gases was reached. Time points of interest were baseline and the time at 
which VE was greatest after 5 minutes of hypoxic exposure. The hypoxic ventilatory 
response (HVR) was calculated using two time points – the 60-second average prior to 
administration of the hypoxic mixture, and the 60-second average during hypoxic 
administration where VE was the greatest. HVR was defined as the change in VE divided 
by the change in SpO2. 
 
Poikilocapnic Hypoxia 
Once baseline measures were obtained, the FIO2 was adjusted, such that PETO2 





subjects remained in this hypoxic condition for 20 minutes. Time points of interest were 
baseline and the time at which VE was greatest after 5 minutes of hypoxic exposure. HVR 
was calculated as above. 
 
Statistical Analyses 
Data were analysed using GraphPad Prism software (v 5.0b). Overall and group 
descriptive statistics (mean, standard deviation, and standard error of the mean) were 
calculated for all test variables. To determine significance between PFO+ and PFO− 
subjects, data were analysed using a two-way mixed ANOVA (PFO x time point) with α 
= .05. When determining the HCVR, individual regression lines were calculated based on 
the +3, +6 and +9 time points. An average regression line was calculated for each group, 
and an independent t-test with α = .05 was run on the average slope.  
To calculate HVR, we used an average of the final 15 seconds prior to hypoxic 
exposure as our baseline. The hypoxic time point was defined as the 15 second average 
with the greatest VE after a minimum of 5-minutes of hypoxic exposure. HVR was 
calculated as the difference in VE between baseline and hypoxic exposure divided by the 
difference in SpO2 between baseline and hypoxic exposure. For all other variables a two-
way mixed ANOVA (PFO x time point) with α = .05 was utilized. 
 
Results 
Anthropometrics and Lung Function  
Anthropometric, pulmonary function, and DLCO data for PFO+ and PFO− 





and PFO– groups (p > .05). However, there were differences between males and females 
in height, weight, FVC, FEV1, and DLCO (Table 6.1) 
 
Hypercapnic Ventilatory Response 
 Figures 6.1 and 6.2 illustrate the group averages during the hyperoxic 
hypercapnia (HH) and normoxic hypercapnia (NH) trials, respectively. During the HH 
trial there were 4 PFO+ (2 male) and 1 PFO– (1 female) subjects that were excluded. 
Similarly, during the NH trial there were 3 PFO+ (1 male) and 3 PFO– (1 male) subjects 
that were excluded. During both trials, PFO+ subjects had a significantly lower HCVR 
than PFO– subjects (p < .05). However, there were no differences in HCVR within each 
group between HH and NH trials (PFO+: 1.24 ± 0.15 L min-1 mmHg-1 vs. 1.23 ± 0.13 L 
min-1 mmHg-1, p > .05; PFO–: 1.80 ± 0.18 L min-1 mmHg-1 vs. 1.77 ± 0.23 L min-1 
mmHg-1, p > .05). 
 
Hypoxic Ventilatory Response 
There was no between group differences (i.e. PFO+ vs. PFO–) in the HVR during 
the isocapnic hypoxia (IH) trial (Figure 6.3) or poikilocapnic hypoxia (PH) trial (Figure 
6.4). However, there was a difference between IH and PH for both groups (PFO+: 1.30 ± 
0.55 L min-1 %SpO2-1, vs. 0.66 ± 0.68 L min-1 %SpO2-1, p < .05; PFO–: 1.26 ± 0.54 L min-







Table 6.1. Anthropometric, and pulmonary function data 
 
 PFO+  
 PFO–  Overall   
 Females n = 8 
Males 
n = 7 
Overall 
n = 15 
 Females 
n = 8 
Males 
n = 8 
Overall 
n = 16 
 Females 
n = 16 
Males 
n = 15 
Overall 
n = 31 
Age (years) 21 ± 1 28 ± 6* 24 ± 5  25 ± 10 28 ± 9 27 ± 9  23 ± 7 28 ± 7 25 ± 7 
Height (cm) 163 ± 8 180 ± 9* 170 ± 11  165 ± 6 180 ± 6* 172 ± 10  164 ± 7 180 ± 7* 171 ± 10 
Weight (kg) 59 ± 8 82 ± 10* 69 ± 14  59 ± 5 82 ± 15* 71 ± 16  59 ± 6 82 ± 12* 70 ± 15 
BSA (m2) 1.6 ± 0.1 2.0 ± 0.2* 1.8 ± 0.2  1.6 ± 0.1 2.0 ± 0.2 1.8 ± 0.2  1.6 ± 0.1 2.0 ± 0.2* 1.8 ± 0.2 
FVC (L) 3.7 ± 0.4 5.5 ± 1.1* 4.5 ± 1.3  3.9 ± 0.5 5.4 ± 0.5* 4.6 ± 0.9  3.8 ± 0.5 5.4 ± 0.8* 4.7 ± 1.1 
FEV1 (L) 3.4 ± 0.3 4.7 ± 0.4* 4.1 ± 0.8  3.3 ± 0.4 4.6 ± 0.3* 4.0 ± 0.7  3.4 ± 0.3 4.6 ± 0.4* 4.0 ± 0.8 
DLCO (mlmin-1Torr-1) 27.0 ± 4.4 45.1 ± 7.9* 36.0 ± 11.2 
 32.1 ± 4.3 39.9 ± 6.7* 36.3 ± 6.9  29.5 ± 5.0 42.3 ± 7.5* 36.1 ± 9.1 
DLCO/VA(mlmin-1Torr-1L-1) 6.0 ± 0.6 6.1 ± 0.4 6.0 ± 0.5 
 6.2 ± 0.5 5.7 ± 0.8 5.9 ± 0.7  6.1 ± 0.5 5.9 ± 0.6 6.0 ± 0.6 







Table 6.2. Ventilatory and cardiovascular measures during hyperoxic and normoxic hypercapnia 
 
    Rest  +3  +6  +9 
   PFO– PFO+  PFO– PFO+  PFO– PFO+  PFO– PFO+ 
Hyperoxic 
Hypercapnia VE (L•min
-1)  16.1 ± 4.8 17.5 ± 4.2 
 
20.0 ± 5.1 19.9 ± 4 
 
25.5 ± 5.3 25.1 ± 5.6 
 
31.9 ± 7.3 28.2 ± 4.0 
 Vt (L)  1.5 ± 0.6 1.4 ± 0.5 
 
1.6 ± 0.5 1.6 ± 0.5 
 
1.8 ± 0.7 1.9 ± 0.5 
 
2.0 ± 0.7 2.0 ± 0.6 
 RR (breaths•min-1)  12.5 ± 4.7 13.2 ± 3.8 
 
13.8 ± 4.9 13.5 ± 3.5 
 
15.3 ± 5.0 14.1 ± 3.5 
 
16.9 ± 5.6 14.8 ± 3.1 
 PETO2 (mmHg)  237.9 ± 29.2 239.9 ± 24 
 
245.5 ± 9.0 234.3 ± 35.2 
 
246.1 ± 3.7 245.2 ± 4.8 
 
245.3 ± 4.1 242 ± 15.5 
 PETCO2 (mmHg)  41.8 ± 3.1 41.7 ± 2.7 
 
45.3 ± 3.2 45.5 ± 3.2 
 
47.9 ± 2.9 48.4 ± 2.6 
 
50.9 ± 2.9 51.2 ± 2.8 
 HR (bpm)  66.4 ± 14.6 65.2 ± 8.0 
 
67.2 ± 14.1 66.1 ± 7.9 
 
69.3 ± 14.8 69.6 ± 9.3 
 
70.9 ± 15 69.1 ± 7.8 
 SpO2 (%)  98.4 ± 1.3 98.3 ± 1.3 
 
98.4 ± 1.9 98.2 ± 1.1 
 
98.5 ± 1.4 98.3 ± 1.1 
 
98.4 ± 1.2 97.9 ± 1.4 
              
              
Normoxic 
Hypercapnia VE (L•min
-1)  14.6 ± 3.9 16.0 ± 5.1  18.9 ± 5.3 19.0 ± 3.2  24.3 ± 6.7 22.5 ± 3.9  29.8 ± 9.5 27.1 ± 5.2 
 Vt (L)  1.4 ± 0.5 1.4 ± 0.6  1.6 ± 0.6 1.6 ± 0.5  1.9 ± 0.8 1.8 ± 0.6  2.1 ± 0.8 2.0 ± 0.7 
 RR (breaths•min-1)  12.1 ± 4.3 12.6 ± 3.3  12.9 ± 4.8 13.0 ± 3.4  14.5 ± 5.2 13.2 ± 3.1  15.3 ± 5.6 14.1 ± 2.8 
 PETO2 (mmHg)  100.6 ± 6.3 99.6 ± 6.9  10.0 ± 4.0 98.6 ± 6.8  100.3 ± 2.7 99.0 ± 5.9  100.1 ± 3.6 98.6 ± 6.3 
 PETCO2 (mmHg)  41.1 ± 3.1 41.9 ± 2.6  44.0 ± 2.8 45.2 ± 2.7  47.2 ± 2.6 48.1 ± 2.1  49.9 ± 2.8 51.0 ± 1.9 
 HR (bpm)  67.9 ± 14.8 65.6 ± 8.7  68.9 ± 14.0 68.2 ± 8.5  71.7 ± 18.3 69.1 ± 9.3  72.7 ± 15.6 70.8 ± 8.7 
 SpO2 (%)  96.6 ± 1.9 96.2 ± 1.6  96.5 ± 2.0 96.3 ± 2.0  96.6 ± 1.5 96.6 ± 1.4  97.2 ± 1.4 97.1 ± 1.3 





Table 6.3. Ventilatory and cardiovascular measures during isocapnic and poikilocapnic hypoxia 
 
  Isocapnic Hypoxia  Poikilocapnic Hypoxia  
  Rest  Max VE  Rest  Max VE  
  PFO– PFO+  PFO– PFO+  PFO– PFO+  PFO– PFO+ 
VE (L•min-1)  12.7 ± 5 11.6 ± 4.7  35.9 ± 11.5 34.4 ± 11.6  12.5 ± 3.6 11.9 ± 4.1  23.3 ± 10.3 22.4 ± 9.4 
Vt (L)  1.2 ± 0.5 1.0 ± 0.4  2.2 ± 0.9 2.1 ± 0.8  1.1 ± 0.4 1.0 ± 0.5  1.9 ± 0.9 1.6 ± 0.9 
RR (breaths•min-1)  11.8 ± 4.5 12.5 ± 2.7  17.7 ± 6.6 17.4 ± 4.4  12.4 ± 4.1 12.8 ± 3.1  13.4 ± 4.7 15.0 ± 4.3 
PETO2 (mmHg)  99.3 ± 4.7 99.4 ± 4.6  43.3 ± 4.5 44.1 ± 4.4  102.0 ± 5.9 101.9 ± 4.8  51.3 ± 5.4 51.5 ± 7.6 
PETCO2 (mmHg)  37.8 ± 3.7 38.2 ± 2.5  40.6 ± 2.9 39.4 ± 3.8  36.0 ± 5.6 38.3 ± 2.9  29.7 ± 9.1 28.5 ± 10.2 
HR (bpm)  62.7 ± 13.4 60.7 ± 8.3  80.4 ± 15.5 82.9 ± 9.3  60.2 ± 12.7 63.5 ± 9  73.0 ± 16.4 76.9 ± 11.5 
SpO2 (%)  97.3 ± 1.7 97.4 ± 1.6  78.6 ± 4.2 78.9 ± 4.6  97.8 ± 1.3 97.3 ± 1.2  79.6 ± 5.4 78.9 ± 4.8 









Figure 6.1 Effect of PFO on HCVR during acute exposure to hyperoxic hypercapnia. Dashed line and open circles represent 
average PETCO2 and VE and the associated regression line for PFO+ subjects. Solid line and filled circles represent average change 
from resting PETCO2 values plotted against VE and the associated regression line for PFO+ subjects. There was a main effect of PFO 
on HCVR during exposure to hyperoxic hypercapnia. * indicates significant difference in slope from PFO+, p < .05. 
  























Figure 6.2. Effect of PFO on HCVR during acute exposure to normoxic hypercapnia. Dashed line and open circles represent 
average PETCO2 and VE and the associated regression line for PFO+ subjects. Solid line and filled circles represent average change 
from resting PETCO2 values plotted against VE and the associated regression line for PFO+ subjects. There was a main effect of PFO 
on HCVR during exposure to normoxic hypercapnia. * indicates significant difference in slope from PFO+, p < .05. 






















Figure 6.3. Effect of PFO on HVR during acute exposure to isocapnic hypoxia. Thick dashed and solid lines represent group 
averages for PFO+ and PFO– subjects respectively. Values are mean ± standard deviation. There was no effect of PFO on HVR 
during exposure to isocapnic hypoxia (p > .05). 
 
  




















Figure 6.4. Effect of PFO on HVR during acute exposure to poikilocapnic hypoxia. Thick dashed and solid lines represent group 
averages for PFO+ and PFO– subjects respectively. Values are mean ± standard deviation. There was no effect of PFO on HVR 
during exposure to poikilocapnic hypoxia (p > .05). 
 
 



















There was no effect of PFO on VE, Vt, RR, PETO2 or PETCO2 during the HH or 
NH trials (p > .05, Table 6.2). Similarly, there was no effect of PFO on VE, Vt, RR, 
PETO2 or PETCO2 during the IH or PH trials (p > .05, Table 3). There was no effect of 
PFO on HR or SpO2 during any of the trials (p > .05, Tables 6.2 and 6.3).  
 
Effect of Biological Sex 
 With the exception of Vt during the IH trial as well as VE and Vt during the PH 
trial, there was no effect of biological sex on any measures for any of the trials (p > .05, 
See Appendix). Despite the differences in VE and Vt, there were no differences in IH 
HVR (Males = 1.4 ± 0.6, Females = 1.2 ± 0.5, p > .05) or PH (Males = 0.8 ± 0.7, Females 
= 0.5 ± 0.3, p > .05). Similarly, there was no effect of biological sex on HVR during the 
IH or PH trials (see Appendix) 
 
Discussion 
In this study we determined that compared to PFO– subjects, PFO+ subjects have 
blunted ventilatory responses to acute normoxic and hyperoxic hypercapnia. However, 
there were no differences in ventilatory responses between PFO+ and PFO– during acute 
hypoxic exposure. These findings suggest that PFO+ subjects have a blunted central 
chemoreflex when compared to PFO– subjects.  
 
Presence of a PFO and Hypercapnic Ventilatory Responses 
 The hypercapnic ventilatory response has been well characterized (Sahn et al., 





increases in carbon dioxide tension cause significant increases in VE. This increase in VE 
is due to an augmentation of both Vt and frequency. However, there is variability within 
this response, as some people are characterized as having a blunted ventilatory response 
to carbon dioxide. We have recently shown in subjects who reached a Tcore threshold for 
thermal hyperpnoea during passive heating, PFO+ subjects have blunted ventilatory 
responses when compared to PFO– subjects (in submission). Furthermore, we have 
shown that during 16 days of exposure to 5260 m, PFO+ subjects had blunted ventilatory 
acclimatization compared to PFO– subjects (Elliott et al., 2015). However, it was 
unknown if PFO+ subjects had blunted ventilatory responses during exposure to acute 
hypercapnia. The present study demonstrated that PFO+ subjects have a blunted 
ventilatory response to acute hypercapnia.  
 Prior to exposure to hypercapnia during hyperoxic and normoxic conditions, there 
were no differences in resting VE or PETCO2 between PFO+ and PFO– subjects. During 
hyperoxic and normoxic hypercapnia, PFO+ subjects had blunted ventilatory responses 
(Figures 6.1 and 6.2).  Since this blunted response only occurred during the hypercapnic 
trials, it follows this is possibly due to a central chemoreflex component. While the 
mechanism behind this blunted response is unknown, it appears that PFO+ subjects have 
decreased sensitivity to CO2. Although we did not detect any differences in resting 
PETCO2 between PFO groups, other studies have demonstrated PFO+ subjects trended 
towards a higher PETCO2 (Davis et al., 2015) or PaCO2 (Lovering et al., 2011; Elliott et 
al., 2015) than PFO– subjects. If PFO+ subjects have a higher PaCO2 of 2-3 mmHg than 
PFO– subjects, as suggested by data from Elliott et al. and Lovering et al. (Lovering et 





higher PaCO2 compared to PFO– subjects. It is also plausible if PFO+ subjects have a 
greater PaCO2 than PFO– subjects, that they have become acclimatized to a PaCO2 and 
have a blunted response for a given increase in PaCO2.  
While findings from this study support the notion that PFO+ subjects have a 
blunted central chemoreflex, they also support the idea that the peripheral chemoreceptor 
is not acutely affected by the presence of a PFO, as there were no differences between 
HCVR during the HH and NH trials within groups. However, the peripheral 
chemoreceptor response during both of these trials would be minimal in healthy 
normoxic humans, since its firing rate does not significantly increase until PaO2 drops 
below 60 mm Hg (Prabhakar & Semenza, 2015). Nevertheless, denervation studies of the 
carotid body have shown a slight decrease in VE at rest in normoxia (Smith et al., 1986; 
Blain et al., 2010). Accordingly, we did see slight, but nonsignificant, differences 
between normoxic and hyperoxic HCVRs in both PFO+ and PFO– groups. 
 
Presence of a PFO and Hypoxic Ventilatory Responses 
 It has been well established that PaO2 is monitored by the peripheral 
chemoreceptor (Prabhakar & Peng, 2004; Prabhakar, 2006; Smith et al., 2010; Prabhakar 
& Semenza, 2015). Under normal resting conditions at sea-level, PaO2 is 100 mm Hg. 
The firing rate of the peripheral chemoreceptor does not significantly increase until PaO2 
drops below ~60 mm Hg (Prabhakar & Semenza, 2015). It is at this point that small 
decreases in PaO2 result in large reductions in SaO2. In an effort to prevent large 
decreases in SaO2, peripheral chemoreceptor firing rate increases when PaO2 decreases 





reduction in the firing rate of the peripheral chemoreceptor, while simultaneously 
increasing SaO2. Thus, the PETO2 utilized for the hypoxia trials in this study was 45 mm 
Hg, which would increase the likelihood that significant differences in VE, if they exist, 
would occur. 
 During IH exposure, VE is regulated by afferent input from the peripheral and 
central chemoreceptors. Completing an IH trial allowed for PaO2 to be reduced, which 
would increase input from the peripheral chemoreceptor, while at the same time afferent 
input from the central chemoreceptor also increases. Similarly, during PH exposure, 
afferent input from the peripheral chemoreceptors will exceed input that occurs during 
normal, resting conditions; however, afferent input from the central chemoreceptor will 
be reduced due to the increase in VE reducing PaCO2. 
While there were differences in HCVR, we did not see any differences in HVR 
during the IH trial. The average HVR that we saw for both groups during IH (PFO+: 1.30 
± 0.55 L min-1 SpO2-1, PFO–: 1.26 ± 0.54 L min-1 SpO2-1) was similar to previous 
research completed in healthy males (Kolb et al., 2004), which suggest there is no 
difference in afferent peripheral input between PFO+ and PFO– groups. Although there 
were differences in HCVR during both hypercapnic trials, there were no differences in 
VE or PETCO2 prior to exposure to acute hypercapnia, with resting afferent central 
chemoreceptor input. Thus, the findings from the hypoxic and hypercapnic trials support 
each other, as well as the notion that the blunted ventilatory responses in PFO+ subjects 
is likely centrally mediated. 
Elliott et al. showed that upon initial ascent to 5260 m there was no effect of PFO 





males and females in each group (PFO+: 63% female, PFO–: 20% female). It is possible 
that the lack of differences seen in that study were caused by this disproportionate 
number of females in the PFO+ group. However, the present study was designed so that 
there were approximately the same proportion of males and females in each group 
(PFO+: 50% female, PFO–: 53% female). Consequently, the present study is better 
designed to determine if PFO has an effect on HVR during acute PH exposure than the 
one completed by Elliott et al. 
Similar to IH, the ventilatory drive to breathe during exposure to PH is regulated 
by afferent input from the peripheral chemoreceptor. However, at the same time that 
peripheral afferent input is increasing, central afferent input is decreasing due to 
decreased PaCO2. This is evident by PETCO2 after PH compared to IH (PFO+: 39.4 ± 3.8 
mm Hg vs. 28.5 ± 10.2; PFO– 40.6 ± 3.0 mm Hg vs. 29.7 ± 9.1 mm Hg). Not 
surprisingly, the HVR for both groups was significantly lower during the PH trial than 
the IH trial (PFO+: 0.66 ± 0.68 L min-1 SpO2-1, PFO–: 0.61 ± 0.35 L min-1 SpO2-1). The 
fact that there were no differences between groups during PH supports work done by 
Elliott et al., which suggested that the presence of a PFO does not affect ventilatory 
responses during initial exposure to 5260 m. In that study SaO2 and PaCO2 values 
decreased by ~20% upon initial exposure to 5260 m. Furthermore, VE increased by ~7 
L/min, which resulted in an HVR of ~0.4. During the PH trial of this study, VE increased 
by ~10 L/min above baseline values during hypoxic exposure, while SpO2 decreased by 
~18%. This resulted in an HVR that was slightly higher than what was seen by Elliott et 
al. These differences are likely explained by the variability that occurs with this measure. 









 It has been shown that female sex hormones can affect ventilatory responses. 
Specifically, ventilation is greatest during the luteal phase when these hormones are their 
highest concentrations (Schoene et al., 1981; Slatkovska et al., 2006). Consequently, it is 
possible that differences in the menstrual cycle might account for some of our findings. 
However, findings reported by Macnutt et al. stated that menstrual cycle phase had no 
effect of HVR (Macnutt et al., 2012).  
 Additionally, it is possible the DEF system induced anxiety in some subjects, as 
resting values for VE were higher than expected. This could have induced a minor 
hyperventilation in subjects, which would have artificially lowered PETCO2. This did not 
appear to occur during the hypercapnic trials, as baseline values were ~40 mmHg for 
both groups. However, it is possible that a minor hyperventilation occurred during the 
hypoxic trials as resting PETCO2 values were ~37 mmHg. Future studies might want to 
allow subjects to have a longer rest period to increase familiarity and decrease anxiety. 
 Furthermore, this study used end-tidal gases as estimates of arterial gases. Tymko 
et al. have recently shown that arterial blood gas values are overestimated by end-tidal 
gas values (Tymko et al., 2015). Since PETO2 and PETCO2 are calculated based on 
expired oxygen and carbon dioxide values, there is no way to account for the blood going 
through the PFO which would decrease PaO2 while increasing PaCO2. Consequently, 





respectively (Tymko et al., 2016). Thus, it is possible that there were differences in PaO2 
and PaCO2 between these two groups that we were unable to detect.  
Finally, PaO2 and PaCO2 in PFO+ subjects are likely affected by the amount of 
blood flowing through a PFO. As the blood flow through a PFO increases, it is plausible 
that PaO2 would decrease while PaCO2 would increase. However, we did not measure 
blood flow through a PFO during this study.  
 
Summary 
This study has demonstrated that PFO+ subjects have blunted ventilatory 
responses to hypercapnia, but not hypoxia. Specifically, we have shown that PFO+ 
subjects have a blunted ventilatory response during acute exposure to hyperoxic and 
normoxic hypercapnia. Additionally, we have shown that there is no difference in 
ventilatory responses between PFO+ and PFO– subjects during acute exposure to 
isocapnic or poikilocapnic hypoxia. While the reason that PFO+ subjects have blunted 
ventilatory responses have yet to be fully elucidated, it appears that there is a centrally 
mediated component, as this study showed differences in HCVR, but not HVR between 
PFO+ and PFO– subjects.  
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 Most research looking at the effect of a PFO on physiological processes has 
focused on clinical populations (i.e. stroke, transient ischemic attack, etc.), and not on 
physiologic processes in a healthy population. Prior to this dissertation, two studies in 
healthy humans had shown that gas exchange and ventilatory acclimatization were 
affected by the presence of a PFO (Lovering et al., 2011; Elliott et al., 2015). In the study 
completed by Lovering et al., the primary finding was that gas exchange efficiency, as 
measured by the AaDO2, was different between PFO+ and PFO– subjects at rest during 
normoxic and hypoxic conditions. An unexpected finding was that PFO+ subjects have a 
higher Tesoph than PFO– subjects. However, proper controls for a thermoregulatory study 
were not implemented, and therefore this study was not designed to find differences in 
Tesoph. Similarly, the work completed by Elliott et al. had an unexpected finding that 
PFO+ subjects had blunted ventilatory acclimatization after 16 days of exposure to 5260 
m.  
The main finding of this dissertation was that the presence of a PFO significantly 
affects physiological responses in otherwise healthy humans, which supports the work 
completed by Lovering et al. and Elliott et al. Specifically, we have shown in Chapters IV 
and V that PFO+ subjects have a Tesoph that is ~0.4 °C higher than PFO– subjects. These 
studies were designed with appropriate controls in place to measure Tesoph including 
subjects coming in fasted, and all trials completed at same time of day. Thus we are 





initially hypothesized that these differences in Tesoph were partially due to decreased 
respiratory heat loss (RHL). However, findings from Chapter V suggest that RHL does 
not play a significant role in the differences in Tesoph. While the reasons for these 
differences have not been elucidated, other plausible explanations include PFO+ subjects 
having a greater concentration of pyrogens, or decreased skin blood flow, which could 
lead to them having a higher Tesoph than PFO– subjects. 
In addition to showing that PFO+ subjects have a Tesoph that is ~0.4 °C higher than 
PFO– subjects, the study in Chapter V also showed that compared to PFO– subjects, 
PFO+ subjects do not cool off as quickly during cold water immersion. However, during 
hot water immersion, PFO+ and PFO– subjects increase Tesoph at the same rate. Taken 
together, results from Chapters IV and V suggest that PFO+ and PFO– subjects operate 
at, and defend, a different Tesoph.  
The main findings from Chapters V and VI demonstrate that PFO+ subjects have 
altered ventilatory responses to heat and acute hypercapnic exposure, respectively. In 
subjects that experience hyperthermia-induced hyperventilation during Chapter V, PFO+ 
subjects increased their ventilation at a higher Tesoph, but not to the same magnitude as 
PFO– subjects. If thermal tachypnea occurs in an effort to dissipate heat, it is plausible 
that PFO+ subjects prefer to be warmer and that PFO– subjects prefer to be cooler, which 
would provide the rationale for the differences in thermoregulation between these two 
groups. Furthermore, the blunted ventilatory responses to heat are likely due to an altered 
hypothalamic response. 
Similarly, during acute exposure to hypercapnic environments, PFO+ subjects had 





sensitivity to carbon dioxide. Since blood flowing across the PFO will increase the 
overall PaCO2 of blood exiting the left side of the heart and entering the systemic 
circulation, it is possible that PFO+ subjects who have a greater resting PaCO2 while 
breathing room air are less sensitive to increases in carbon dioxide since their resting 
PaCO2 could potentially be higher than PFO– subjects (Lovering et al., 2011; Elliott et 
al., 2015). 
While there were differences in HCVR, we saw no differences in ventilatory 
responses during acute exposure to isocapnic or poikilocapnic hypoxia. This was not 
surprising since findings from Elliott et. al showed no differences in HVR between PFO+ 
and PFO– subjects upon initial exposure to 5260 m. Thus, it might be possible that the 
differences, or lack thereof, in acute ventilatory responses to hypercapnia or hypoxia are 
mediated by central chemoreceptors, while the blunted ventilatory acclimatization to 
altitude is primarily mediated by the peripheral chemoreceptor. However, these 
conclusions are speculative at this time.   
 
Summary and Future Directions 
 Existence of a PFO and its high prevalence is not novel. However, despite this 
fact, little research has examined its effect on physiological processes in otherwise 
healthy humans. It has now been confirmed that PFO+ subjects have a higher Tesoph than 
PFO– subjects. However, the mechanism behind this finding has not been completely 
elucidated. It is plausible that these differences can be explained in part by respiratory 
heat loss. However, findings from this dissertation have not shown differences in RHL. 





that is metabolized by the lungs. For example, if there exists a pyrogen that increases Tcore 
which is cleared out in the lungs, it follows that PFO+ subjects would have a higher Tcore, 
since they would metabolize less of this pyrogen. Similarly, PFO+ subjects could simply 
have a higher blood concentration of a pyrogen. Another possibility for this difference in 
Tesoph is that there are differences in heat loss mechanisms between PFO+ and PFO– 
subjects such as skin blood flow. If PFO+ subjects have reduced skin blood flow, this 
would attenuate the amount of heat loss they experience, which would result in a higher 
Tcore. Therefore, future studies need to be designed in a way to accurately measure 
respiratory heat loss, pyrogen concentrations and skin blood flow. 
Interestingly, findings from Chapters IV and V also suggest that PFO+ subjects 
have a greater resting HR than PFO– subjects in thermoneutral environments, as well as 
during cold water immersion. Potential explanations for this finding include increased 
Tesoph or decreased oxygen content. Conversely, the findings from Chapter VI did not 
indicate there were any differences in HR between the two groups. This could be 
explained by the studies completed in Chapters V and VI only had male subjects, while 
the studies completed in Chapter VI had male and female subjects.  
Therefore, the work completed in this dissertation has not provided definitive 
evidence that the presence of a PFO has any effect on HR. Consequently, future studies 
could include those where a true, resting HR is obtained. Findings from this type of study 
could provide strong evidence as to whether or not the presence of a PFO affects HR. 
Similarly, during the first two studies contained in this dissertation, HR was measured 
with a pulse oximeter, which is less accurate than an EKG. Consequently, studies aiming 





Additionally, none of the thermoregulation studies completed for this dissertation 
involved females. Therefore, it is possible that the differences we are seeing only occur in 
males. Although previous research has shown that Tcore only varies by ~0.3°C during the 
menstrual cycle (Pivarnik et al., 1992; Fukuoka et al., 2002; Kuwahara, 2005), it is 
possible the presence of a PFO can affect the difference in Tcore between the luteal and 
follicular phase. Consequently, similar studies done in Chapters IV and V could be 
completed in women while accounting for menstrual cycle.  
 Finally, Chapters IV and V of this dissertation have demonstrated that Tcore as 
measured by Tesoph was greater in PFO+ subjects. While Tesoph is considered to be the 
gold standard measure of Tcore, because it provides an estimate of left ventricle 
temperature, there are other measures of Tcore that can, and should be, utilized. For 
example, rectal temperature, a commonly used analogue of core temperature, was not 
used during any studies of this dissertation. Similarly, as mentioned earlier, research 
comprising this dissertation did not measure skin temperature. Skin temperature in 
conjunction with Tcore can be used to determine whole body temperature. Utilizing all 
these measures can help determine if the effects of a PFO are localized to Tesoph, or if they 
are more systemic.  
The presence of a PFO definitely plays a role in physiological processes in 
healthy humans, as has been demonstrated within Chapters IV-VI. However, the work 
completed within this dissertation has only answered a couple of questions. Accordingly, 
the potential for future research looking at the effects of a PFO is exciting, as there 







HEART RATE DURING VO2MAX TEST 
 
Figure 7.1. Effect of PFO on HR during a VO2MAX test. Dashed and solid lines represent group averages for PFO+ and PFO– 
subjects respectively. Values are mean ± standard deviation. There was no effect of PFO on HR prior to and during a VO2MAX test (p > 
.05). 




















VO2 DURING VO2MAX TEST 
 
Figure 7.2. Effect of PFO on VO2 during a VO2MAX test. Dashed and solid lines represent group averages for PFO+ and PFO– 
subjects respectively. Values are mean ± standard deviation. There was no effect of PFO on VO2 prior to and during a VO2MAX test (p 
> .05). 
  





















CHANGE IN TOESOPH DURING VO2MAX TEST 
 
Figure 7.3. Effect of PFO on change in Toesoph during a VO2MAX test. Dashed and solid lines represent group averages for PFO+ 
and PFO– subjects respectively. Values are mean ± standard deviation. There was no effect of PFO on change in Toesoph during a 




































HEAT OF BLOOD CROSSING PFO 
Blood entering the right atrium has a temperature of 37.5°C;  
Blood crossing the PFO also has a temperature of 37.5°C (TPFO);  
Blood cooled by respiratory system heat loss which enters the left atrium via the pulmonary vein has a temperature of 36.5°C (Tresp),  
Total cardiac output at rest is 5 Lmin-1 (QTOT);  
Blood flow across the PFO is 250 mlmin-1 (QPFO),  
Specific heat of blood is 3.49 kJL-1°C,  
Effect of QPFO on Tcore can then be calculated using the following equation: 
 
Specific heat of QTOT = (3.49 kJQPFO-1TPFO-1) + (3.49 kJ · (QTOT-QPFO) -1Tresp-1) 
(3.49 kJL-1°C0.25 L37.5 °C) + (3.49 kJL-1°C(5.00 – 0.25) L36.5°C) 
(32.72 kJL-1°C) + (605.08 kJL-1°C) 
637.80 kJL-1°C 
 






Toesoph IN SUBJECTS WHO SHIVERED 
 
Figure 7.4. Effect of PFO on Toesoph in subjects who shivered during cold water immersion. Dashed and solid lines represent 
group averages for PFO+ and PFO– subjects respectively. Values are mean ± standard deviation. There was no effect of PFO on 
Toesoph in subjects who shivered prior to and during cold water immersion (p > .05). 





























RESPIRATORY HEAT LOSS DURING COLD WATER IMMERSION 
 
Figure 7.5. Effect of PFO on respiratory heat loss during cold water immersion. 
Dashed and solid lines represent group averages for PFO+ and PFO– subjects 
respectively. Values are mean ± standard deviation. There was no effect of PFO on 
convective heat loss (Panel A), evaporative heat loss (Panel B) or total respiratory heat 
loss (Panel C) during cold water immersion (p > .05). 











































































RESPIRATORY HEAT LOSS DURING HOT WATER IMMERSION 
 
Figure 7.6. Effect of PFO on respiratory heat loss during hot water immersion. 
Dashed and solid lines represent group averages for PFO+ and PFO– subjects 
respectively. Values are mean ± standard deviation. There was no effect of PFO on 
convective heat loss (Panel A), evaporative heat loss (Panel B) or total respiratory heat 
loss (Panel C) during hot water immersion  (p > .05).











































































EFFECT OF BIOLOGICAL SEX DURING ACUTE EXPOSURE TO HYPERCAPNIA AND HYPOXIA 
Table 7.1. Effect of biological sex on ventilatory and cardiovascular measures during acute exposure to hyperoxic and normoxic 
hypercapnia 
 
    Rest  +3  +6  +9 
   Male Female  Male Female  Male Female  Male Female 
Hyperoxic 
Hypercapnia VE (L•min
-1)  14.1 ± 5.3 10.4 ± 2.6  18.3 ± 5.0 15.6 ± 3.3  21.5 ± 4.9 18.7 ± 3.3  27.9 ± 5.8 22.8 ± 3.4 
 Vt (L)  1.3 ± 0.6 0.9 ± 0.3  1.6 ± 0.6 1.3 ± 0.4  1.8 ± 0.6 1.4 ± 0.3  2.1 ± 0.7 1.6 ± 0.3 
 RR (breaths•min-1)  12.2 ± 4.7 12.0 ± 3.7  12.3 ± 4.5 13.4 ± 4.1  13.2 ± 4.6 14.1 ± 4.0  14.5 ± 4.8 14.8 ± 4.1 
 PETO2 (mmHg)  98.5 ± 8.4 96.6 ± 6.1  246.3 ± 13.7 246.2 ± 16.5  244.1 ± 6.8 244.4 ± 9.6  245.7 ± 3.7 245.4 ± 4.8 
 PETCO2 (mmHg)  40.5 ± 4.3 39.2 ± 2.7  42.0 ± 2.8 41.4 ± 3.0  45.9 ± 3.5 44.7 ± 2.8  48.3 ± 2.9 47.7 ± 2.5 
 HR (bpm)  63.2 ± 12.5 66.2 ± 7.2  64.2 ± 14.3 67.9 ± 8.3  64.9 ± 13.5 69.2 ± 8.3  67.5 ± 15 72.2 ± 8.3 
 SpO2 (%)  96.7 ± 3.7 97.2 ± 2.2  98.1 ± 1.2 98.6 ± 1.5  98.4 ± 1.1 98.6 ± 1.2  98.2 ± 1.4 98.6 ± 1.1 
              
              
Normoxic 
Hypercapnia VE (L•min
-1)  14.4 ± 4.1 12.0 ± 5.7  17.0 ± 5.5 13.5 ± 2.4  20.8 ± 4.3 17.1 ± 3.7  25.2 ± 6.2 21.6 ± 4 
 Vt (L)  1.3 ± 0.4 1.0 ± 0.4  1.6 ± 0.7 1.2 ± 0.3  1.8 ± 0.7 1.4 ± 0.4  2.1 ± 0.8 1.6 ± 0.4 
 RR (breaths•min-1)  12.4 ± 5.4 12.1 ± 3.6  12.1 ± 4.4 12.6 ± 3.3  12.4 ± 3.7 13.5 ± 4.5  13.3 ± 4.5 14.4 ± 4.1 
 PETO2 (mmHg)  102.2 ± 13.7 99.5 ± 5.5  99.1 ± 7.5 101.0 ± 5.3  99.1 ± 6.7 100.5 ± 4.3  99.4 ± 5.6 100.0 ± 3.4 
 PETCO2 (mmHg)  38.8 ± 3.4 39.9 ± 2.6  42.1 ± 3.1 40.9 ± 2.4  45.1 ± 2.8 44.0 ± 2.7  48.1 ± 2.1 47.1 ± 2.7 
 HR (bpm)  63.0 ± 13.1 68.4 ± 12  63.2 ± 10.1 70.3 ± 13.0  64.9 ± 9.5 72.1 ± 12.2  65.8 ± 10.5 74.9 ± 16.5 
 SpO2 (%)  97.4 ± 1.4 98.0 ± 1.2  96.1 ± 1.9 96.7 ± 1.6  96.5 ± 1.8 96.3 ± 2.2  96.3 ± 1.5 96.9 ± 1.3 





Table 7.2. Effect of biological sex on ventilatory and cardiovascular measures during isocapnic and poikilocapnic hypoxia 
 
  Isocapnic Hypoxia  Poikilocapnic Hypoxia  
  Rest  Max VE  Rest  Max VE  
  Males Females  Males Females  Males Females  Males Females 
VE (L•min-1)  14.5 ± 4.9 10.0 ± 3.3  37.4 ± 13.6 32.9 ± 8.0  13.9 ± 4.2 10.6 ± 2.5*  27.2 ± 11.5 18.5 ± 4.7* 
Vt (L)  1.3 ± 0.6 0.9 ± 0.3*  2.6 ± 1.0 1.7 ± 0.2*  1.3 ± 0.6 0.9 ± 0.2*  2.3 ± 1.0 1.3 ± 0.3* 
RR (breaths•min-1)  12.7 ± 3.4 11.8 ± 4.1  15.6 ± 5.2 19.7 ± 5.1  12.3 ± 3.6 12.9 ± 3.7  12.9 ± 3.7 15.6 ± 4.9 
PETO2 (mmHg)  98.4 ± 4.3 100.5 ± 4.6  45.3 ± 3.0 42.1 ± 5.0  102.8 ± 6.2 101.2 ± 4.3  64.4 ± 40.3 48.9 ± 5.5 
PETCO2 (mmHg)  38.6 ± 2.1 37.2 ± 3.9  39.8 ± 3.9 40.2 ± 2.8  35.6 ± 5.5 38.7 ± 2.7  26.5 ± 10.9 31.7 ± 7.2 
HR (bpm)  61.0 ± 13.5 64.3 ± 8.8  78.3 ± 13.6 86.4 ± 10.7  60 ± 12.6 67.1 ± 16.7  70.3 ± 14.0 79.2 ± 13.3 
SpO2 (%)  96.6 ± 1.6 98.2 ± 1.3  78.8 ± 3.7 78.3 ± 5.1  97.2 ± 1.3 97.9 ± 1.2  79.2 ± 5.3 79.3 ± 5.0 







Figure 7.7. Effect of biological sex on HCVR.   Filled symbols and solid lines represent average change from resting PETCO2 values 
plotted against VE and the associated regression line for female subjects. Open symbols and dashed lines represent average change 
from resting PETCO2 values plotted against VE and the associated regression line for male subjects. Circles represent females and 
squares represent males. There was no effect of biological sex on HCVR, p > .05. 
  























Figure 7.8. Effect of biological sex on HVR. Panel A shows HVR during isocapnic hypoxia and Panel B shows HVR during 
poikilocapnic hypoxia. Thick dashed and solid lines represent group averages for male and female subjects respectively. Values are 
mean ± standard deviation. There was no effect of biological sex on HVR during exposure to isocapnic or poikilocapnic hypoxia (p > 
.05). 
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